var title_f32_55_33648="Sleeve gastrectomy PI";
var content_f32_55_33648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Sleeve gastrectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a sleeve gastrectomy, the stomach is cut down in size and made into a banana shape. The new stomach is smaller and doesn't stretch, which helps with controlling appetite and losing weight.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33648=[""].join("\n");
var outline_f32_55_33648=null;
var title_f32_55_33649="Fibrillary glomerulonephritis IF";
var content_f32_55_33649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibrillary glomerulonephritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in fibrillary glomerulonephritis shows coarse linear pattern of IgG deposition (best seen at arrows). The coarseness and the lack of circulating anti-GBM antibodies distinguish this disorder from anti-GBM antibody disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33649=[""].join("\n");
var outline_f32_55_33649=null;
var title_f32_55_33650="Corn - plantar";
var content_f32_55_33650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Corn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperkeratotic papule with a central \"core\" is present on the plantar surface near the base of the second toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33650=[""].join("\n");
var outline_f32_55_33650=null;
var title_f32_55_33651="US Y funnel cervix";
var content_f32_55_33651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    US Y funnel cervix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 394px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Funneling cervix, with walls of funnel in \"Y-shaped\" configuration. Membranes are not visible separately, and there is no evidence of prolapsed membranes beyond internal os.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey R. Johnson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33651=[""].join("\n");
var outline_f32_55_33651=null;
var title_f32_55_33652="Pilocarpine (systemic): Drug information";
var content_f32_55_33652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pilocarpine (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/52/28484?source=see_link\">",
"    see \"Pilocarpine (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7876?source=see_link\">",
"    see \"Pilocarpine (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Salagen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9509745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Cholinergic Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Xerostomia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Following head and neck cancer:",
"     </i>",
"     5 mg 3 times/day, titration up to 10 mg 3 times/day may be considered for patients who have not responded adequately; do not exceed 2 tablets/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Sj&ouml;gren's syndrome:",
"     </i>",
"     5 mg 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9505215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9505216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment: 5 mg 2 times/day regardless of indication; adjust dose based on response and tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh score &gt;10): Contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9505264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 7.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Salagen&reg;: 5 mg, 7.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9505218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Avoid administering with high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Symptomatic treatment of xerostomia caused by salivary gland hypofunction resulting from radiotherapy for cancer of the head and neck or Sj&ouml;gren's syndrome",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Salagen&reg; may be confused with selegiline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (8% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chills (3% to 15%), dizziness (5% to 12%), headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (6% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency (9% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (5% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (29% to 68%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (&lt;1% to 5%), facial edema, hypertension (3%), palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (4%), fever, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (4% to 7%), dyspepsia (7%), vomiting (3% to 4%), constipation, flatulence, glossitis, salivation increased, stomatitis, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis, urinary incontinence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgias, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Lacrimation (6%), amblyopia (4%), abnormal vision, blurred vision, conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough increased, dysphagia, epistaxis, sinusitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal dreams, alopecia, angina pectoris, anorexia, anxiety, arrhythmia, body odor, bone disorder, cholelithiasis, colitis, confusion, dry eyes, dry mouth, ECG abnormality, myasthenia, photosensitivity reaction, nervousness, pancreatitis, paresthesia, salivary gland enlargement, sputum increased, taste loss, tongue disorder, urinary impairment, urinary urgency, yawning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pilocarpine or any component of the formulation; uncontrolled asthma; angle-closure glaucoma, severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease; may have difficulty compensating for transient changes in hemodynamics or rhythm induced by pilocarpine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholelithiasis: Use caution with cholelithiasis or biliary tract disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Adjust dose with moderate hepatic impairment; contraindicated in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrolithiasis: Use caution in patients with a history of nephrolithiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disorders: Use caution with controlled asthma, chronic bronchitis, or COPD; may increase airway resistance, bronchial smooth muscle tone, and bronchial secretions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9505095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Avoid administering with high-fat meal; fat decreases the rate of absorption, maximum concentration and increases the time it takes to reach maximum concentration.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9505065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9606980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid taking with a high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9505266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pilocarpine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $152.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $199.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Salagen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $201.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $247.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9505221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure, funduscopic exam, visual field testing",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9505105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.76-1.35 hours; increased with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hawthorne M and Sullivan K, \"Pilocarpine for Radiation-Induced Xerostomia in Head and Neck Cancer,\"",
"      <i>",
"       Int J Palliat Nurs",
"      </i>",
"      , 2000, 6(5):228-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/12419994/pubmed\" id=\"12419994\" target=\"_blank\">",
"        12419994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobs CD and van der Pas M, &ldquo;A Multicenter Maintenance Study of Oral Pilocarpine Tablets for Radiation-Induced Xerostomia,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 1996, 10(3 Suppl):16-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/8723429/pubmed\" id=\"8723429\" target=\"_blank\">",
"        8723429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson JT, Ferretti GA, Nethery WJ, et al, &ldquo;Oral Pilocarpine for Postirradiation Xerostomia in Patients With Head and Neck Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(6):390-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/8326972/pubmed\" id=\"8326972\" target=\"_blank\">",
"        8326972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeVeque FG, Montgomery M, Potter D, et al, &ldquo;A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Oral Pilocarpine for Treatment of Radiation-Induced Xerostomia in Head and Neck Cancer Patients,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1993, 11(6):1124-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/8501499/pubmed\" id=\"8501499\" target=\"_blank\">",
"        8501499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rieke JW, Hafermann MD, Johnson JT, et al, &ldquo;Oral Pilocarpine for Radiation-Induced Xerostomia: Integrated Efficacy and Safety Results From Two Prospective Randomized Clinical Trials,&rdquo;",
"      <i>",
"       Int J Radiat Oncol Biol Phys",
"      </i>",
"      , 1995, 31(3):661-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/7852133/pubmed\" id=\"7852133\" target=\"_blank\">",
"        7852133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuller DE, Stevens P, Clausen KP, et al, &ldquo;Treatment of Radiation Side Effects With Oral Pilocarpine,&rdquo;",
"      <i>",
"       J Surg Oncol",
"      </i>",
"      , 1989, 42(4):272-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/2687586/pubmed\" id=\"2687586\" target=\"_blank\">",
"        2687586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor SE, \"Efficacy and Economic Evaluation of Pilocarpine in Treating Radiation-Induced Xerostomia,\"",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2003, 4(9):1489-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33652/abstract-text/12943478/pubmed\" id=\"12943478\" target=\"_blank\">",
"        12943478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9905 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33652=[""].join("\n");
var outline_f32_55_33652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505050\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505051\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9509745\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505214\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505215\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505216\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505264\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505053\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505218\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505054\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505046\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505075\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505066\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505067\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505085\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505086\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505095\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505064\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887311\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505065\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9606980\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505266\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505221\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505105\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9905\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9905|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4548?source=related_link\">",
"      Pilocarpine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?18/3/18484?source=related_link\">",
"      Pilocarpine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/40/25219?source=related_link\">",
"      Pilocarpine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/52/28484?source=related_link\">",
"      Pilocarpine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/44/7876?source=related_link\">",
"      Pilocarpine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33653="Megestrol acetate: Drug information";
var content_f32_55_33653=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Megestrol acetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/37/12885?source=see_link\">",
"    see \"Megestrol acetate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/0/6149?source=see_link\">",
"    see \"Megestrol acetate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; ES",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Megestrol&reg;;",
"     </li>",
"     <li>",
"      Megace&reg;;",
"     </li>",
"     <li>",
"      Megace&reg; OS;",
"     </li>",
"     <li>",
"      Nu-Megestrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F192330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Hormone;",
"     </li>",
"     <li>",
"      Appetite Stimulant;",
"     </li>",
"     <li>",
"      Progestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F192316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Megace&reg; ES suspension is not equivalent to other formulations on a mg-per-mg basis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast carcinoma (females):",
"     </b>",
"     Refer to individual protocols: Oral: Tablet: 40 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial carcinoma:",
"     </b>",
"     Refer to individual protocols: Oral: Tablet: 40-320 mg/day in divided doses; use for 2 months to determine efficacy; maximum doses used have been up to 800 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HIV-related cachexia (males/females):",
"     </b>",
"     Oral: Suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Megace&reg;: Initial dose: 800 mg/day; daily doses of 400 and 800 mg/day were found to be clinically effective",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Megace&reg; ES: 625 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F192317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F192318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No data available; however, the urinary excretion of megestrol acetate administered in doses of 4-90 mg ranged from 57% to 78% within 10 days.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16317898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F192294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as acetate: 40 mg/mL (10 mL, 20 mL, 237 mL, 240 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megace&reg;: 40 mg/mL (240 mL) [contains ethanol 0.06%, sodium benzoate; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Megace&reg; ES: 125 mg/mL (150 mL) [contains ethanol 0.06%, sodium benzoate; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as acetate: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F192278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes Megace&reg; ES",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F192298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Megestrol acetate (Megace&reg;) oral suspension is compatible with water, orange juice, apple juice, or Sustacal H.C. for immediate consumption. Shake suspension well before use.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F192297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Palliative treatment of breast and endometrial carcinoma; treatment of anorexia, cachexia, or unexplained significant weight loss in patients with AIDS",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F192337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Megace&reg; may be confused with Reglan&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Megestrol may be confused with mesalamine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F192328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension (&le;8%), cardiomyopathy (1% to 3%), chest pain (1% to 3%), edema (1% to 3%), palpitation (1% to 3%), peripheral edema (1% to 3%), heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (&le;10%), insomnia (&le;6%), fever (1% to 6%), pain (&le;6%, similar to placebo), abnormal thinking (1% to 3%), confusion (1% to 3%), depression (1% to 3%), hypoesthesia (1% to 3%), seizure (1% to 3%), mood changes, malaise, lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 12%), alopecia (1% to 3%), pruritus (1% to 3%), vesiculobullous rash (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (&le;6%), gynecomastia (1% to 3%), adrenal insufficiency, amenorrhea, breakthrough bleeding, cervical erosion and secretions (changes), breast tenderness increased, Cushing's syndrome, diabetes, glucose intolerance, HPA axis suppression, hot flashes, hypercalcemia, menstrual flow changes, spotting, vaginal bleeding pattern changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (6% to 15%, similar to placebo), flatulence (&le;10%), vomiting (&le;6%), nausea (&le;5%), dyspepsia (&le;4%), abdominal pain (1% to 3%), constipation (1% to 3%), salivation increased (1% to 3%), xerostomia (1% to 3%), weight gain (not attributed to edema or fluid retention)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence (4% to 14%), decreased libido (&le;5%), urinary incontinence (1% to 3%), urinary tract infection (1% to 3%), urinary frequency (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia (&le;5%), leukopenia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatomegaly (1% to 3%), LDH increased (1% to 3%), cholestatic jaundice, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (2% to 6%), neuropathy (1% to 3%), paresthesia (1% to 3%), carpal tunnel syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Amblyopia (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea (1% to 3%), cough (1% to 3%), pharyngitis (1% to 3%), pneumonia (&le;2%), hyperpnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1% to 3%), herpes infection (1% to 3%), infection (1% to 3%), moniliasis (1% to 3%), tumor flare",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Thromboembolic phenomena (including deep vein thrombosis, pulmonary embolism, thrombophlebitis)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F192301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to megestrol or any component of the formulation; pregnancy (suspension)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F192282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May suppress hypothalamic-pituitary-adrenal (HPA) axis during chronic administration; consider the possibility of adrenal suppression in any patient receiving or being withdrawn from chronic therapy when signs/symptoms suggestive of hypoadrenalism are noted (during stress or in unstressed state). Laboratory evaluation and replacement/stress doses of rapid-acting glucocorticoid should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: New-onset diabetes mellitus and exacerbation of pre-existing diabetes have been reported with long-term use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism: Use with caution in patients with a history of thromboembolic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in older adults due to minimal effect on weight, and an increased risk of thrombosis and possibly death (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Vaginal bleeding or discharge may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Concentrated suspension: Megace&reg; ES suspension in not equivalent to other formulations on a mg-per-mg basis; Megace&reg; ES suspension 625 mg/5 mL is equivalent to megestrol acetate suspension 800 mg/20 mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F192287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Megestrol may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F192310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid herbs with progestogenic properties (eg, bloodroot, chasteberry, damiana, oregano, and yucca); may enhance the adverse/toxic effect of megestrol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F192290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (tablet) / X (suspension) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4627707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were demonstrated in animal studies. Use during pregnancy is contraindicated (suspension).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F192322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4627709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for adverse reaction in the newborn, the manufacturer recommends discontinuing breast-feeding while receiving megestrol. In addition, HIV-infected mothers are discouraged from breast-feeding to decrease the potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Megace ES Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg/5 mL (150 mL): $752.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Megace Oral Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (240 mL): $170.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Megestrol Acetate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/mL (240 mL): $143.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Megestrol Acetate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $67.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $116.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F192292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for signs of thromboembolic events; blood pressure, weight; serum glucose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F192303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apetrol (KP);",
"     </li>",
"     <li>",
"      Endace (IN);",
"     </li>",
"     <li>",
"      Maygace (ES);",
"     </li>",
"     <li>",
"      Megace (AR, AT, AU, BD, BE, BG, CL, CN, CO, CZ, EE, FR, GB, GR, HK, HN, IE, IT, JP, MY, NL, NO, NZ, PK, PL, PT, RU, SG, TH, TR, TW, UY);",
"     </li>",
"     <li>",
"      Megaplex (ID, PH, RU, TH);",
"     </li>",
"     <li>",
"      Megase (VE);",
"     </li>",
"     <li>",
"      Megastrol (PY);",
"     </li>",
"     <li>",
"      Megatus (TW);",
"     </li>",
"     <li>",
"      Megejohn (TW);",
"     </li>",
"     <li>",
"      Megesia (KP);",
"     </li>",
"     <li>",
"      Megestat (BR, DE);",
"     </li>",
"     <li>",
"      Megetrol (KP);",
"     </li>",
"     <li>",
"      Megex-I (PE);",
"     </li>",
"     <li>",
"      Megostat (AU);",
"     </li>",
"     <li>",
"      Mestrel (MX, TH);",
"     </li>",
"     <li>",
"      Mestrol (TW);",
"     </li>",
"     <li>",
"      Neoxia (KP);",
"     </li>",
"     <li>",
"      Tracetate (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F192281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A synthetic progestin with antiestrogenic properties which disrupt the estrogen receptor cycle. Megestrol interferes with the normal estrogen cycle and results in a lower LH titer. May also have a direct effect on the endometrium. Megestrol is an antineoplastic progestin thought to act through an antileutenizing effect mediated via the pituitary. May stimulate appetite by antagonizing the metabolic effects of catabolic cytokines.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F192300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed orally",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (to free steroids and glucuronide conjugates)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 13-105 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (57% to 78%; 5% to 8% as metabolites); feces (8% to 30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33653/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canetta R, Florentine S, Hunter H, et al, &ldquo;Megestrol Acetate,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1983, 10(3);141-57.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chang AY, \"Megestrol Acetate as a Biomodulator,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1998, 25(2 Suppl 6):58-61.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farrar DJ, \"Megestrol Acetate: Promises and Pitfalls,\"",
"      <i>",
"       AIDS Patient Care STDS",
"      </i>",
"      , 1999, 13(3):149-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33653/abstract-text/10375262/pubmed\" id=\"10375262\" target=\"_blank\">",
"        10375262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fietkau R, Riepl M, Kettner H, et al, &ldquo;Supportive Use of Megestrol Acetate in Patients With Head and Neck Cancer During Radio(Chemo)Therapy,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1997, 33(1):75-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33653/abstract-text/9071903/pubmed\" id=\"9071903\" target=\"_blank\">",
"        9071903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lentz SS, Brady MF, Major FJ, et al, &ldquo;High-Dose Megestrol Acetate in Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(2):357-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33653/abstract-text/8636744/pubmed\" id=\"8636744\" target=\"_blank\">",
"        8636744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schacter L, Rozencweig M, Canett R, et al, &ldquo;Megestrol Acetate: Clinical Experience,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1989, 16(1):49-63.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Strang P, &ldquo;The Effect of Megestrol Acetate on Anorexia, Weight Loss and Cachexia in Cancer and AIDS Patients,&rdquo;",
"      <i>",
"       Anticancer Res",
"      </i>",
"      , 1997, 17(1B):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/55/33653/abstract-text/9066597/pubmed\" id=\"9066597\" target=\"_blank\">",
"        9066597",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9603 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33653=[""].join("\n");
var outline_f32_55_33653=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192315\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192330\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192316\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192317\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192318\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16317898\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192294\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192298\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192297\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192337\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192328\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192301\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192282\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299657\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192310\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4627707\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192322\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4627709\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524681\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192292\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192303\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192281\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192300\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/37/12885?source=related_link\">",
"      Megestrol acetate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/0/6149?source=related_link\">",
"      Megestrol acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33654="Balanoposthitis in children: Epidemiology and pathogenesis";
var content_f32_55_33654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Balanoposthitis in children: Epidemiology and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Matthew Tews, DO",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33654/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/55/33654/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis describes inflammation of the glans penis and the foreskin (prepuce) in uncircumcised males (",
"    <a class=\"graphic graphic_picture graphicRef67724 \" href=\"mobipreview.htm?43/35/44606\">",
"     picture 1",
"    </a>",
"    ). Although the etiology is multifactorial in children, balanoposthitis typically results from poor hygiene that is sometimes complicated by secondary infection. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Irritant balanoposthitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With general treatment, most patients with balanoposthitis have complete resolution of symptoms. In selected cases, topical or oral antibiotic therapy may be indicated. Pediatric urologic consultation is reserved for patients with acute urinary obstruction, prolonged and refractory disease course, recurrence, or development of true phimosis.",
"   </p>",
"   <p>",
"    Balanitis, inflammation of the glans penis only, often occurs in conjunction with diaper dermatitis in young boys, both circumcised and uncircumcised. Local care and topical treatment aimed at the most likely etiology is rapidly curative and similar to balanoposthitis.",
"   </p>",
"   <p>",
"    Balanitis and balanoposthitis must be differentiated from lesions that are sexually transmitted, indicative of systemic disease, or precancerous. These lesions are more common in adolescents and adults. However, vigilance is required to recognize sexually transmitted infection in prepubertal victims of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will address the epidemiology, pathogenesis, and clinical features of balanoposthitis. Specific diagnosis and treatment of balanoposthitis and routine care of the circumcised penis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/23/24953?source=see_link\">",
"     \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link\">",
"     \"Care of the uncircumcised penis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common terminology used to describe inflammation with or without infection in the glans penis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    foreskin (prepuce) is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balanitis refers to the inflammation of the glans penis alone.",
"     </li>",
"     <li>",
"      Posthitis is inflammation of the prepuce alone.",
"     </li>",
"     <li>",
"      Balanoposthitis means inflammation of both the glans penis and the foreskin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These terms are sometimes used interchangeably and inappropriately in clinical practice and in the literature. Balanoposthitis occurs only in uncircumcised males with the rare exception of a circumcised boy with a large preputial remnant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanoposthitis affects males of all ages and ethnicity worldwide. Among Japanese boys, 1.5 percent of 603 uncircumcised males had balanoposthitis on routine examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/1\">",
"     1",
"    </a>",
"    ]. Most cases occurred in toddlers. Other studies confirm that balanoposthitis occurs often in children between ages two and five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Reports from China and Japan that include toilet-trained and school-age uncircumcised boys have found prevalences less than 1 in 1000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little data exist regarding incidence or prevalence of balanoposthitis in adolescents and adults. One report identified balanoposthitis in 11 percent of uncircumcised male patients undergoing urologic referral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7\">",
"     7",
"    </a>",
"    ]. Irritant and infectious balanoposthitis are most common among patients referred to genitourinary clinics. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathophysiology'",
"    </a>",
"    below.) In addition, trauma from foreskin manipulation or sexual activity is sometimes a contributing cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the pediatric population, several studies have addressed the prevalence of penile inflammation of varying types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. The results are discordant as to whether uncircumcised or circumcised males have a greater frequency of penile inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the uncircumcised male, the prepuce naturally covers the glans penis at birth, and is attached to the glans by preputial adhesions. The prepuce functions to physically and immunologically protect the glans and external urethral orifice. The adhesions cause a physiologically natural phimosis, where the foreskin cannot be retracted. Physiologic adhesions do not interfere with urination. The adhesions gradually separate secondary to hormonal influence and intermittent erection (",
"    <a class=\"graphic graphic_picture graphicRef61428 \" href=\"mobipreview.htm?39/30/40416\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link&amp;anchor=H86213710#H86213710\">",
"     \"Care of the uncircumcised penis\", section on 'Phimosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link&amp;anchor=H172410114#H172410114\">",
"     \"Care of the uncircumcised penis\", section on 'Physiologic phimosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies of prepuce development have found that approximately half of uncircumcised males have fully retractable foreskins by age 10 years. By the age of 17, 95 to 99 percent of foreskins are fully retractable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=see_link&amp;anchor=H86213584#H86213584\">",
"     \"Care of the uncircumcised penis\", section on 'Foreskin retraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute balanoposthitis may be classified into infectious, irritant and traumatic causes (",
"    <a class=\"graphic graphic_table graphicRef67799 \" href=\"mobipreview.htm?19/58/20396\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infectious balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the uncircumcised male, the area between the glans and inner foreskin is a moist environment. Physiologic secretions from the meatus, prostate, and bladder collect in the preputial space. These secretions function to provide a protective barrier for the urethral meatus and glans penis. In addition, lysozyme in these secretions provides some defense against infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/12\">",
"     12",
"    </a>",
"    ]. This natural barrier may be disrupted by excessive smegma, drying from excessive cleansing, or trauma. This compromise of host defense may allow secondary infection. In this situation, the causative organism can arise from overgrowth of organisms normally residing in the groin region, spread of adjacent cutaneous infection, or pathogens introduced by sexual contact (",
"    <a class=\"graphic graphic_table graphicRef67799 \" href=\"mobipreview.htm?19/58/20396\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fungal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida albicans is the most common fungal pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. In the pediatric patient, the acquisition of Candida albicans is related to local skin conditions and is frequently seen as a component of diaper dermatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .) In addition, infection with Candida albicans often follows antibiotic use.",
"   </p>",
"   <p>",
"    In adolescents and adults, Candidal infection may be sexually acquired. Fourteen to 18 percent of men are carriers, with no difference between circumcised and uncircumcised males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Bacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infection may arise from overgrowth of normal preputial flora. In a study of uncircumcised children, the most common organisms found by age were E. coli (ages 0 to 2 years), enterococci (ages 3 to 6 years), and Staphylococcus aureus and group A beta-hemolytic streptococci (ages 7 to 12 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/16\">",
"     16",
"    </a>",
"    ]. With increasing age, there is colonization with Corynebacterium spp., Candida albicans, gram-negative anaerobes, and potentially pathogenic Mycobacterium smegmatis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group A beta-hemolytic streptococci (GAS) typically cause impetigo and pharyngitis in the child, but have also been documented as a cause of balanoposthitis (",
"    <a class=\"graphic graphic_picture graphicRef61240 \" href=\"mobipreview.htm?12/30/12772\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Balanoposthitis due to GAS usually occurs in a child with a previously documented Group A streptococcal infection at another site. In adults, this is a rare cause of balanoposthitis, but has been documented to be sexually transmitted after fellatio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Group B beta-hemolytic streptococci also cause balanoposthitis, presenting in 13 percent of adult males with penile inflammation in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Males can be asymptomatic carriers and presentation is a nonspecific erythema with or without exudates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staphylococcus aureus is an infrequent cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gardnerella vaginalis has been documented as a source of sexually acquired balanoposthitis in adult males, but is infrequently reported in prepubertal males [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Balanoposthitis caused by Neisseria gonorrhoeae, Chlamydia trachomatis, or rarely, Treponema pallidum may occur in sexually active patients and victims of sexual abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37689?source=see_link&amp;anchor=H11#H11\">",
"     \"Sexually transmitted diseases: Overview of issues specific to adolescents\", section on 'STD clinical patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaerobic infections are most commonly caused by Bacteroides spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/27\">",
"     27",
"    </a>",
"    ]. There is an association with nonspecific urethritis and balanoposthitis in postpubertal patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Viral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papilloma virus and herpes simplex types 1 and 2 have been associated with acute balanoposthitis although both are rare etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7\">",
"     7",
"    </a>",
"    ]. Herpes simplex presents as a necrotizing balanitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Human papilloma virus is frequently difficult to eradicate and may follow self-inoculation or sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Protozoan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trichomonas vaginalis causes an erosive balanoposthitis following sexual contact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7\">",
"     7",
"    </a>",
"    ]. Anogenital contact has been associated with Entamoeba histolytica balanoposthitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Irritant balanoposthitis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Poor hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant balanoposthitis often results from poor hygiene with accumulation of smegma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/26\">",
"     26",
"    </a>",
"    ]. Smegma is a collection of desquamated squamous epithelial cells, squalene, beta-cholestanol, and long-chain fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/3\">",
"     3",
"    </a>",
"    ]. When smegma accumulation causes irritation and swelling of the glans and inner foreskin, this type of irritant balanoposthitis is termed nonspecific balanoposthitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Irritant contact dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This condition, often due to excessive cleansing of the foreskin with soap, may also cause balanoposthitis. In one prospective study of 43 male patients with recurrent or persistent balanoposthitis, 31 (72 percent) were diagnosed with an irritant contact dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/8\">",
"     8",
"    </a>",
"    ]. Spermicides and condom lubricants are common culprits in older adolescents and adults. Patients with eczema appear to be predisposed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Allergic/Immunologic balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic allergic reactions are uncommon, although balanoposthitis has been described as a component of Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, fixed-drug eruptions of the glans",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    foreskin may follow ingestion of tetracyclines, salicylates, phenacetin, phenolphthalein, and some hypnotic drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7,34,35\">",
"     7,34,35",
"    </a>",
"    ]. These eruptions typically occur with reintroduction of the offending agent and resolve once the agent is stopped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Traumatic balanoposthitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Forceful retraction of the foreskin may cause incidental abrasion and tearing of the synechial membranes found in the unseparated foreskin of the young boy. Avoidance of cleansing due to pain sets up conditions for the development of balanoposthitis. In addition, trauma can serve as a nidus for infectious balanoposthitis. This mechanism is prevalent in young infants whose parents lack knowledge of proper care of the foreskin. Attempting to forcefully retract the foreskin before the complete breakdown of these physiologic adhesions may also cause paraphimosis, an inability to reduce the foreskin back over the corona of the glans. Paraphimosis is a true urologic emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=see_link\">",
"     \"Paraphimosis: Definition, pathophysiology, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33543?source=see_link\">",
"     \"Paraphimosis reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other forms of trauma that increase the risk of balanoposthitis include friction or entrapment against clothing, masturbation (foreskin fiddling), sexual intercourse, and zip-fastener injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/33,36,37\">",
"     33,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity, co-existing chronic diseases (especially diabetes mellitus), and immunodeficiency (especially",
"    <span class=\"nowrap\">",
"     HIV/AIDS)",
"    </span>",
"    increase the risk of balanoposthitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33654/abstract/21,38,39\">",
"     21,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/29/40401?source=see_link\">",
"       \"Patient information: Balanitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Balanoposthitis describes inflammation of the glans penis and the foreskin (prepuce) in uncircumcised males and consists of the following types: irritant, infectious,",
"      <span class=\"nowrap\">",
"       allergic/immunologic,",
"      </span>",
"      and traumatic (",
"      <a class=\"graphic graphic_picture graphicRef67724 \" href=\"mobipreview.htm?43/35/44606\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61240 \" href=\"mobipreview.htm?12/30/12772\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67799 \" href=\"mobipreview.htm?19/58/20396\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Balanoposthitis affects males of all ages and ethnicity worldwide. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/23/24953?source=see_link\">",
"       \"Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/1\">",
"      Kayaba H, Tamura H, Kitajima S, et al. Analysis of shape and retractability of the prepuce in 603 Japanese boys. J Urol 1996; 156:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/2\">",
"      Fergusson DM, Lawton JM, Shannon FT. Neonatal circumcision and penile problems: an 8-year longitudinal study. Pediatrics 1988; 81:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/3\">",
"      Cold CJ, Taylor JR. The prepuce. BJU Int 1999; 83 Suppl 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/4\">",
"      Edwards SK, European Branch of the International Union against Sexually Transmitted Infection and the European Office of the World Health Organization. European guideline for the management of balanoposthitis. Int J STD AIDS 2001; 12 Suppl 3:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/5\">",
"      Imamura E. Phimosis of infants and young children in Japan. Acta Paediatr Jpn 1997; 39:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/6\">",
"      Hsieh TF, Chang CH, Chang SS. Foreskin development before adolescence in 2149 schoolboys. Int J Urol 2006; 13:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/7\">",
"      Edwards S. Balanitis and balanoposthitis: a review. Genitourin Med 1996; 72:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/8\">",
"      Birley HD, Walker MM, Luzzi GA, et al. Clinical features and management of recurrent balanitis; association with atopy and genital washing. Genitourin Med 1993; 69:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/9\">",
"      Abdullah AN, Drake SM, Wade AA, Walzman M. Balanitis (balanoposthitis) in patients attending a department of genitourinary medicine. Int J STD AIDS 1992; 3:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/10\">",
"      Van Howe RS. Neonatal circumcision and penile inflammation in young boys. Clin Pediatr (Phila) 2007; 46:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/11\">",
"      Herzog LW, Alvarez SR. The frequency of foreskin problems in uncircumcised children. Am J Dis Child 1986; 140:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/12\">",
"      Fleiss PM, Hodges FM, Van Howe RS. Immunological functions of the human prepuce. Sex Transm Infect 1998; 74:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/13\">",
"      Dockerty WG, Sonnex C. Candidal balano-posthitis: a study of diagnostic methods. Genitourin Med 1995; 71:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/14\">",
"      Davidson F. Yeasts and circumcision in the male. Br J Vener Dis 1977; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/15\">",
"      Rodin P, Kolator B. Carriage of yeasts on the penis. Br Med J 1976; 1:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/16\">",
"      Agartan CA, Kaya DA, Ozturk CE, Gulcan A. Is aerobic preputial flora age dependent? Jpn J Infect Dis 2005; 58:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/17\">",
"      Porter WM, Bunker CB. The dysfunctional foreskin. Int J STD AIDS 2001; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/18\">",
"      Schwartz RH, Rushton HG. Acute balanoposthitis in young boys. Pediatr Infect Dis J 1996; 15:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/19\">",
"      Kyriazi NC, Costenbader CL. Group A beta-hemolytic streptococcal balanitis: it may be more common than you think. Pediatrics 1991; 88:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/20\">",
"      Guerrero-Vazquez J, Sebastian-Planes M, Olmedo-Sanlaureano S. Group A streptococcal proctitis and balanitis. Pediatr Infect Dis J 1990; 9:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/21\">",
"      Wakatsuki A. [Clinical experience of streptococcal balanoposthitis in 47 healthy adult males]. Hinyokika Kiyo 2005; 51:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/22\">",
"      Sakuma S, Komiya H. Balanitis caused by Streptococcus pyogenes: a report of two cases. Int J STD AIDS 2005; 16:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/23\">",
"      Bhargava RK, Thin RN. Subpreputial carriage of aerobic micro-organisms and balanitis. Br J Vener Dis 1983; 59:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/24\">",
"      Brook I. Balanitis caused by group B beta-hemolytic streptococci. Sex Transm Dis 1980; 7:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/25\">",
"      Wahl NG, Castilla MA, Lewis-Abney K. Prevalence of Gardnerella vaginalis in prepubertal males. Arch Pediatr Adolesc Med 1998; 152:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/26\">",
"      Vohra S, Badlani G. Balanitis and balanoposthitis. Urol Clin North Am 1992; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/27\">",
"      Cree GE, Willis AT, Phillips KD, Brazier JS. Anaerobic balanoposthitis. Br Med J (Clin Res Ed) 1982; 284:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/28\">",
"      Peutherer JF, Smith IW, Robertson DH. Necrotising balanitis due to a generalised primary infection with herpes simplex virus type 2. Br J Vener Dis 1979; 55:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/29\">",
"      Powers RD, Rein MF, Hayden FG. Necrotizing balanitis due to herpes simplex type 1. JAMA 1982; 248:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/30\">",
"      Arumainayagam JT, Sumathipala AH, Smallman LA, Shahmanesh M. Flat condylomata of the penis presenting as patchy balanoposthitis. Genitourin Med 1990; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/31\">",
"      Birley HD, Luzzi GA, Walker MM, et al. The association of human papillomavirus infection with balanoposthitis: a description of five cases with proposals for treatment. Int J STD AIDS 1994; 5:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/32\">",
"      COOKE RA, RODRIGUE RB. AMOEBIC BALANITIS. Med J Aust 1964; 1:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/33\">",
"      Leslie JA, Cain MP. Pediatric urologic emergencies and urgencies. Pediatr Clin North Am 2006; 53:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/34\">",
"      Thankappan TP, Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol 1991; 30:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/35\">",
"      Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol 2003; 49:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/36\">",
"      Hoppa EC, Wiley JF 2nd. Bathing suit mesh entrapment: an unusual case of penile injury. Pediatr Emerg Care 2006; 22:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/37\">",
"      Kanegaye JT, Schonfeld N. Penile zipper entrapment: a simple and less threatening approach using mineral oil. Pediatr Emerg Care 1993; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/38\">",
"      Manian FA, Alford RH. Nosocomial infectious balanoposthitis in neutropenic patients. South Med J 1987; 80:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33654/abstract/39\">",
"      Drivsholm T, de Fine Olivarius N, Nielsen AB, Siersma V. Symptoms, signs and complications in newly diagnosed type 2 diabetic patients, and their relationship to glycaemia, blood pressure and weight. Diabetologia 2005; 48:210.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6480 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-18D72DAC39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33654=[""].join("\n");
var outline_f32_55_33654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infectious balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fungal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Bacterial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Viral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Protozoan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Irritant balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Poor hygiene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Irritant contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Allergic/Immunologic balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Traumatic balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6480|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/35/44606\" title=\"picture 1\">",
"      Balanoposthitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/30/40416\" title=\"picture 2\">",
"      Infant prepuce",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?12/30/12772\" title=\"picture 3\">",
"      Group A streptococcal balanoposthitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6480|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/58/20396\" title=\"table 1\">",
"      Etiology balanoposthitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/23/24953?source=related_link\">",
"      Balanoposthitis in children: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/18/11559?source=related_link\">",
"      Care of the uncircumcised penis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33543?source=related_link\">",
"      Paraphimosis reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29302?source=related_link\">",
"      Paraphimosis: Definition, pathophysiology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/29/40401?source=related_link\">",
"      Patient information: Balanitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/51/37689?source=related_link\">",
"      Sexually transmitted diseases: Overview of issues specific to adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33655="Thyroid storm";
var content_f32_55_33655=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thyroid storm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33655/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/55/33655/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid storm is a rare, life-threatening condition characterized by severe clinical manifestations of thyrotoxicosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/1\">",
"     1",
"    </a>",
"    ]. In a national survey from Japan, the incidence of thyroid storm in hospitalized patients was 0.20 per 100,000 per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/2\">",
"     2",
"    </a>",
"    ]. Although thyroid storm can develop in patients with long-standing untreated hyperthyroidism (Graves&rsquo; disease, toxic multinodular goiter, solitary toxic adenoma), it is often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, an acute iodine load, or parturition. The advent of appropriate preoperative preparation of patients undergoing thyroidectomy for hyperthyroidism has led to a dramatic reduction in the prevalence of surgically-induced thyroid storm. Several other factors may lead to hospitalization of patients with severe thyrotoxicosis, including co-morbid conditions, poor compliance with specific therapy, and low socioeconomic status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why certain factors result in the development of thyroid storm. Hypotheses include a rapid rate of increase in serum thyroid hormone levels, increased responsiveness to catecholamines, or enhanced cellular responses to thyroid hormone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/1\">",
"     1",
"    </a>",
"    ]. The degree of thyroid hormone excess (elevation of T4 and T3, suppression of TSH) typically is not more profound than that seen in patients with uncomplicated thyrotoxicosis. However, one study found that while the total T4 and T3 levels were similar to those seen in uncomplicated patients, the free T4 and free T3 concentrations were higher in patients with thyroid storm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and management of thyroid storm will be reviewed here. The clinical manifestations, diagnosis, and treatment of hyperthyroidism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=see_link\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13827326\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of thyroid storm is based upon clinical findings. Patients with severe and life-threatening thyrotoxicosis typically have an exaggeration of the usual symptoms of hyperthyroidism. Cardiovascular symptoms in many patients include tachycardia to rates that can exceed 140",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    and congestive heart failure. Hypotension, cardiac arrhythmia, and death from cardiovascular collapse may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/5\">",
"     5",
"    </a>",
"    ]. Hyperpyrexia to 104 to 106&ordm;F is common. Agitation, anxiety, delirium, psychosis, stupor, or coma are also common and are considered by many to be essential to the diagnosis. Severe nausea, vomiting, diarrhea, abdominal pain, or hepatic failure with jaundice can also occur. Physical examination may reveal goiter, ophthalmopathy (in the presence of Graves&rsquo; disease), lid lag, hand tremor, and warm and moist skin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no universally accepted criteria or validated clinical tools for diagnosing thyroid storm. In 1993, Burch and Wartofsky introduced a scoring system using precise clinical criteria for the identification of thyroid storm (",
"    <a class=\"graphic graphic_table graphicRef60908 \" href=\"mobipreview.htm?34/24/35213\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/6\">",
"     6",
"    </a>",
"    ]. A score of 45 or more is highly suggestive of thyroid storm, whereas a score below 25 makes thyroid storm unlikely. A score of 25 to 44 is suggestive of impending storm. While this scoring system is likely sensitive, it is not very specific. Other diagnostic criteria based upon similar clinical findings (central nervous system manifestations, fever, tachycardia, congestive heart failure, gastrointestinal manifestations) have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thyroid function tests (TSH, free T4, and T3) should be assessed in all patients in whom there is a clinical suspicion of thyroid storm. The degree of hyperthyroidism (suppressed TSH and elevated T3 and free T4) in patients with thyroid storm is, in general, comparable to that in patients with uncomplicated overt hyperthyroidism. Thus, the degree of hyperthyroidism is not a criterion for diagnosing thyroid storm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=see_link&amp;anchor=H25975064#H25975064\">",
"     \"Diagnosis of hyperthyroidism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other nonspecific laboratory findings may include mild hyperglycemia, mild hypercalcemia, abnormal liver function tests, leukocytosis, or leukopenia. Hyperglycemia is secondary to a catecholamine-induced inhibition of insulin release and increased glycogenolysis. Hypercalcemia may occur due to hemoconcentration and enhanced bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/7\">",
"     7",
"    </a>",
"    ]. Radioiodine uptake is not necessary for the diagnosis of thyroid storm, and treatment should not be delayed for scanning in patients with clinical manifestations of thyroid storm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic options for thyroid storm are the same as those for uncomplicated hyperthyroidism, except that the drugs are given in higher doses and more frequently. In addition, full support of the patient in an intensive care unit is essential, since the mortality rate of thyroid storm is substantial (10 to 30 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The principles of treatment outlined below are based upon clinical experience and case studies. They are frequently also applied to patients with severe hyperthyroidism who do not fully meet the criteria for thyroid storm. For patients meeting criteria for thyroid storm, supportive therapy and recognition and treatment of any precipitating factors (eg, infection), in addition to specific therapy directed against the thyroid, may be critical to the final outcome. Many patients require substantial amounts of fluid, while others may require diuresis because of congestive heart failure.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    and beta-blocker requirements may be quite high because of increased drug metabolism. Infection needs to be identified and treated, and hyperpyrexia should be aggressively corrected.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    is preferable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , which can increase serum free thyroxine (T4) and triiodothyronine (T3) concentrations by interfering with their protein binding.",
"   </p>",
"   <p>",
"    The therapeutic regimen typically consists of multiple medications, each of which has a different mechanism of action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A beta-blocker to control the symptoms and signs induced by increased adrenergic tone",
"     </li>",
"     <li>",
"      A thionamide to block new hormone synthesis",
"     </li>",
"     <li>",
"      An iodine solution to block the release of thyroid hormone",
"     </li>",
"     <li>",
"      An iodinated radiocontrast agent (if available) to inhibit the peripheral conversion of T4 to T3",
"     </li>",
"     <li>",
"      Glucocorticoids to reduce T4-to-T3 conversion, promote vasomotor stability, and possibly treat an associated relative adrenal insufficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with clinical manifestations of thyroid storm or with severe thyrotoxicosis who do not fully meet the criteria for thyroid storm (ie, impending storm), we begin immediate treatment with a beta blocker (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in a dose to achieve adequate control of heart rate, typically 60 to 80 mg orally every four to six hours, with appropriate adjustment for heart rate and blood pressure) and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU) 200 mg every four hours or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    (20 mg orally every four to six hours). One hour",
"    <strong>",
"     after",
"    </strong>",
"    the first dose of thionamide is taken, we administer iodine (SSKI, five drops orally every six hours, or Lugol's solution, 10 drops every eight hours). For patients with clinical manifestations of thyroid storm, we also administer glucocorticoids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , 100 mg intravenously every eight hours). Propranolol, PTU, and methimazole can be administered through a nasogastric tube. Other formulations are reviewed below. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Beta blockers'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Thionamides'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-blockers are of major importance in treating most patients with severe hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .) These drugs should be used with extreme caution if the patient has heart failure or other contraindications to beta-blockade. It is important to note, however, that control of tachycardia may lead to improvement in cardiac function.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    is frequently selected for initial therapy because it can be given intravenously, but this should only be done in a setting where hemodynamics can be monitored. The intravenous dose is 0.5 to 1 mg over 10 minutes followed by 1 to 2 mg over 10 minutes every few hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/6,9\">",
"     6,9",
"    </a>",
"    ]. Higher doses may occasionally be required but care should be taken to avoid hypotension and aggravation of existing heart failure. As an alternative to intravenous administration, propranolol can be given orally or via nasogastric tube in a dose to achieve adequate control of heart rate, typically 60 to 80 mg orally every four to six hours. When transitioning from intravenous to",
"    <span class=\"nowrap\">",
"     oral/nasogastric",
"    </span>",
"    treatment, intravenous therapy may need to be continued until adequate effectiveness of the",
"    <span class=\"nowrap\">",
"     oral/nasogastric",
"    </span>",
"    treatment is ascertained.",
"   </p>",
"   <p>",
"    An alternative regimen is to utilize the short-acting beta-blocker",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/37/40536?source=see_link\">",
"     esmolol",
"    </a>",
"    . A loading dose of 250 to 500",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    is given, followed by an infusion at 50 to 100",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. This regimen permits rapid titration of the drug to achieve adequate beta-blockade while minimizing adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/10\">",
"     10",
"    </a>",
"    ]. In patients with reactive airways disease, cardioselective beta-blockers such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    could be considered, but this should be done carefully. In some patients with severe asthma in whom beta-blockers might be contraindicated, rate control can be achieved with calcium channel blockers such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thionamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thionamides block de novo thyroid hormone synthesis within one to two hours after administration. However they have no effect on the release of preformed hormone from the thyroid gland.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     Propylthiouracil",
"    </a>",
"    (PTU) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    are the thionamide drugs available in the United States. Carbimazole, a third drug which is metabolized to methimazole, is available in the United Kingdom and some former British Commonwealth countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there are no data showing that patients do better clinically with one thionamide over another, we suggest PTU for the acute treatment of life-threatening thyroid storm in an intensive care unit (ICU) setting, where it can be administered regularly every four hours. PTU, but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    , blocks T4 to T3 conversion, and there is some evidence that over the first few hours after administration, PTU more rapidly reduces serum T3 concentrations than methimazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/12\">",
"     12",
"    </a>",
"    ]. However, because methimazole has a longer duration of action, and after weeks of treatment results in more rapid normalization of serum T3 compared to PTU, and because methimazole is less hepatotoxic, methimazole may be preferred for severe but not life-threatening hyperthyroidism. Patients started on PTU in the ICU should be transitioned to methimazole before discharge from the hospital. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of thionamide given to patients with thyroid storm is higher than that required to block thyroid hormone synthesis. Both the substantial mortality associated with thyroid storm and the possibility of poor absorption because of concurrent gastrointestinal dysfunction have been used to justify the higher dose. We typically administer 200 mg of PTU every four hours or 20 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    every four to six hours, orally or via nasogastric tube.",
"   </p>",
"   <p>",
"    Both drugs can be suspended in liquid or made up as a suppository for rectal administration, which should be ordered well in advance from the pharmacy (",
"    <a class=\"graphic graphic_table graphicRef79245 \" href=\"mobipreview.htm?16/13/16604\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/7,13-16\">",
"     7,13-16",
"    </a>",
"    ]. In one study comparing the use of an enema versus a suppository preparation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    , 15 patients with newly diagnosed hyperthyroidism were randomly assigned to a PTU enema (eight 50 mg tablets of propylthiouracil were dissolved in 90 mL of sterile water) versus two PTU suppositories (200 mg of propylthiouracil were dissolved in a polyethylene glycol base and put into each suppository) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/16\">",
"     16",
"    </a>",
"    ]. The enema form provided better bioavailability than the suppository form (time to peak level 85 versus 172 minutes, maximum peak level 3.89 versus 2.01",
"    <span class=\"nowrap\">",
"     microgm/mL).",
"    </span>",
"    However, both preparations proved to have comparable therapeutic effect, as measured by a significant decrease in serum free T3 levels.",
"   </p>",
"   <p>",
"    For patients intolerant of oral or rectal thionamides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    can be prepared for intravenous administration by dissolving the tablets in pH-neutral isotonic saline and by filtering through a 0.22 &micro;m filter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/17\">",
"     17",
"    </a>",
"    ]. PTU can be prepared for intravenous administration by dissolving the tablets in isotonic saline made alkaline (pH 9.25) with sodium hydroxide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/18\">",
"     18",
"    </a>",
"    ]. Routine pharmacologic sterility tests are required as dictated by individual hospitals. In one preliminary report, intravenous PTU given in a dose of 576",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    was used to attain euthyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/19\">",
"     19",
"    </a>",
"    ]. Lower doses are used in patients with severe thyrotoxicosis who do not meet criteria for thyroid storm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3999987\">",
"    <span class=\"h3\">",
"     Patients unable to take a thionamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thionamide toxicity is uncommon, some patients are unable to continue thionamides because of rare side effects such as agranulocytosis or hepatotoxicity, or because of allergy. Thyroid storm has been reported in patients with Graves&rsquo; disease after discontinuation of thionamides due to agranulocytosis or hepatotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In such patients who require urgent treatment of hyperthyroidism, thyroidectomy is the treatment of choice. Patients who are to undergo surgery require preoperative treatment of thyrotoxicosis. We typically treat with beta blockers (if not contraindicated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    in a dose to achieve adequate control of heart rate, typically 60 to 80 mg every four to six hours), glucocorticoids to inhibit conversion of T4 to T3 (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , 1 to 2 mg every six hours), and, in patients with Graves&rsquo; disease, iodine (SSKI, five drops [20",
"    <span class=\"nowrap\">",
"     drops/mL,",
"    </span>",
"    38 mg",
"    <span class=\"nowrap\">",
"     iodide/drop]",
"    </span>",
"    orally every six hours, or Lugol's solution, 10 drops [20",
"    <span class=\"nowrap\">",
"     drops/mL,",
"    </span>",
"    8 mg",
"    <span class=\"nowrap\">",
"     iodine/drop]",
"    </span>",
"    every eight hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Iodinated contrast agents have also been used to prepare hyperthyroid patients for urgent surgery, but they are no longer available in most countries. We continue treatment for up to five to seven days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Preoperative preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery should not be delayed for more than 8 to 10 days because of a phenomenon called escape from the Wolff-Chaikoff effect. Large doses of exogenous iodine inhibit the organification of iodine in the thyroid gland (the Wolff-Chaikoff effect). However, this effect is transient. The iodide transport system is able to adapt to higher concentrations of iodine, allowing thyroid hormone synthesis to proceed, with potential exacerbation of thyrotoxicosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link\">",
"     \"Iodine-induced thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodine-containing solutions have traditionally been utilized for the treatment of thyroid storm, since iodine blocks the release of T4 and T3 from the gland within hours. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=see_link\">",
"     \"Iodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .) It is therefore prudent to treat patients in thyroid storm with iodide. The administration of iodine should be delayed for at least one hour",
"    <strong>",
"     after",
"    </strong>",
"    thionamide administration to prevent the iodine from being used as substrate for new hormone synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral doses are Lugol's solution, 10 drops (20",
"    <span class=\"nowrap\">",
"     drops/mL,",
"    </span>",
"    8 mg",
"    <span class=\"nowrap\">",
"     iodine/drop)",
"    </span>",
"    three times daily, or SSKI, five drops (20",
"    <span class=\"nowrap\">",
"     drops/mL,",
"    </span>",
"    38 mg",
"    <span class=\"nowrap\">",
"     iodide/drop)",
"    </span>",
"    every six hours. It has been suggested that 10 drops of Lugol's solution can be directly added to intravenous fluids since it is sterile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/24\">",
"     24",
"    </a>",
"    ]. The iodine solution can also be given rectally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although iodine is typically well tolerated, local esophageal or duodenal mucosal injury and hemorrhage have been reported after administration of Lugol&rsquo;s solution (960 mg",
"    <span class=\"nowrap\">",
"     iodine/day)",
"    </span>",
"    for the treatment of thyroid storm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687055\">",
"    <span class=\"h2\">",
"     Iodinated radiocontrast agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodinated contrast agents previously used to treat hyperthyroidism are currently not available in the United States or in most other countries.",
"   </p>",
"   <p>",
"    Iopanoic acid and other iodinated radiocontrast agents used for oral cholecystography have been used to treat hyperthyroidism, but there are little published data on their efficacy in thyroid storm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37779?source=see_link\">",
"     \"Iodinated radiocontrast agents in the treatment of hyperthyroidism\"",
"    </a>",
"    .) They are, however, potent inhibitors of T4 to T3 conversion, and the release of iodine in pharmacologic quantities from these agents has the additional benefits of blocking thyroid hormone release. They have been extremely useful in treating severe hyperthyroidism or in preparing hyperthyroid patients for urgent surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. If available, these agents can be given to patients with severe hyperthyroidism at a dose of 0.5 to 1 g given once daily.",
"   </p>",
"   <p>",
"    Because they are iodinated, they should be given at least one hour",
"    <strong>",
"     after",
"    </strong>",
"    the thionamide to prevent the iodine from being used as substrate for new hormone synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids also reduce T4 to T3 conversion, and may have a direct effect on the underlying autoimmune process if the thyroid storm is due to Graves' disease, and treat potentially associated limited adrenal reserve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/29\">",
"     29",
"    </a>",
"    ]. Their use for the treatment of thyroid storm appears to have improved outcome in at least one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/30\">",
"     30",
"    </a>",
"    ]. It is therefore reasonable to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    100 mg intravenously every eight hours in patients with thyroid storm; in contrast, we do not routinely use glucocorticoids in patients with severe, but not life-threatening, hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13827734\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    has also been given to acutely block the release of thyroid hormone. However, its renal and neurologic toxicity limit its utility. Plasmapheresis has been tried when traditional therapy has not been successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In one case report, a woman with Graves&rsquo; disease and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    -induced agranulocytosis developed thyroid storm after methimazole was discontinued. Treatment with plasmapheresis resulted in marked improvement in thyrotoxicosis within three days, allowing thyroidectomy for definitive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33655/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1687118\">",
"    <span class=\"h2\">",
"     Long-term management",
"    </span>",
"    &nbsp;&mdash;&nbsp;After there is evidence of clinical improvement (afebrile, resolution of CNS and cardiovascular manifestations), iodine therapy can be discontinued and glucocorticoids tapered and discontinued. Beta blockers can be withdrawn, but only after thyroid function tests have returned to normal. The dose of thionamides should be titrated to maintain euthyroidism. PTU, if given, should be switched to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    because of methimazole&rsquo;s better safety profile and better compliance rates. Monitoring, dosing, and duration of thionamide therapy are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12696?source=see_link&amp;anchor=H5#H5\">",
"     \"Thionamides in the treatment of Graves' disease\", section on 'Monitoring and duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with Graves&rsquo; disease, definitive therapy with radioactive iodine or thyroidectomy is important to prevent a recurrence of severe thyrotoxicosis. We suggest radioiodine therapy as our first choice for definitive therapy for hyperthyroidism, given its lower cost and lower complication rate than surgery. If the patient received iodine within a few weeks of planned radioiodine treatment, a radioiodine uptake should be obtained to calculate the radioiodine treatment dose rather than using fixed-dose radioiodine treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link&amp;anchor=H30632293#H30632293\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery is an option for patients with hyperthyroidism due to a very large or obstructive goiter. Preparation for treatment with radioiodine or surgery is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=see_link&amp;anchor=H30632321#H30632321\">",
"     \"Radioiodine in the treatment of hyperthyroidism\", section on 'Treatment regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\", section on 'Preoperative preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13827637\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid storm is a rare, life-threatening condition characterized by severe clinical manifestations of thyrotoxicosis. Although thyroid storm can develop in patients with long-standing untreated hyperthyroidism (Graves&rsquo; disease, toxic multinodular goiter, solitary toxic adenoma), it is often precipitated by an acute event such as thyroid or nonthyroidal surgery, trauma, infection, an acute iodine load, or parturition. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of thyroid storm is based upon clinical findings (",
"      <a class=\"graphic graphic_table graphicRef60908 \" href=\"mobipreview.htm?34/24/35213\">",
"       table 1",
"      </a>",
"      ). Patients with severe and life-threatening thyrotoxicosis typically have an exaggeration of the usual symptoms of hyperthyroidism. The classical symptoms include tachycardia, hyperpyrexia, central nervous system dysfunction (agitation, delirium, psychosis, stupor, or coma), and gastrointestinal symptoms (nausea, vomiting, abdominal pain). Physical examination may reveal goiter, ophthalmopathy (in the presence of Graves&rsquo; disease), lid lag, hand tremor, and warm and moist skin. Thyroid function tests show hyperthyroidism (suppressed TSH, elevated free T4 and T3) generally comparable to that in patients with uncomplicated overt hyperthyroidism. (See",
"      <a class=\"local\" href=\"#H13827326\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to specific therapy directed against the thyroid, supportive therapy in an intensive care unit and recognition and treatment of any precipitating factors is essential, since the mortality rate of thyroid storm is substantial (20 to 30 percent). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with clinical manifestations of thyroid storm, we begin immediate treatment with a beta blocker (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      in a dose to achieve adequate control of heart rate, typically 60 to 80 mg orally every four to six hours), a thionamide, and glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      , 100 mg intravenously every eight hours). One hour after a thionamide is given, we administer iodine (SSKI, five drops [20",
"      <span class=\"nowrap\">",
"       drops/mL,",
"      </span>",
"      38 mg",
"      <span class=\"nowrap\">",
"       iodide/drop]",
"      </span>",
"      orally every six hours, or Lugol's solution, 10 drops [20",
"      <span class=\"nowrap\">",
"       drops/mL,",
"      </span>",
"      8 mg",
"      <span class=\"nowrap\">",
"       iodine/drop]",
"      </span>",
"      every eight hours). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with life-threatening thyroid storm admitted to an ICU, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/9/5271?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      (PTU) (200 mg orally every four hours) rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/39/19062?source=see_link\">",
"       methimazole",
"      </a>",
"      as initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). PTU blocks T4 to T3 conversion and results in lower serum T3 levels for the first several days of treatment. However, for severe but not life-threatening hyperthyroidism, methimazole (20 mg every six hours) may be preferred because of its longer half life, lower risk of hepatic toxicity, and because it ultimately restores euthyroidism more quickly than PTU. Patients initially treated with PTU should be transitioned to methimazole before discharge from the hospital. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Thionamides'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41303?source=see_link\">",
"       \"Pharmacology and toxicity of thionamides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with contraindications to thionamides who require urgent correction of hyperthyroidism, surgery is the treatment of choice. Patients who are to undergo surgery require preoperative treatment of thyrotoxicosis. We typically treat with beta blockers (if not contraindicated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      60 to 80 mg every four to six hours), glucocorticoids to inhibit conversion of T4 to T3 (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , 1 to 2 mg every six hours), and, in patients with Graves&rsquo; disease, iodine (SSKI, five drops [20",
"      <span class=\"nowrap\">",
"       drops/mL,",
"      </span>",
"      38 mg",
"      <span class=\"nowrap\">",
"       iodide/drop]",
"      </span>",
"      orally every six hours, or Lugol's solution, 10 drops [20",
"      <span class=\"nowrap\">",
"       drops/mL,",
"      </span>",
"      8 mg",
"      <span class=\"nowrap\">",
"       iodine/drop]",
"      </span>",
"      every eight hours). We continue treatment for up to five to seven days. (See",
"      <a class=\"local\" href=\"#H3999987\">",
"       'Patients unable to take a thionamide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=see_link\">",
"       \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After the clinical manifestations of thyroid storm are improved, long-term therapy is required to prevent a recurrence of severe thyrotoxicosis. For definitive therapy of patients with hyperthyroidism secondary to Graves&rsquo; disease, toxic multinodular goiter, or toxic adenoma, we suggest radioiodine therapy as our first choice, given its lower cost and lower complication rate than surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Surgery is an option for patients with hyperthyroidism due to a very large or obstructive goiter. (See",
"      <a class=\"local\" href=\"#H1687118\">",
"       'Long-term management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=see_link\">",
"       \"Treatment of Graves' hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=see_link\">",
"       \"Treatment of toxic adenoma and toxic multinodular goiter\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/1\">",
"      Sarlis NJ, Gourgiotis L. Thyroid emergencies. Rev Endocr Metab Disord 2003; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/2\">",
"      Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. Thyroid 2012; 22:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/3\">",
"      Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med 1996; 101:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/4\">",
"      Brooks MH, Waldstein SS. Free thyroxine concentrations in thyroid storm. Ann Intern Med 1980; 93:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/5\">",
"      Ngo SY, Chew HC. When the storm passes unnoticed--a case series of thyroid storm. Resuscitation 2007; 73:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/6\">",
"      Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/7\">",
"      Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/8\">",
"      Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011; 21:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/9\">",
"      Das G, Krieger M. Treatment of thyrotoxic storm with intravenous administration of propranolol. Ann Intern Med 1969; 70:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/10\">",
"      Brunette DD, Rothong C. Emergency department management of thyrotoxic crisis with esmolol. Am J Emerg Med 1991; 9:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/11\">",
"      Milner MR, Gelman KM, Phillips RA, et al. Double-blind crossover trial of diltiazem versus propranolol in the management of thyrotoxic symptoms. Pharmacotherapy 1990; 10:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/12\">",
"      Cooper DS, Saxe VC, Meskell M, et al. Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. J Clin Endocrinol Metab 1982; 54:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/13\">",
"      Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/14\">",
"      Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 1990; 88:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/15\">",
"      Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 1995; 5:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/16\">",
"      Jongjaroenprasert W, Akarawut W, Chantasart D, et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 2002; 12:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/17\">",
"      Hodak SP, Huang C, Clarke D, et al. Intravenous methimazole in the treatment of refractory hyperthyroidism. Thyroid 2006; 16:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/18\">",
"      Giles HG, Roberts EA, Orrego H, Sellers EM. Disposition of intravenous propylthiouracil. J Clin Pharmacol 1981; 21:466.",
"     </a>",
"    </li>",
"    <li>",
"     Gregoire, G, Aris-Jilwan, N, Ninet, B, et al. Intravenous administration of propylthiouracil in treatment of a patient with Graves' disease (abstract). 77th Annual Meeting, The Endocrine Society, 1995, Abstract P3-464.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/20\">",
"      Kandil E, Khalek MA, Thethi T, et al. Thyroid storm in a patient with fulminant hepatic failure. Laryngoscope 2011; 121:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/21\">",
"      Vyas AA, Vyas P, Fillipon NL, et al. Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis. Endocr Pract 2010; 16:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/22\">",
"      Panzer C, Beazley R, Braverman L. Rapid preoperative preparation for severe hyperthyroid Graves' disease. J Clin Endocrinol Metab 2004; 89:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/23\">",
"      Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am 2003; 32:519.",
"     </a>",
"    </li>",
"    <li>",
"     Benua RS, Becker DV, Hurley JR. Thyroid storm. In: Current Therapy in Endocrinology and Metabolism, Bardin CW (Ed), Mosby, St. Louis 1994. p.75.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/25\">",
"      Kinoshita H, Yasuda M, Furumoto Y, et al. Severe duodenal hemorrhage induced by Lugol's solution administered for thyroid crisis treatment. Intern Med 2010; 49:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/26\">",
"      Myung Park J, Seok Lee I, Young Kang J, et al. Acute esophageal and gastric injury: complication of Lugol's solution. Scand J Gastroenterol 2007; 42:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/27\">",
"      Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf) 1988; 28:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/28\">",
"      Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf) 1991; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/29\">",
"      Tsatsoulis A, Johnson EO, Kalogera CH, et al. The effect of thyrotoxicosis on adrenocortical reserve. Eur J Endocrinol 2000; 142:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/30\">",
"      Mazzaferri EL, Skillman TG. Thyroid storm. A review of 22 episodes with special emphasis on the use of guanethidine. Arch Intern Med 1969; 124:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/31\">",
"      Petry J, Van Schil PE, Abrams P, Jorens PG. Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy. Ann Thorac Surg 2004; 77:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33655/abstract/32\">",
"      Koball S, Hickstein H, Gloger M, et al. Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: a case report. Artif Organs 2010; 34:E55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7885 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33655=[""].join("\n");
var outline_f32_55_33655=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13827637\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13827326\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thionamides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3999987\">",
"      - Patients unable to take a thionamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Iodine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1687055\">",
"      Iodinated radiocontrast agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13827734\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1687118\">",
"      Long-term management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13827637\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7885\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7885|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/24/35213\" title=\"table 1\">",
"      Criteria for thyroid storm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/13/16604\" title=\"table 2\">",
"      Preparation of rectal formulations of thionamides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37779?source=related_link\">",
"      Iodinated radiocontrast agents in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/38/10852?source=related_link\">",
"      Iodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/30/41448?source=related_link\">",
"      Treatment of toxic adenoma and toxic multinodular goiter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33656="Cholesterol lowering after an acute coronary syndrome";
var content_f32_55_33656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cholesterol lowering after an acute coronary syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33656/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/55/33656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with an acute coronary syndrome (ACS), including ST elevation (Q wave) myocardial infarction (STEMI), non-ST elevation (non-Q wave) myocardial infarction (NSTEMI), or unstable angina (UA), should receive long-term lipid-lowering therapy with a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This recommendation is largely derived from multiple secondary prevention trials that demonstrated a benefit from statin therapy in patients who had had an ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss when to initiate statin therapy, how to manage patients already on statin, the choice of statin, and how to manage patients with a low baseline low-density lipoprotein cholesterol. General treatment guidelines for hypercholesterolemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVIDENCE OF LONG-TERM BENEFIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of lipid-lowering with dietary intervention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharmacologic therapy, primarily with a statin, was initially demonstrated in patients with elevated serum cholesterol. However, post-MI patients with high normal or only mildly elevated lipid levels also benefit from therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. This was illustrated in the CARE trial, which evaluated the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo in 4159 survivors of acute MI with baseline total cholesterol levels &lt;240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (mean 209",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.4",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After five years,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    therapy produced significant reductions in the combined incidence of coronary death and nonfatal MI (10.2 versus 13.2 percent) (",
"    <a class=\"graphic graphic_figure graphicRef82485 \" href=\"mobipreview.htm?23/30/24045\">",
"     figure 1",
"    </a>",
"    ) and the need for revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) (14.1 versus 18.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIATION OF THERAPY BEFORE DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence that benefit from statin therapy involves mechanisms (referred to as pleiotropic effects) that can be important early after an ACS, including plaque stabilization, reversal of endothelial dysfunction, decreased thrombogenicity, and reduced inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although acute coronary syndromes are usually caused by rupture of an unstable coronary plaque that appears as a single culprit lesion on angiography, systemic changes, including increased markers of inflammation, suggest a more widespread disorder within the coronary circulation that can lead to instability of multiple plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, interventions aimed only at the culprit lesion may not be optimal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=see_link&amp;anchor=H13452891#H13452891\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\", section on 'Vulnerable plaques and future rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pleiotropic effects of statins may produce short-term benefits in the post-ACS coronary circulation, providing the rationale for early initiation of statin therapy during hospitalization for an ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12-18\">",
"     12-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     PROVE IT-TIMI 22 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of this approach was best evaluated in the PROVE IT-TIMI 22 trial, which randomly assigned 4162 patients with an ACS (35 percent STEMI, 36 percent NSTEMI, and 29 percent UA) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12\">",
"     12",
"    </a>",
"    ]. Treatment was initiated within 10 days of presentation, but after PCI if one was performed. Participants were required to have a baseline total cholesterol of 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less, or 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.18",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or less if they were receiving long-term lipid-lowering therapy at the time of their ACS. The median LDL-cholesterol (LDL-C) at initiation of therapy was 106",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.74",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    a mean follow-up of two years, the following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median LDL-C achieved was significantly lower with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (62 versus 95",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.60 versus 2.46",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      The primary end point (all-cause mortality, MI, UA requiring rehospitalization, revascularization more than 30 days after randomization, or stroke) was significantly reduced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (22.4 versus 26.3 percent). The benefit of atorvastatin was apparent as early as 30 days after randomization and was persistent over time.",
"     </li>",
"     <li>",
"      There was a nonsignificant trend toward lower all-cause mortality with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (2.2 versus 3.2 percent).",
"     </li>",
"     <li>",
"      Study medication was discontinued because of myalgias or elevations in serum creatine kinase in approximately 3 percent of patients, independent of drug; there were no cases of rhabdomyolysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subset analysis revealed a trend toward benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    as early as 30 days after the initiation of therapy; the risk reduction was similar to that seen at later time periods. In a second subgroup analysis, the benefit from atorvastatin was significant for patients with a baseline LDL-C &ge;125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (hazard ratio [HR] 0.66) but not for those with a baseline LDL-C &lt;125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (HR 0.93).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     MIRACL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of PROVE IT-TIMI 22 are consistent with earlier findings in the MIRACL trial. In this study, 3086 adults with a non-ST elevation ACS were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo between 24 and 96 hours after hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/13\">",
"     13",
"    </a>",
"    ]. Atorvastatin was associated with a reduction in mean LDL-C concentration from 124 to 72",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.2 to 1.9",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    16 week follow-up, the primary end point (nonfatal MI, cardiac arrest with resuscitation, or recurrent symptomatic ischemia requiring hospitalization) was less frequent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (14.8 versus 17.4 percent for placebo); the benefit was primarily due to a reduction in recurrent symptomatic ischemia requiring emergency hospitalization (6.2 versus 8.4 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H35#H35\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Early use of statins after an ACS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     A to Z trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of early statin therapy seen at one to four months in PROVE IT-TIMI 22 and MIRACL was not reproduced in phase Z of the A to Z trial. In this trial, patients with an ACS were randomly assigned to aggressive statin therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one month, then 80",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to delayed conservative statin therapy (placebo for four months, then simvastatin 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/14\">",
"     14",
"    </a>",
"    ]. At one month and four months, patients in the aggressive therapy arm (taking 40 mg of simvastatin) had a marked reduction in LDL-C concentration, but",
"    <strong>",
"     no",
"    </strong>",
"    reduction (hazard ratio 1.01) in the incidence of the primary end point (cardiovascular death, MI, readmission for ACS, or stroke). In contrast, aggressive simvastatin therapy was associated with a significant reduction in the primary end point from four months to the end of the study (hazard ratio 0.75, 95% CI 0.60-0.95). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H40#H40\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Phase Z of the A to Z trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The difference in early outcomes in PROVE IT-TIMI 22 and Phase Z of the A to Z trial was seen even though the comparison groups (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    and placebo) favored a larger effect in Phase Z. There was no significant difference in outcomes between the trials after four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several factors may contribute to the difference in early outcomes in the two trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      provided a more powerful statin effect than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This was manifested by a greater proportion of patients in PROVE IT-TIMI 22 reaching the dual cutoffs at one year of LDL-C&lt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.82",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      and hs-CRP &lt;2",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      (44 versus 24 percent in Phase Z).",
"     </li>",
"     <li>",
"      The patient populations were different as 79 percent of patients were from the United States in PROVE IT-TIMI 22 compared to 21 percent in Phase Z. This may be an important feature since both trials found substantial (18 to 33 percent) and equivalent risk reductions in the United States patients and small (6 to 8 percent), nonsignificant risk reductions in patients outside the United States. This difference may in part reflect the much higher rate of PCI in the United States in the two trials (79 versus 34 to 44 percent in other countries). Failure to stabilize the culprit lesion with PCI may leave a thrombotic culprit lesion that is able to produce recurrent thrombotic events which are not likely to be prevented by statins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of placebo-controlled trials concluded that early initiation of statin therapy (within 14 days of an ACS) did not reduce death, MI, or stroke at 30 days or four months but did appear to decrease unstable angina at four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the benefits may have been minimized since the meta-analysis excluded the PROVE IT-TIMI 22 trial because it was a comparison of two different statins rather than being placebo-controlled. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was associated with significant benefits compared to the less potent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in PROVE IT-TIMI 22. Furthermore, pravastatin was used in many of the trials in the meta-analysis and, as noted in the preceding section,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    was used in the A to Z trial.",
"   </p>",
"   <p>",
"    All patients with an ACS should receive long-term statin therapy. Thus, the only contested issue is when to start therapy. We feel that the available data support early initiation of statin therapy, particularly since serious adverse effects with this regimen are rare, as noted in the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     At the time of PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;As expected, based on the above evidence, patients with ACS who undergo urgent or emergent percutaneous coronary intervention benefit from the early initiation of statin therapy. The trials supporting this conclusion are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link&amp;anchor=H22#H22\">",
"     \"General principles of the use of intracoronary stents\", section on 'Statin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Continuation of prior statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients taking statins prior to the onset of an ACS, observational data are consistent with the hypothesis that continuation of therapy during hospitalization is associated with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/18,22\">",
"     18,22",
"    </a>",
"    ]. This is consistent with the data from PROVE IT-TIMI 22 and MIRACL showing benefit from early initiation of statin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both of these trials used",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and, in PROVE IT-TIMI 22, this regimen was more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    This raises the issue of whether therapy should be changed in patients in whom prior statin therapy was less intensive.",
"   </p>",
"   <p>",
"    Subset analysis in PROVE IT-TIMI 22 revealed a significant reduction in events at two years with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in patients who had not received prior statin therapy (20.6 versus 25.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, the reduction in events with atorvastatin was much smaller and not significant (27.5 versus 28.9 percent) in the 25 percent of patients who had received prior statin therapy. However, there was no overall statistical difference between the benefits of atorvastatin in these two groups; as a result, the possible lack of benefit in patients already on a statin is at present unproven.",
"   </p>",
"   <p>",
"    We suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    be started in patients who were on a different statin regimen. This is based upon the better outcomes with atorvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in PROVE IT-TIMI 22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12\">",
"     12",
"    </a>",
"    ] and the lack of benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    compared to placebo at one month in Phase Z of the A to Z trial despite a 39 percent reduction in LDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pleiotropic effects of statins'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This is a relatively weak recommendation since there are no convincing data that directly support benefit from switching patients taking another statin to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    . In subgroup analysis in PROVE IT-TIMI 22, 25 percent of patients had been receiving statin therapy and were switched to study drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12\">",
"     12",
"    </a>",
"    ]. In these patients, the benefit from atorvastatin on two-year event rates was small and not significant (27.5 versus 28.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Choice of statin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether the benefits seen with early therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg in patients with ACS represent a class effect of high-intensity statin therapy or are specific to atorvastatin.",
"   </p>",
"   <p>",
"    Although it is generally reasonable to assume class effects of agents such as statins, the contrasting results of PROVE IT-TIMI 22 and Phase Z of the A to Z trial raise the likelihood that the benefits early after an ACS may not be seen equally with all statins.",
"   </p>",
"   <p>",
"    As discussed above, in PROVE IT-TIMI 22",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg showed evidence of superiority to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg during the first 30 days of therapy. In contrast, in Phase Z of the A to Z trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg showed no evidence of benefit during the first 30 days even though the control group was taking a placebo (as compared with a lower intensity statin).",
"   </p>",
"   <p>",
"    Possible explanations for these discordant results include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Only very intensive statin therapy may have early benefits",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      may have benefits not seen with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      and perhaps other statins",
"     </li>",
"     <li>",
"      Chance may have led to positive results in one trial and negative results in the other",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    really has similar benefits in ACS to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , it seems surprising that it could not be demonstrated when compared with placebo, even with a less intensive regimen of simvastatin, since atorvastatin could show benefit in comparison with a moderate dose of another statin.",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg had early clinical benefits in at least two other trials, MIRACL and ARMYDA-ACS.",
"   </p>",
"   <p>",
"    In summary, until other statin regimens have been proven in clinical trials to have early benefits, we do not think it is safe to assume that benefit in ACS is a class effect of all high-intensity statin regimens. We recommend that patients with an ACS receive early therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Low baseline LDL-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue not addressed in the above trials is the efficacy of statin therapy in patients with a baseline LDL-C &le;80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who are not already on a statin.",
"   </p>",
"   <p>",
"    A retrospective study identified 155 such patients with an ACS (mean LDL-C 63",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.6",
"    <span class=\"nowrap\">",
"     mmol/L]);",
"    </span>",
"    follow-up data were available on 132, 63 of whom were discharged on a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/23\">",
"     23",
"    </a>",
"    ]. The only significant difference between the two groups is that the patients discharged on a statin were less likely to have sinus tachycardia on admission (16 versus 30 percent) and were more likely to undergo percutaneous coronary intervention (49 versus 26 percent). At six months, the patients treated with a statin had a significantly lower rate of death, reinfarction, or stroke (9.5 versus 29.0 percent) that was mostly due to a lower rate of death (5 versus 22 percent).",
"   </p>",
"   <p>",
"    An explanation for these findings might be the pleiotropic effects of statins more than cholesterol lowering, although larger studies and clinical trials are required to confirm this initial observation. Another concern might be an LDL-C that is too low. However, in a substudy from PROVE IT-TIMI 22, there was no apparent increase in toxicity and benefit was maintained in patients with four month LDL-C below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and between 40 and 60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.0 and 1.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    compared to those with higher values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pleiotropic effects of statins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Goal LDL-cholesterol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) established guidelines for the secondary prevention of coronary heart disease in 2002 that included an LDL-C goal of &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"mobipreview.htm?11/4/11340\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines did not distinguish between patients with chronic coronary disease and those with an ACS. Similar goals were recommended by American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    on non-ST elevation acute coronary syndromes and ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent studies examined the potential benefit of targeting a lower LDL-C goal. The Heart Protection Study, although not limited to patients who have had an ACS, and two year follow-up from the PROVE IT-TIMI 22 trial demonstrated that benefit from statin therapy is seen with serum LDL-C values below 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and suggested that the goal LDL-C concentration should be 70 to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12,25\">",
"     12,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Heart Protection Study'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'PROVE IT-TIMI 22 trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In July, 2004, the Coordinating Committee of the National Cholesterol Education Program (NCEP) of the National Heart, Lung and Blood Institute proposed modifications to the ATP III guidelines. These guidelines were endorsed by the ACC and the AHA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/10\">",
"     10",
"    </a>",
"    ]. For very high-risk patients, including all patients with an ACS, the proposed recommendations suggest consideration of an optional goal LDL-C below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef67460 graphicRef54585 \" href=\"mobipreview.htm?32/5/32861\">",
"     table 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2007 focused update of the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with ST-elevation MI recommended a target LDL-C level of less than 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    and further reduction to less than 70 mg per dL [1.8",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    was thought reasonable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, an initial retrospective study suggested substantial benefit from statin therapy in previously untreated patients with a baseline LDL-C &le;80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/23\">",
"     23",
"    </a>",
"    ]. This observation is consistent with the recommendations that all patients with an ACS should be treated with statin therapy and are also consistent with the hypothesis that the pleiotropic effects of statins contribute to the therapeutic benefit. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Low baseline LDL-C'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pleiotropic effects of statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;While LDL-C reduction has been considered the primary goal of lipid lowering therapy, the pleiotropic effects of statins (eg, plaque stabilization, reversal of endothelial dysfunction, decreased thrombogenicity, and reduced inflammation) may confer additional benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One effect of statin therapy that has been associated with clinical benefit independent of lipid lowering is reduction in the serum concentration of C-reactive protein (CRP). CRP is an acute phase protein that is present in increased concentrations in the setting of inflammation. The serum CRP concentration is a risk factor for cardiovascular disease and has prognostic importance in patients who have coronary disease. Increased serum CRP concentrations at admission are a marker for a worse short- and long-term prognosis in patients with an ACS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical trials have provided supportive evidence for the suggestion that the benefit of statin therapy after an ACS can be attributed in part to a reduction in serum CRP:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Phase Z of the A to Z trial cited above, patients with an ACS were randomly assigned to aggressive statin therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one month, then 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to delayed conservative statin therapy (placebo for four months, then simvastatin 20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/14\">",
"       14",
"      </a>",
"      ]. The late benefit seen in Phase Z corresponded to the timing of a reduction in serum CRP seen when the dose of simvastatin was increased from 40 to 80",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'A to Z trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In an analysis from the PROVE IT-TIMI 22 trial, there were significant reductions in serum CRP by 30 days in both treatment arms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/26\">",
"       26",
"      </a>",
"      ]. There was only a limited correlation between the achieved levels of CRP and the achieved levels of LDL-C; less than 3 percent of the variance in achieved serum CRP was explained by the variance in achieved LDL-C. Despite the nearly complete independence of these two factors, there was also a linear relationship between the levels of CRP achieved after statin therapy and the risk of recurrent MI or coronary death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H37#H37\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'PROVE IT-TIMI 22 trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a small randomized trial in which 90 consecutive patients with an ACS and elevated baseline CRP were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo, serum CRP levels were similar in the two groups at presentation (60 versus 46",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      but significantly lower in the atorvastatin group four days later at discharge (17 versus 41",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      and at 30 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/27\">",
"       27",
"      </a>",
"      ]. There was no correlation between the changes in CRP and LDL-C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not known if the rapid reduction in serum CRP contributes to the benefit from statin therapy. There is some evidence that CRP directly promotes inflammation and coagulation rather than merely being a marker of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible use of elevations in serum C-reactive protein to identify patients at higher risk who may warrant more aggressive therapy, is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H15#H15\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Possible role of CRP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Initial lipid-lowering therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy should be initiated prior to hospital discharge in all patients with an ACS. Furthermore, therapy should be continued in patients already taking a statin, since cessation of therapy may be associated with worse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, all patients should receive dietary instruction (step II diet). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the results of PROVE IT-TIMI 22 and MIRACL, we recommend therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    early in the hospital course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Among patients who were on a different statin regimen on admission, we suggest switching to atorvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Continuation of prior statin therapy'",
"    </a>",
"    above.) How early has not been defined. The ARMYDA-ACS trial provides evidence that atorvastatin therapy started 12 hours before PCI in patients NSTEMI is associated with significant benefit (primarily a lower rate of periprocedural MI defined by CK-MB rise) and no apparent harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/29\">",
"     29",
"    </a>",
"    ]. Based upon these findings, we recommend initiation of atorvastatin 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    at the time of diagnosis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Initiation of therapy before discharge'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients who were on a different statin regimen on admission, we suggest switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    based in equivalent changes in coronary atherosclerosis in SATURN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Continuation of prior statin therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link&amp;anchor=H3#H3\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\", section on 'Intensive therapy with statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial intensive statin therapy, rather than gradual dose titration upward, is recommended because of the suggestion of benefit in PROVE IT-TIMI 22 within 30 days, an interval before the first serum cholesterol measurement on therapy would usually be obtained. In our view, in the absence of additional data on individual statins, it seems prudent in the setting of an ACS to use the statin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    ) that has shown early benefit.",
"   </p>",
"   <p>",
"    Evaluation of the response to statin therapy after an acute coronary syndrome should be deferred for two months, since acute phase responses and perhaps other factors can transiently lower LDL-cholesterol by 40 to 50 percent and thus, in some patients, cause spuriously normal-appearing levels following an acute coronary syndrome (",
"    <a class=\"graphic graphic_figure graphicRef67633 \" href=\"mobipreview.htm?7/47/7933\">",
"     figure 2",
"    </a>",
"    ). However, the magnitude of this effect, at least soon after hospitalization, appears to be less with current therapies that limit the degree of myocardial injury, such as percutaneous coronary intervention or fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/31\">",
"     31",
"    </a>",
"    ]. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=see_link&amp;anchor=H24362763#H24362763\">",
"     \"Measurement of serum lipids and lipoproteins\", section on 'After an ACS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term LDL-C goals are those recommended for secondary prevention, an issue that is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other dyslipidemias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute MI also may have other lipid abnormalities (eg, low HDL-cholesterol, high triglycerides) that predispose to coronary disease. Patients who have a persistently low HDL-C concentration (&lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.03",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    after the goal LDL-C has been achieved should be started on nonpharmacologic therapy (eg, exercise, smoking cessation, weight loss in obese subjects); niacin or a fibrate can be added if this is ineffective. Since niacin may elicit an acute reduction in blood pressure, we recommend delayed initiation in the ACS patients who are having their anti-anginal medications and vasodilators adjusted.",
"   </p>",
"   <p>",
"    In addition, there may be benefit to lowering serum triglycerides if the value is above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    after appropriate nonpharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential concern with combined statin-fibrate therapy is an increased risk of muscle toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    is the fibrate of choice in this setting because it does not result in increased blood levels of statins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33656/abstract/32\">",
"     32",
"    </a>",
"    ]. Certain statins (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ) appear to have less intrinsic muscle toxicity than other statins. However, combination therapy should be used cautiously and only if the benefit is likely to outweigh the low risk of muscle toxicity. Such an interaction with statin therapy appears to be rare with nicotinic acid. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, JL, Adams, CD, Antman, EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007).",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/4\">",
"      Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/5\">",
"      Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/6\">",
"      Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/7\">",
"      Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/8\">",
"      Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001; 1:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/9\">",
"      Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004; 292:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/10\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/11\">",
"      Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/12\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/13\">",
"      Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/14\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/15\">",
"      Stenestrand U, Wallentin L, Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/16\">",
"      Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/17\">",
"      Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287:3087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/18\">",
"      Spencer FA, Allegrone J, Goldberg RJ, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med 2004; 140:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/19\">",
"      Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006; 113:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/20\">",
"      Brown BG. Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression. Circulation 2006; 113:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/21\">",
"      Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/22\">",
"      Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 2005; 96:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/23\">",
"      Tsai TT, Nallamothu BK, Mukherjee D, et al. Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein&lt;or=80 mg/dl. Am J Cardiol 2005; 96:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/24\">",
"      Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/25\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/26\">",
"      Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/27\">",
"      Macin SM, Perna ER, Far&iacute;as EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005; 149:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/28\">",
"      Bisoendial RJ, Kastelein JJ, Levels JH, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/29\">",
"      Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007; 49:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/30\">",
"      Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/31\">",
"      Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33656/abstract/32\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 100 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-74C7246191-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33656=[""].join("\n");
var outline_f32_55_33656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVIDENCE OF LONG-TERM BENEFIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIATION OF THERAPY BEFORE DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROVE IT-TIMI 22 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MIRACL trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      A to Z trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      At the time of PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Continuation of prior statin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Choice of statin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Low baseline LDL-C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Goal LDL-cholesterol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pleiotropic effects of statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Initial lipid-lowering therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other dyslipidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/100|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/30/24045\" title=\"figure 1\">",
"      Pravastatin CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/47/7933\" title=\"figure 2\">",
"      Short-term effects of MI on blood lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/4/11340\" title=\"table 1\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/46/10989\" title=\"table 2A\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/56/11147\" title=\"table 2B\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31222?source=related_link\">",
"      Measurement of serum lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33657="Hereditary angioedema: Treatment of acute attacks";
var content_f32_55_33657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary angioedema: Treatment of acute attacks",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Bruce Zuraw, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33657/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/55/33657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is a rare disorder characterized by recurrent episodes of well-demarcated angioedema without urticaria, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although swelling resolves spontaneously in two to four days in the absence of treatment, laryngeal edema may cause fatal asphyxiation, and the pain of gastrointestinal attacks may be incapacitating.",
"   </p>",
"   <p>",
"    The evaluation and treatment of acute attacks of HAE in adults and children will be reviewed here. Other aspects of these conditions are discussed elsewhere:",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEDICATION OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The medications used for acute treatment of episodes of angioedema in hereditary angioedema are discussed in this section, with proposed mechanism of action, dosing, efficacy data, and side effects (",
"    <a class=\"graphic graphic_table graphicRef87450 \" href=\"mobipreview.htm?31/29/32220\">",
"     table 1",
"    </a>",
"    ). An approach to using these medications to manage acute angioedema is discussed subsequently. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Approach to treating acute attacks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     C1-inhibitor (plasma-derived)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate",
"    </a>",
"    , also known as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=see_link\">",
"     C1 inhibitor concentrate (human)",
"    </a>",
"    and C1 inhibitor replacement protein (C1INHRP), is obtained from pooled human plasma. It is administered intravenously (IV) for treatment of acute attacks. C1INHRP is the best studied first-line therapy for acute episodes of angioedema in patients with HAE. C1-inhibitor acts at several points in the pathways important in the generation of angioedema (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"mobipreview.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=see_link&amp;anchor=H20554842#H20554842\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two C1INHRP products are derived from pooled human plasma: Cinryze (ViroPharma Inc), and Berinert or Berinert P (both from CSL Behring). Plasma derived products have been available for many years in the EU, Canada, Japan, and Argentina, and became available in the US in",
"    <span class=\"nowrap\">",
"     2008/9",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of C1INHRP for treatment of acute episodes is based upon weight, and the recommended dose is 20",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Each vial of drug contains 500 units of C1INHRP. Thus, doses for patients of different weight ranges are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administer 1000 units if weight is &le;50 kg (110 pounds)",
"     </li>",
"     <li>",
"      Administer 1500 units if weight is &gt;50 kg (110 pounds) and &le;100 kg (220 pounds)",
"     </li>",
"     <li>",
"      Administer 2000 units if weight is &gt;100 kg (220 pounds)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    C1INHRP should be reconstituted, warmed to body temperature before administration, and given through a peripheral vein over 10 minutes. The solution",
"    <strong>",
"     must not be shaken",
"    </strong>",
"    , as this can cause denaturation of the protein. In an emergency, it can be given without prewarming.",
"   </p>",
"   <p>",
"    Stabilization or improvement in symptoms is usually seen within 30 minutes in laryngeal or gastrointestinal attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/5\">",
"     5",
"    </a>",
"    ]. In one author's experience (MC), fewer than 5 percent of attacks require a second dose. However, if symptoms persist, a second dose can be given approximately two hours after the first, and if symptoms are worsening after the initial dose of C1INHRP, a second dose can be administered after 30 minutes.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration has not yet approved Cinryze for treatment of acute attacks (only for prophylaxis). However, there is no empiric reason to suspect that Cinryze would be less effective than the C1 inhibitor products used for years in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Efficacy and adverse effects",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Efficacy",
"    </strong>",
"    &mdash; The efficacy of C1INHRP for treatment of acute attacks of HAE was first reported in 1980 and has been well-demonstrated in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/3,6-11\">",
"     3,6-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest randomized trial of C1INHRP (Cinryze) in the treatment of acute attacks involved 68 patients, assigned to either 1000 units (with the possibility of another 1000 units after one hour based on clinician and patient assessment of need) of C1INHRP, regardless of weight, or placebo for nonlaryngeal attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/11\">",
"       11",
"      </a>",
"      ]. The median time to onset of unequivocal relief (the primary endpoint) was two hours in the C1INHRP group, compared with over four hours in the placebo group.",
"     </li>",
"     <li>",
"      A subsequent randomized trial of 125 patients with acute gastrointestinal or facial cutaneous attacks compared C1INHRP at doses of 10",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      or 20",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/3\">",
"       3",
"      </a>",
"      ]. Patients were treated within five hours of the symptoms reaching moderate intensity. Time to onset of relief was significantly shorter with the higher dose of C1INHRP (0.5 hours) compared to the lower dose of C1INHRP (1.2 hours) or placebo (1.5 hours).",
"     </li>",
"     <li>",
"      The effect of C1INHRP on laryngeal attacks was evaluated in a retrospective study comparing C1INHRP to conservative management in 193 episodes of laryngeal swelling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/10\">",
"       10",
"      </a>",
"      ]. The mean duration of laryngeal edema was 15.3 hours in patients who received C1INHRP concentrate and 101 hours in those who did not. A subsequent nonrandomized trial also confirmed the efficacy of C1INHRP (20",
"      <span class=\"nowrap\">",
"       units/kg)",
"      </span>",
"      in patients with laryngeal edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An observational trial suggested that the response could be improved when patients were able to self-administer C1INHRP at home at the first sign of swelling (C1INHRP \"on demand\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/13\">",
"     13",
"    </a>",
"    ]. The patients in this study had disease that was refractory to prophylactic therapy with androgens, antifibrinolytics, or both. They reported initiation of relief in a mean of approximately 40 minutes after the onset of symptoms, as compared to about 2.5 hours when the patients were dependent on a health care facility for administration.",
"   </p>",
"   <p>",
"    C1INHRP is the preferred treatment for acute attacks in pregnant women with HAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Adverse effects",
"    </strong>",
"    &mdash; Side effects are unusual and include headache and fever. Rare allergic reactions to C1INHRP have been described, which presented as generalized itching, urticaria, and edema of the tongue and oral mucosa, or as anaphylactic shock shortly after infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. A retrospective analysis of the US Food and Drug Administration (FDA) event reporting system database identified an association between thrombotic events and use of Cinryze, although no conclusions about causality or frequency could be made from the data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease transmission is a theoretical risk of C1INHRP treatment, since it is obtained from pooled human plasma that has been pasteurized and ultrafiltrated. However, there have been no reported cases of viral transmission with the most extensively used preparation (Berinert P), despite the administration of over 100 million units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/16,21-23\">",
"     16,21-23",
"    </a>",
"    ]. The issue of disease transmission with C1 inhibitor products is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Overview of available agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no indication that &ldquo;resistance&rdquo; to C1INHRP develops with repeated use, at least in most patients. This was evaluated in a study of 18 patients treated for at least 15 attacks over a mean duration of 34 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/24\">",
"     24",
"    </a>",
"    ]. No decrease in time to relief of symptoms or interval between attacks was observed. However, rare patients have been reported who experience an increase in the frequency of attacks during periods in which C1INHRP was administered for treatment of acute attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/25\">",
"     25",
"    </a>",
"    ]. These patients were not receiving C1INHRP for prophylaxis. C1INHRP infusions remained successful in treating acute symptoms, although the frequency of attacks gradually increased over a period of years. The mechanism responsible for this paradoxical response is not known. It may be related to the production of antibodies to the C1 inhibitor, although this has not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297494\">",
"    <span class=\"h2\">",
"     Recombinant C1-inhibitor (EU only)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant human C1-inhibitor (rhC1INH, conestat alfa) (Ruconest, Pharming Technologies BV in Europe, Rhucin in other countries) became available in Europe in 2011. It is collected from the milk of transgenic rabbits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Compared to the plasma product, rhC1-INH has identical protease inhibitory activity, but a shorter half-life. Thus, higher doses are required to achieve adequate plasma levels, compared to the plasma-derived product.",
"   </p>",
"   <p>",
"    Patients should be screened prior to use for allergic sensitization to rabbit dander and should not receive the medication if skin testing or in vitro IgE immunoassay is positive. The relative advantages and disadvantages of rhC1INH compared with plasma derived C1INHRP have not yet been described. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Efficacy and adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297538\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended dose of Ruconest is 50",
"    <span class=\"nowrap\">",
"     units/kg.",
"    </span>",
"    Patients generally do not require repeat dosing and relapse is not reported. The medication is a lyophilized powder that is reconstituted in sterile water and administered intravenously. The patient should be observed during administration for signs or symptoms of an allergic reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297667\">",
"    <span class=\"h3\">",
"     Effectiveness and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two similar randomized trials, patients received rhC1INH at doses of 100",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    (n = 29), 50 (n = 12)",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    or placebo (n = 29) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/29\">",
"     29",
"    </a>",
"    ]. The primary endpoint was time to the beginning of relief of symptoms, which was a median of 66 minutes (95% CI, 61-122) with the higher dose, 122 (72 to 136) minutes with the lower dose, and 495 (245 to 520) minutes with placebo. In these same groups, 10, 0, and 60 percent of patients did not begin to respond within four hours, but none of the responders relapsed and none required second doses.",
"   </p>",
"   <p>",
"    RhC1INH was well-tolerated at both doses in the previously mentioned studies. A severe allergic reaction was reported in a patient with pre-existing rabbit allergy, hence the recommendation to screen patients for this. No postexposure antibody responses against the product have been detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297196\">",
"    <span class=\"h2\">",
"     Bradykinin B2 receptor antagonist",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     Icatibant",
"    </a>",
"    (Firazyr) is a synthetic bradykinin B2 receptor antagonist, which has been available in the EU since 2008 and became available in the US in 2011 (for patients 18 years of age and older) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. It is a synthetic polypeptide that is structurally analogous to bradykinin and acts by selectively and competitively antagonizing the bradykinin B2 receptor (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"mobipreview.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ). It is approved for treatment of acute attacks of angioedema in adults with C1-inhibitor deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297223\">",
"    <span class=\"h3\">",
"     Icatibant dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    is 30 mg, given by slow subcutaneous",
"    <span class=\"nowrap\">",
"     injection/infusion",
"    </span>",
"    because of the relatively large volume (3 mL) involved, preferably in the abdominal region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/34\">",
"     34",
"    </a>",
"    ]. It can be self-administered.",
"   </p>",
"   <p>",
"    Most patients require only one dose to treat symptoms adequately. However, if clinical response is inadequate, a second injection can be given after six hours and a third injection, if needed, after an additional six hours. A maximum of three doses within 24 hours is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297230\">",
"    <span class=\"h3\">",
"     Studies of efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FAST-1 and FAST-2 trials were randomized, multicenter, phase III trials, in which 130 adults with C1-INH deficiency were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    for acute laryngeal, gastrointestinal, and cutaneous attacks of moderate to severe intensity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/35\">",
"     35",
"    </a>",
"    ]. FAST-1 compared icatibant to placebo, and FAST-2 compared icatibant to oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (TA). The primary endpoint was median time to onset of symptom relief, which was not met in FAST-1 (2.0 with icatibant versus 4.2 hours with placebo), but was met in FAST-2 (2 versus 11 hours with TA). In a pooled analysis of the two trials, significantly more patients receiving icatibant had symptom relief within four hours, compared with placebo or TA (73 versus 45 and 29 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, median time to near-complete symptom relief was significantly shorter with icatibant, compared to placebo or TA (15, 21, and 36 hours, respectively).",
"   </p>",
"   <p>",
"    In a third trial, FAST-3, 83 patients were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    or placebo for moderate to severe attacks at any location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/37\">",
"     37",
"    </a>",
"    ]. Icatibant significantly reduced median times to &ge;50 percent reduction in symptom severity (2.0 versus 19.8 hours, primary endpoint), onset of primary symptom relief (1.5 versus 18.5 hours, secondary endpoint), or near-complete symptom relief (8 versus 36 hours) and provided a shorter time to initial symptom relief (0.8 versus 3.5 hours). For laryngeal attacks, median times to &ge;50 percent reduction in symptom severity were 2.5 and 3.2 hours for icatibant and placebo, respectively. None of the patients receiving icatibant required rescue therapy before symptom relief occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2297237\">",
"    <span class=\"h3\">",
"     Adverse effects and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild and transient injection site reactions are the most common adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    . Other uncommon adverse effects include nausea, gastrointestinal colic, fever, asthenia, dizziness, increase in transaminases, and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/38\">",
"     38",
"    </a>",
"    ]. Icatibant should be used with caution in patients with acute ischemic heart disease or unstable angina, since antagonism of the bradykinin 2 receptor can reduce coronary blood flow in animal models and patients with these comorbidities were excluded from clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Kallikrein inhibitor (US only)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    (Kalbitor, Dyax Corp) is a genetically engineered recombinant plasma kallikrein inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/40\">",
"     40",
"    </a>",
"    ]. This drug blocks the production of bradykinin by inhibiting plasma kallikrein (",
"    <a class=\"graphic graphic_figure graphicRef87451 \" href=\"mobipreview.htm?40/51/41791\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/31,41-45\">",
"     31,41-45",
"    </a>",
"    ]. Ecallantide was approved by the US FDA in 2009 for the treatment of acute attacks of HAE in patients 16 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/46\">",
"     46",
"    </a>",
"    ]. It is only available in the US at present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like C1INHRP,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    is a first-line therapy for acute laryngeal angioedema (following airway protection) and for gastrointestinal attacks. It is occasionally used for severe cutaneous attacks. However, clinical experience with ecallantide is obviously more limited.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    should be administered by a physician or a nurse in a medical setting equipped to manage anaphylaxis, as well as severe angioedema related to HAE. Anaphylaxis and allergic reactions were reported in a small percentage of patients in clinical trials. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Efficacy studies and safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ecallantide dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    is available in 1 mL vials of 10 mg each, and the adult dose is 30 mg. Injections should be given as three separate injections of 10 mg in the abdomen, upper arm, or thigh. The sites of injection should be anatomically distant from the area affected by the angioedema.",
"   </p>",
"   <p>",
"    A second dose of 30 mg may be administered if symptoms persist. Based on limited information, the second dose could be given as early as 1 hour and up to 24 hours after the first dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy studies and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    was assessed in two Dyax-sponsored randomized trials, EDEMA3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/35\">",
"     35",
"    </a>",
"    ] and EDEMA4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/47\">",
"     47",
"    </a>",
"    ]. In an analysis of the pooled data from these studies, 143 subjects were treated with either ecallantide or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/48\">",
"     48",
"    </a>",
"    ]. All types of attacks occurred (gastrointestinal, laryngeal, and cutaneous), with gastrointestinal attacks being most common. Change from baseline mean symptom complex score (MSCS) at four hours after dosing was significantly greater in the ecallantide group compared with the placebo group (-0.97 &plusmn; 0.78 and -0.47 &plusmn;0.71, respectively). The percentages of ecallantide- and placebo-treated patients with meaningful improvement at four hours were 70 and 38, respectively.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     Ecallantide",
"    </a>",
"    caused allergic reactions and anaphylaxis in approximately 2.7 percent of patients receiving it subcutaneously in the clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/35,47\">",
"     35,47",
"    </a>",
"    ]. Anaphylaxis presented within one hour of administration as rhinitis, chest discomfort, flushing, pharyngeal edema, pruritus, urticaria, wheezing,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension. One-half of patients received epinephrine. Because some symptoms of anaphylaxis overlap with those of HAE (ie, angioedema, throat discomfort), clinicians must observe patients carefully following administration. Anaphylaxis may occur with the first or any subsequent dose. Until more information is available, patients experiencing anaphylaxis or clear symptoms of hypersensitivity should not be given the drug again until evaluated by an allergy specialist. In addition, ecallantide must be administered in a supervised setting by a medically trained provider.",
"   </p>",
"   <p>",
"    Other adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    were generally mild and included headache, nausea, fatigue, and diarrhea (in 16, 13, 12, and 11 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/47\">",
"     47",
"    </a>",
"    ]. Injection site reactions were reported in 7 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma is a second-line therapy in the treatment of acute laryngeal attacks and severe gastrointestinal attacks, and should be used only if the therapies discussed above are not available. There have been no studies directly comparing plasma with C1INHRP,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Plasma is available as",
"    <span class=\"nowrap\">",
"     solvent/detergent-treated",
"    </span>",
"    plasma",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    plasma) or fresh frozen plasma (FFP).",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma carries a lower risk of viral transmission compared with FFP, although most of the case reports of HAE treatment used FFP. This is potentially relevant, because",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    treatment removes some plasma components, and the effect on C1 inhibitor specifically has not been investigated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing of plasma preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two units of plasma are given initially. This dose can be repeated every two to four hours until there is clinical improvement. Once the attack begins to subside, further plasma is not usually required. If a patient has comorbid conditions that increase the risk for volume overload, then dosing of 10 to 15 mL per kg body weight is recommended instead, with monitoring of volume status and cardiopulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of plasma in treating acute attacks has been suggested by case reports; no controlled trials have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. The majority of reports used fresh frozen plasma (FFP) because this was the leading therapy for acute attacks in the United States for many years. A review of the literature included 23 case reports in which FFP was used for treatment of acute attacks, and revealed improvement in 22 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/57\">",
"     57",
"    </a>",
"    ]. The time to first signs of improvement ranged from 30 minutes to 12 hours. No clinical improvement was noted in one case, and transient worsening of symptoms, followed by improvement, was reported in two cases. Plasma could theoretically exacerbate angioedema because it contains not only C1 inhibitor, but also substrate proteins (prekallikrein and high molecular weight kininogen) that could consume the available inhibitor and paradoxically worsen the angioedema, although this has been reported only rarely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data on",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma are scant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/58\">",
"     58",
"    </a>",
"    ], and we know of no reports comparing",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma and FFP for the treatment of acute angioedema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=see_link\">",
"     \"Clinical use of plasma components\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary concern with plasma products is disease transmission, and the risks of this must be presented to the patient prior to each administration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Solvent/detergent",
"      </span>",
"      treatment inactivates enveloped viruses (such as HIV, HTLV, and hepatitis B and C), but not prions or non-enveloped viruses (eg, hepatitis A, parvovirus).",
"     </li>",
"     <li>",
"      FFP does not undergo processing to remove infectious agents; however, it is obtained from single-donor units rather than pooled plasma, and each unit undergoes serological testing for viral markers. The risk of infection for a unit of FFP is identical to that of red blood cells, which are also obtained from single donors. The risk of disease transmission from red blood cells (and FFP) is summarized in the table and presented in more detail elsewhere (",
"      <a class=\"graphic graphic_table graphicRef69661 \" href=\"mobipreview.htm?30/59/31676\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=see_link\">",
"       \"Transfusion transmitted HIV infection and AIDS\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2859370\">",
"    <span class=\"h2\">",
"     Cost of first-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;All first-line therapies for acute attacks of HAE are costly. In the US, the cost of one treatment with C1INHRP,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    ranged from $5000 to $10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/59\">",
"     59",
"    </a>",
"    ]. The cost of one treatment with C1INHRP, rhC1INH, or icatibant in the European Union is about 1500 to 2000 euros.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Ineffective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angioedema of HAE responds poorly or not at all to treatments for allergic angioedema, including epinephrine, antihistamines, and glucocorticoids.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are isolated case reports suggesting benefit from epinephrine in HAE attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. However, most experts believe it is not helpful in the majority of cases, and do not recommend its use. The pharmacologic effects of epinephrine do not address the known pathophysiologic perturbations underlying C1 inhibitor deficiency, although its action on the alpha-1 receptors may help decrease mucosal edema.",
"     </li>",
"     <li>",
"      Glucocorticoids and antihistamines are NOT effective for angioedema associated with disorders of C1 inhibitor and should not be given once the diagnosis of a C1 inhibitor disorder has been made.",
"     </li>",
"     <li>",
"      A few studies have examined the effects of inhaled or injected",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or heparin-like compounds in treating (and preventing) the symptoms of HAE attacks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/62-64\">",
"       62-64",
"      </a>",
"      ]. However, more data are needed before this therapy can be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATING ACUTE ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attacks of HAE or acquired angioedema that involve the airway are potentially life-threatening. In contrast, gastrointestinal attacks can range from mild to severe, but usually resolve without serious complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/65\">",
"     65",
"    </a>",
"    ]. Cutaneous attacks are not associated with substantial morbidity, although patients' lives can be significantly disrupted by repeated episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Consensus guidelines for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, a multinational committee formulated evidence based recommendations for the management of adolescents and adults with hereditary angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/66\">",
"     66",
"    </a>",
"    ]. These guidelines expanded upon previous recommendations and incorporated randomized trials of the newer therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/2,67\">",
"     2,67",
"    </a>",
"    ]. The approach presented in this topic review is consistent with these guidelines.",
"   </p>",
"   <p>",
"    There is also a guideline for the management of women with hereditary angioedema, which reviews the data about treatment of acute angioedema during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26697634\">",
"     'Pregnant women'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The mechanisms, dosing, side effects, and efficacy of the different agents were reviewed previously. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Medication options'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LARYNGEAL ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal attacks are the most dangerous type of attack because edema can lead to fatal airway obstruction. Airway angioedema usually progresses over hours, although it can escalate precipitously. Intubation may become very difficult due to distortion of the anatomy of the upper airway. Patients who have first-line therapies at home and self-administer an initial dose should still seek medical care promptly, in case further intervention is required. Features of laryngeal attacks and patterns of progression are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link&amp;anchor=H14#H14\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Laryngeal attacks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment and protection of the upper airway is the first and most important management issue in the patient with an acute attack involving any part of the airway, because none of the available therapies, including C1-inhibitor replacement (C1INHRP),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , can be considered universally effective in all cases. In addition, these agents take time to work, and the patient's airway must be protected in the interim.",
"   </p>",
"   <p>",
"    Intubation should be performed immediately if stridor or signs of respiratory arrest are present. A clinician trained in difficult airway management should be summoned if possible, because failed attempts can lead to fatal obstruction. Emergent cricothyroidotomy may be required in rare cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the patient is assessed and either intubated or deemed stable, additional therapies can be considered. Transfer to the intensive care unit should be arranged. Frequent and meticulous monitoring of airway status should continue throughout the course of the attack until complete resolution, and patients should not be discharged until all airway symptoms have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     First-line therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line pharmacotherapy should consist of either a C1-inhibitor product (C1INHRP or rhC1INH),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    (only in the US) (",
"    <a class=\"graphic graphic_table graphicRef87450 \" href=\"mobipreview.htm?31/29/32220\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69098 \" href=\"mobipreview.htm?25/14/25836\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/2,10,66,68\">",
"     2,10,66,68",
"    </a>",
"    ]. The efficacy of these three agents has not been compared in a head-to-head manner, so the choice of agent usually depends upon availability. Dosing is described above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'C1-inhibitor (plasma-derived)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2297494\">",
"     'Recombinant C1-inhibitor (EU only)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2297223\">",
"     'Icatibant dose and administration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Ecallantide dosing and administration'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;If none of the first-line therapies is available, other options for acute laryngeal attacks are",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treated plasma (preferred) or fresh frozen plasma (",
"    <a class=\"graphic graphic_table graphicRef69098 \" href=\"mobipreview.htm?25/14/25836\">",
"     table 3",
"    </a>",
"    ). The risks of disease transmission must be discussed with the patient prior to administration (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Risks'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient with known or suspected HAE presents with gastrointestinal colic, the clinician must determine if the",
"    <strong>",
"    </strong>",
"    abdominal symptoms are actually due to angioedema or to an unrelated process. Patients who have had previous gastrointestinal attacks should be questioned carefully to ascertain if their current symptoms are similar to past episodes.",
"   </p>",
"   <p>",
"    Gastrointestinal attacks present with varying degrees of gastrointestinal colic, nausea, vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea, which result from bowel wall edema. The clinical presentation and evaluation of gastrointestinal attacks is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=see_link&amp;anchor=H15#H15\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\", section on 'Gastrointestinal attacks'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment of angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line therapies are (",
"    <a class=\"graphic graphic_table graphicRef69098 \" href=\"mobipreview.htm?25/14/25836\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/2,10,66,68\">",
"     2,10,66,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A C1-inhibitor product (plasma-derived or recombinant)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      (only in the US)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing is described above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'C1-inhibitor (plasma-derived)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2297494\">",
"     'Recombinant C1-inhibitor (EU only)'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2297223\">",
"     'Icatibant dose and administration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Ecallantide dosing and administration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Dosing of plasma preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinical response to one of these first-line therapies is a valuable tool in distinguishing gastrointestinal attacks of C1 inhibitor disorders from other abdominal pathologies. With all of the first-line therapies, clinical response should be evident within two hours. If there is no response after the initial dose, then evaluation for other problems should proceed.",
"   </p>",
"   <p>",
"    If none of the first-line therapies (C1INHRP,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    ) is available, then management of gastrointestinal attacks is largely supportive. Two units of fresh frozen plasma can be administered, after the patient is informed about risk of disease transmission. Dosing is reviewed above. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Dosing of plasma preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Rehydration and symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy to abort the attack is most important, but some (not all) patients with gastrointestinal attacks also require treatment for dehydration and pain. The following are sometimes required:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IV rehydration with normal saline.",
"     </li>",
"     <li>",
"      For pain:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      , 100 mg orally (or 75 mg intravenously if vomiting) daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      , 50 mg orally or intravenously every four to six hours as needed (maximum 300 mg per day for five days) for adults.",
"     </li>",
"     <li>",
"      Parenteral narcotics, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      , 75 mg administered intramuscularly, may be administered for severe pain. However, as with any chronic disease, a small subset of patients may make inappropriate use of narcotics, although the vast majority does not. Any patient who is experiencing regular attacks requiring emergency care should be reevaluated to assess compliance with prophylactic therapy. Adjustments in prophylactic medications may be necessary. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Care following attacks'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For gastrointestinal cramping: butylscopolamine (not available in the US), 20 mg intravenously every four to six hours as needed for adults.",
"     </li>",
"     <li>",
"      For nausea and vomiting:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      (10 mg intravenously or intramuscularly, every two to three hours for adults) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      (25 mg rectally every 12 hours for adults).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     CUTANEOUS ATTACKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cutaneous attacks usually do not require treatment in the emergency setting (",
"    <a class=\"graphic graphic_table graphicRef69098 \" href=\"mobipreview.htm?25/14/25836\">",
"     table 3",
"    </a>",
"    ). However, if the attack is severe or disfiguring, the following options are suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C1 inhibitor: Dosing is described above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'C1-inhibitor (plasma-derived)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      : Dosing is described above. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Kallikrein inhibitor (US only)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"      : Dosing is described above. (See",
"      <a class=\"local\" href=\"#H2297196\">",
"       'Bradykinin B2 receptor antagonist'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26697634\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred treatment of acute attacks of HAE in pregnant women is plasma-derived C1INHRP because there is extensive experience with the products that have been available in the EU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/17\">",
"     17",
"    </a>",
"    ]. Few data are available regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"     icatibant",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    , or recombinant C1INH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Care following attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following any acute attack, events leading up to the attack should be examined to determine if an identifiable trigger was present. Based on our experience, common nontraumatic triggers include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regularly missing doses of medication",
"     </li>",
"     <li>",
"      Running out of medication",
"     </li>",
"     <li>",
"      Initiating interfering medications (such as estrogens or ACE inhibitors)",
"     </li>",
"     <li>",
"      Narcotic addiction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discussing these common errors with the patient directly after an event should help prevent repetition of the same mistake. In addition, the clinician should review how and when the patient sought medical attention, and whether the written plan of action was available and utilized. It has been the experience of the authors that such review sessions are consistently illuminating and critical to improving care.",
"   </p>",
"   <p>",
"    If no precipitating trigger can be identified, then preventative therapy should be increased. As an example, we suggest increasing the dose of C1INHRP or shortening the interval between infusions, or for patients taking long-term androgen prophylaxis, increasing the daily dose by 50 to 100 percent. Prophylactic therapy for HAE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Home therapy for acute attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option for the treatment of acute attacks of all types is home-based administration of one of the acute therapies \"on demand\" (ie, at the first sign of symptoms) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33657/abstract/66,69\">",
"     66,69",
"    </a>",
"    ]. It is important that patients be able to quickly and efficiently administer the therapies to themselves (ie, be capable of self-infusing without difficulty in the case of C1INH replacement) or else have a trained health care provider who can come to the home quickly (in the case of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"     ecallantide",
"    </a>",
"    ). We also advise patients who treat at home that they should still seek urgent care for laryngeal attacks, even though they have self-administered or received a first-line therapy, because of the unpredictable nature of airway angioedema. For example, patients should administer C1INHRP (or another suitable therapy) and then immediately proceed to a medical facility for observation (preferably not driving themselves).",
"   </p>",
"   <p>",
"    Although this approach is technically a form of acute treatment, it is reviewed separately with other forms of outpatient management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=see_link&amp;anchor=H39#H39\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Long-term prophylactic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema is a rare condition characterized by recurrent episodes of angioedema affecting the upper airway, bowel wall, or skin. Laryngeal swelling can result in fatal asphyxiation. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with laryngeal attacks require immediate assessment of the airway. Those with respiratory distress or stridor may require intubation, because even the most effective therapies take approximately 30 minutes or more to begin working. An expert should manage the airway if possible. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Laryngeal attacks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Airway management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that patients with any severity of laryngeal attack, moderate to severe gastrointestinal attacks, or severe cutaneous attacks be treated with a first-line therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). First-line therapies for HAE are (",
"      <a class=\"graphic graphic_table graphicRef87450 \" href=\"mobipreview.htm?31/29/32220\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Human plasma-derived",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/57/23444?source=see_link\">",
"       C1 inhibitor concentrate",
"      </a>",
"      (C1INHRP). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'C1-inhibitor (plasma-derived)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recombinant human C1 inhibitor (available only in the European Union). (See",
"      <a class=\"local\" href=\"#H2297494\">",
"       'Recombinant C1-inhibitor (EU only)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/36/4675?source=see_link\">",
"       Icatibant",
"      </a>",
"      , a bradykinin B2 receptor antagonist. (See",
"      <a class=\"local\" href=\"#H2297196\">",
"       'Bradykinin B2 receptor antagonist'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/23/23923?source=see_link\">",
"       Ecallantide",
"      </a>",
"      , a kallikrein inhibitor (available only in the US). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Kallikrein inhibitor (US only)'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These agents have not been compared in a head-to-head manner, so the choice of agent should be based upon availability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If none of the first-line agents are available, then the approach to treatment depends upon the type of attack:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with laryngeal edema or severe, debilitating gastrointestinal attacks, we suggest either solvent-detergent treated plasma or fresh frozen plasma (FFP) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Laryngeal attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild to moderate gastrointestinal attacks, we suggest supportive therapy (rehydration and symptomatic therapy) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with cutaneous attacks not involving skin adjacent to the airway, we suggest no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After an acute attack, the patient's situation should be evaluated to determine what factors contributed to triggering the attack. If no factors are identified, then prophylactic medications should be increased. As an example, a patient receiving C1 inhibitor prophylactically may require more frequent dosing. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Other issues'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11799266\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors of this topic and the editorial staff at UpToDate, Inc. would like to acknowledge Dr. Albert L Sheffer, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/1\">",
"      Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/2\">",
"      Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/3\">",
"      Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/4\">",
"      Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/5\">",
"      Martinez-Saguer I, Rusicke E, Ayg&ouml;ren-P&uuml;rs&uuml;n E, et al. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Transfusion 2010; 50:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/6\">",
"      Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 1980; 44:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/7\">",
"      Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996; 334:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/8\">",
"      Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998; 38:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/9\">",
"      De Serres J, Gr&ouml;ner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. jean.de.serres@aventis.com. Transfus Apher Sci 2003; 29:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/10\">",
"      Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/11\">",
"      Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/12\">",
"      Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010; 30:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/13\">",
"      Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006; 117:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/14\">",
"      Hermans C. Successful management with C1-inhibitor concentrate of hereditary angioedema attacks during two successive pregnancies: a case report. Arch Gynecol Obstet 2007; 276:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/15\">",
"      Caliskaner Z, Ozturk S, Gulec M, et al. A successful pregnancy and uncomplicated labor with C1INH concentrate prophylaxis in a patient with hereditary angioedema. Allergol Immunopathol (Madr) 2007; 35:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/16\">",
"      Farkas H, Jakab L, Temesszentandr&aacute;si G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/17\">",
"      Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/18\">",
"      Zingale LC, Pappalardo E, Zanichelli A, Cicardi M. C1 inhibitor concentrate: efficacy and adverse reaction. Int Immunopharmacol 2002; 318:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/19\">",
"      Cicardi M, Zingale L. How do we treat patients with hereditary angioedema. Transfus Apher Sci 2003; 29:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/20\">",
"      Gandhi PK, Gentry WM, Bottorff MB. Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting System Database. Pharmacotherapy 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/21\">",
"      Agostoni A, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/22\">",
"      Cicardi M, Zingale LC, Zanichelli A, et al. The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema. Expert Opin Pharmacother 2007; 8:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/23\">",
"      Gr&ouml;ner A, Nowak T, Sch&auml;fer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012; 52:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/24\">",
"      Craig TJ, Bewtra AK, Hurewitz D, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 2012; 33:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/25\">",
"      Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009; 122:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/26\">",
"      Choi G, Soeters MR, Farkas H, et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007; 47:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/27\">",
"      Koles K, van Berkel PH, Pieper FR, et al. N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits. Glycobiology 2004; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/28\">",
"      van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005; 116:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/29\">",
"      Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/30\">",
"      Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 2011; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/31\">",
"      Han Lee ED, Pappalardo E, Scafidi J, Davis AE 3rd. Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett 2003; 89:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/32\">",
"      Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/33\">",
"      Icatibant: HOE 140, JE 049, JE049. Drugs R D 2004; 5:343.",
"     </a>",
"    </li>",
"    <li>",
"     Information about Firazry. file://emc.medicines.org.uk/medicine/21761/SPC/Firazyr%2030%20mg%20solution%20for%20injection%20in%20pre-filled%20syringe/#POSOLOGY (Accessed on February 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/35\">",
"      Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/36\">",
"      Riedl M. Icatibant, a selective bradykinin B2 receptor antagonist, proves effective and safe in treating the symptoms of hereditary angioedema (HAE) attacks. J Allergy Clin Immunol 2008; 121:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/37\">",
"      Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B��� receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/38\">",
"      Deeks ED. Icatibant. Drugs 2010; 70:73.",
"     </a>",
"    </li>",
"    <li>",
"     file://emc.medicines.org.uk/medicine/21761/SPC/Firazyr (Accessed on September 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/40\">",
"      Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther 2008; 8:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/41\">",
"      Schneider L, Lumry W, Vegh A, et al. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/42\">",
"      Turner MD, Oughourli A, Heaney K, Selvaggi T. Use of recombinant plasma kallikrein inhibitor in hereditary angioedema: a case report and review of the management of the disorder. J Oral Maxillofac Surg 2004; 62:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/43\">",
"      Lehmann A. Ecallantide (Dyax/Genzyme). Curr Opin Investig Drugs 2006; 7:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/44\">",
"      Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/45\">",
"      Frank MM, Jiang H. New therapies for hereditary angioedema: disease outlook changes dramatically. J Allergy Clin Immunol 2008; 121:272.",
"     </a>",
"    </li>",
"    <li>",
"     Approval history is available on the FDA website. file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist/ (Accessed on September 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/47\">",
"      Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/48\">",
"      Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 2011; 128:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/49\">",
"      Kreuz W, Fischer D, Martinez-Saguer I, et al. C1-esterase inhibitor substitution in hereditary angioedema. Biomed Prog 1999; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/50\">",
"      Zuraw BL. Diagnosis and management of hereditary angioedema: an American approach. Transfus Apher Sci 2003; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/51\">",
"      Pickering RJ, Good RA, Kelly JR, Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/52\">",
"      Cohen G, Peterson A. Treatment of hereditary angioedema with frozen plasma. Ann Allergy 1972; 30:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/53\">",
"      Atkinson JP. Diagnosis and management of hereditary angioedema (HAE). Ann Allergy 1979; 42:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/54\">",
"      Beck P, Willis D, Davies GT, et al. A family study of hereditary angioneurotic oedema. Q J Med 1973; 42:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/55\">",
"      Hill BJ, Thomas SH, McCabe C. Fresh frozen plasma for acute exacerbations of hereditary angioedema. Am J Emerg Med 2004; 22:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/56\">",
"      Pekdemir M, Ersel M, Aksay E, et al. Effective treatment of hereditary angioedema with fresh frozen plasma in an emergency department. J Emerg Med 2007; 33:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/57\">",
"      Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/58\">",
"      Longhurst HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence? Int J Clin Pract 2005; 59:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/59\">",
"      Three new drugs for hereditary angioedema. Med Lett Drugs Ther 2010; 52:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/60\">",
"      Roth M, Schreier L, Cutler R. Adrenalin treatment for hereditary angioneurotic edema. Ann Allergy 1975; 35:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/61\">",
"      Trachsel D, Hammer J. A vote for inhaled adrenaline in the treatment of severe upper airway obstruction caused by piercing of the tongue in hereditary angioedema. Intensive Care Med 1999; 25:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/62\">",
"      Majluf-Cruz A, Nieto-Mart&iacute;nez S. Long-term follow up analysis of nadroparin for hereditary angioedema. A preliminary report. Int Immunopharmacol 2011; 11:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/63\">",
"      Weiler JM, Quinn SA, Woodworth GG, et al. Does heparin prophylaxis prevent exacerbations of hereditary angioedema? J Allergy Clin Immunol 2002; 109:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/64\">",
"      Perricone R, De Carolis C, Fontana L. Intravenous heparin did not prevent exacerbations of hereditary angioedema in a patient on maintenance hemodialysis. J Allergy Clin Immunol 2003; 111:1137; reply 1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/65\">",
"      Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/66\">",
"      Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/67\">",
"      Bowen T, Brosz J, Brosz K, et al. Management of hereditary angioedema: 2010 Canadian approach. Allergy Asthma Clin Immunol 2010; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/68\">",
"      Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33657/abstract/69\">",
"      Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol 2007; 147:11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8104 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-27EA24A548-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33657=[""].join("\n");
var outline_f32_55_33657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEDICATION OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      C1-inhibitor (plasma-derived)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Efficacy and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2297494\">",
"      Recombinant C1-inhibitor (EU only)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297538\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297667\">",
"      - Effectiveness and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2297196\">",
"      Bradykinin B2 receptor antagonist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297223\">",
"      - Icatibant dose and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297230\">",
"      - Studies of efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2297237\">",
"      - Adverse effects and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Kallikrein inhibitor (US only)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ecallantide dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy studies and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Plasma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing of plasma preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2859370\">",
"      Cost of first-line therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Ineffective therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      APPROACH TO TREATING ACUTE ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Consensus guidelines for treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LARYNGEAL ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      First-line therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      GASTROINTESTINAL ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment of angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Rehydration and symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      CUTANEOUS ATTACKS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26697634\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Care following attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Home therapy for acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11799266\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8104|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/51/41791\" title=\"figure 1\">",
"      HAE pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8104|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/29/32220\" title=\"table 1\">",
"      Tx acute HAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/59/31676\" title=\"table 2\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/14/25836\" title=\"table 3\">",
"      Therapy for different types of acute HAE attacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/33/9752?source=related_link\">",
"      Clinical use of plasma components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33658="Therapeutic use and toxicity of high-dose methotrexate";
var content_f32_55_33658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use and toxicity of high-dose methotrexate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Ann S LaCasce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/55/33658/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/55/33658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Folate antagonists were among the first antineoplastic agents to be developed. In 1948, aminopterin was used to induce remission in childhood acute lymphoblastic leukemia (ALL), and the related agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) is still an important component of modern treatment for ALL as well as a number of other hematologic malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/1\">",
"     1",
"    </a>",
"    ]. MTX was the first drug shown to cure a cancer when given as monotherapy, and single agent MTX remains a cornerstone of treatment for malignant gestational trophoblastic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The broad range of antitumor activity seen with MTX is reflected in the large number of malignant conditions for which MTX is a component of the treatment regimen (",
"    <a class=\"graphic graphic_table graphicRef60020 \" href=\"mobipreview.htm?12/27/12731\">",
"     table 1",
"    </a>",
"    ). Furthermore, in addition to antiproliferative activity, MTX also has antiinflammatory and immunomodulating properties, leading to its use in a wide range of doses for a broad range of therapeutic indications across multiple specialties (",
"    <a class=\"graphic graphic_table graphicRef76707 \" href=\"mobipreview.htm?0/7/120\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will cover the clinical use of high-dose MTX for treatment of malignancy, focusing on the prevention and management of toxicity. Intrathecal use of MTX and clinical use of low-dose and intermediate-dose MTX for both malignant and nonmalignant conditions are covered elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF HIGH-DOSE MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The side effect profile of MTX varies markedly according to dose. Regimens containing MTX are classified as high, intermediate, or low-dose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most clinicians reserve the term high-dose MTX (HDMTX) for doses &ge;500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      as are used for central nervous system (CNS) prophylaxis in patients with leukemia and high-risk lymphoma, and for the treatment of leptomeningeal metastases, primary CNS lymphoma, and osteosarcoma. These regimens deliver an otherwise lethal dose of MTX in a 4 to 36 hour infusion, followed by a two to three day period of multiple",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      doses to terminate the toxic effect of MTX (termed leucovorin \"rescue\"). Successful rescue by leucovorin depends on rapid elimination of MTX by the kidneys, which requires aggressive pretreatment as well as posttreatment hydration and urinary alkalinization. The main toxicities of HDMTX are elevated serum transaminase levels and renal insufficiency, which can delay drug clearance.",
"     </li>",
"     <li>",
"      Doses between 50 and 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      as used for malignant gestational trophoblastic disease (GTD), are considered intermediate-dose MTX. In general, these patients do not require aggressive hydration or urinary alkalinization.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      rescue is rarely needed with doses &le;250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      unless unexpected toxicity is encountered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link&amp;anchor=H11#H11\">",
"       \"Gestational trophoblastic neoplasia: Staging and treatment\", section on 'Methotrexate with and without leucovorin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low-dose MTX (&lt;50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      is used intravenously for the treatment of bladder and breast cancer and desmoid tumors, and orally for patients with T-cell large granular lymphocyte (LGL) leukemia, ALL, acute promyelocytic leukemia, mycosis fungoides, and various nonmalignant immune-mediated disorders (",
"      <a class=\"graphic graphic_table graphicRef76707 \" href=\"mobipreview.htm?0/7/120\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The side effect profile of chronic low-dose oral MTX, as used for the treatment of nonmalignant disorders, differs from that of cyclical parenteral administration in the setting of cancer, particularly with regard to myelosuppression, hepatic fibrosis, and pulmonary toxicity. The major side effects of low-dose oral MTX for nonmalignant disorders are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low doses of MTX (typically 12 mg total dose) also can be given intrathecally for treatment of leptomeningeal metastases or CNS prophylaxis in patients with leukemia or high-risk lymphoma. In this setting, the major toxicities are neurologic; there is a very small risk of myelosuppression because MTX is eliminated from the cerebrospinal fluid by slow passive diffusion into the systemic circulation. Because of this, some experts recommend a short course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue in this situation, particularly for patients with renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX enters the cell via the same energy-dependent, saturable carrier protein that transports naturally occurring folates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Some tumors have reduced or no transport capability; in such cases, high extracellular concentrations of MTX permit the drug to enter the cell by passive diffusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A third mechanism of MTX entry is through endocytosis, mediated by folate binding proteins, which may be overexpressed in malignant as compared to normal cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69716673\">",
"    <span class=\"h3\">",
"     Interference with folate metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiproliferative activity of antifolates such as MTX results from interference with folate metabolism. A normal dividing cell uses large amounts of reduced folates to maintain ongoing purine and thymidine synthesis (",
"    <a class=\"graphic graphic_figure graphicRef52756 \" href=\"mobipreview.htm?9/39/9847\">",
"     figure 1",
"    </a>",
"    ); demand is even greater for rapidly dividing malignant cells.",
"   </p>",
"   <p>",
"    Several key enzymes of these synthetic pathways are targets of MTX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The critical factor for the cell's ongoing production of thymidylate, and to a lesser extent the purines, is its ability to regenerate reduced folates from the oxidized forms. The key enzyme in this process is dihydrofolate reductase (DHFR), which converts dihydrofolate to tetrahydrofolate, thus continuously replenishing the cell's supply of reduced folates. Competitive inhibition of DHFR represents the main mechanism of action for antifolates such as MTX, but other synthetic enzymes are also inhibited by polyglutamated forms of MTX (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Importance of polyglutamation'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Within the thymidine synthetic pathway, the enzyme thymidylate synthetase (TS) uses a methyl group from the reduced folate, 5-methylenetetrahydofolate, to synthesize deoxythymidylate monophosphate (dTMP) from deoxyuridylate monophosphate (dUMP).",
"     </li>",
"     <li>",
"      Within the purine synthetic pathway, the enzymes glycinamide ribonucleotide transformylase (GARFT) and aminoimidazole carboxamide transformylase (AICARFT) both use the formyl groups of the reduced folate N(10)-formyltetrahydofolate to initiate synthesis of adenosine and guanosine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intracellularly, MTX competitively inhibits DHFR because it has a higher affinity for the enzyme than the naturally occurring dihydrofolate. The depletion of reduced folates (tetrahydrofolates) causes an abrupt cessation of thymidine synthesis, DNA synthesis, and eventually cell death. This process is accentuated in rapidly dividing cells (ie, those in the S-phase of the cell cycle), which require more DNA precursors. As a result, MTX is considered an S-phase specific cytotoxic drug.",
"   </p>",
"   <p>",
"    The level of DHFR in any given cell is in great excess of what is needed to provide normal levels of reduced folates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, tetrahydrofolate synthesis continues until more than 95 percent of DHFR activity has been inhibited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, high levels of MTX are required to successfully compete with other folates for DHFR binding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h4\">",
"     Importance of polyglutamation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As part of normal cellular physiology, multiple glutamate residues are added to carboxyfolates by the enzyme folyl polyglutamate synthetase (FPGS), a process referred to as polyglutamation (",
"    <a class=\"graphic graphic_figure graphicRef52756 \" href=\"mobipreview.htm?9/39/9847\">",
"     figure 1",
"    </a>",
"    ). Polyglutamation increases the intracellular pool of folates, as polyglutamated folates are not easily transported out of the cell because of their size and charge. Folate polyglutamation also influences the equilibrium balance in favor of continual cellular uptake of folates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/5,11\">",
"     5,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When significant intracellular levels are present, MTX is polyglutamated by the same enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/12\">",
"     12",
"    </a>",
"    ]. However, in most cell lines studied, conversion to polyglutamated MTX (PGMTX) does not occur until cells have been exposed to the drug for at least six hours at concentrations of at least 2",
"    <span class=\"nowrap\">",
"     micromoles/liter",
"    </span>",
"    (2 microM, 2 X 10 [-6] M) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. These concentrations are easily achievable in plasma with HDMTX but not with intermediate or low-dose regimens.",
"   </p>",
"   <p>",
"    The accumulation of PGMTX metabolites serves to further amplify and prolong the antiproliferative effects of MTX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracellular accumulation and decreased efflux of PGMTX enhances and prolongs inhibition of DHFR, since PGMTX is less readily dissociable from the enzyme than is free MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/8,10\">",
"       8,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polyglutamated forms of MTX also bind to other enzymes involved in DNA synthesis such as TS, AICARFT, and GARFT; this further depletes intracellular thymidine and inhibits purine synthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Inhibition of TS also leads to accumulation of dUMP, which cannot be incorporated into DNA, further disrupting DNA synthesis and repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Besides being a main determinant of antitumor activity, MTX polyglutamation is also thought to be mainly responsible for the greater incidence and severity of all HDMTX-related side effects when there is prolonged MTX excretion or if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue is delayed beyond 36 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/10,16-18\">",
"     10,16-18",
"    </a>",
"    ]. Higher plasma MTX concentrations and longer exposure times increase the formation of longer polyglutamated MTX molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/8,13,19,20\">",
"     8,13,19,20",
"    </a>",
"    ]. When the polyglutamated tail has a larger number of glutamic acid residues (ie, greater than five), there is greater affinity for DHFR and TS, and degradation and diffusion out of the cell is slowed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, variability in polyglutamation between tumor cells and normal (nonmalignant) cells is thought to provide at least part of the explanation for why",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    can selectively rescue normal cells from the effects of HDMTX but does not compromise tumor cell cytotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69716653\">",
"    <span class=\"h3\">",
"     Other mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to involvement of pathways involved in folate metabolism, newer data suggest that upregulation of mitochondrial enzymes involved in the metabolism of serine and glycine may also influence tumor cell sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/21\">",
"     21",
"    </a>",
"    ]. Whether this finding is relevant to all tumors, especially osteosarcoma, is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Rationale for leucovorin rescue",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with many other anticancer drugs, MTX has little selectivity for tumor cells, and its effectiveness is limited by toxicity to normal tissue, particularly the gastrointestinal (GI) epithelium and bone marrow. To improve the therapeutic index of MTX, Goldin developed the concept of rescuing normal cells from toxicity by providing reduced folates (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , also called folinic acid, N5-formyl-tetrahydrofolate, citrovorum factor) to bypass the metabolic block induced by MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/22\">",
"     22",
"    </a>",
"    ]. In these pioneering experiments, administration of leucovorin within 24 to 36 hours after administration of MTX was able to prevent MTX-induced host toxicity without diminishing antitumor activity.",
"   </p>",
"   <p>",
"    The reason why",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    selectively rescues normal but not malignant cells is incompletely understood. The original premise that providing reduced folate would circumvent the metabolic block produced by MTX is not easily explained except in situations where folate transport is deficient in the malignant cells. In such cases, leucovorin cannot be transported into the malignant cell, but it can enter normal cells and compete with MTX for binding sites on DHFR because they retain a normal folate carrier protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]. If leucovorin is present in sufficient quantities, the enzyme is reactivated, and purine and thymidine synthesis can be reinitiated. This situation is thought to be relatively uncommon.",
"   </p>",
"   <p>",
"    As noted above, cellular differences in polyglutamation have been suggested as an alternative explanation for selective",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue. Intracellularly, leucovorin is able to compete with free but not polyglutamated MTX for binding to DHFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast to tumor cells, comparatively little PGMTX synthesis occurs in normal gut epithelium and bone marrow precursors under similar conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/18,24\">",
"     18,24",
"    </a>",
"    ]. It is hypothesized that because of the lower levels of intracellular PGMTX, leucovorin can more effectively curtail DHFR inhibition in normal as compared to malignant cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/11,14,18,24-26\">",
"     11,14,18,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    can only rescue normal cells that have not already had lethal DNA damage from the toxic effects of MTX. Thus, to be effective, treatment with leucovorin must be initiated within 24 to 36 hours of starting HDMTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7\">",
"     7",
"    </a>",
"    ]. Issues relevant to the dose, route of administration, and duration of leucovorin rescue after HDMTX are discussed below. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Leucovorin administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Resistance to MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplastic cells may be innately resistant or acquire resistance to MTX. As an example, MTX is not a useful agent for treatment of acute myeloid leukemia because the leukemic cells cannot polyglutamate the drug once it enters the cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More often resistance is acquired through one or more of the following mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/3,27-29\">",
"     3,27-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased drug transport due to gene mutations or a change in the rate of transcription of the folate carrier",
"     </li>",
"     <li>",
"      Increased DHFR activity, typically due to gene amplification",
"     </li>",
"     <li>",
"      Mutations in the DHFR protein, which decrease its affinity for MTX",
"     </li>",
"     <li>",
"      Decreased cellular polyglutamation of MTX due to increased folyl polyglutamate hydrolase activity or decreased FPGS activity",
"     </li>",
"     <li>",
"      Decreased TS activity or affinity for the folate antagonists",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the frequent development of acquired resistance, MTX is not typically used as a single agent for treatment of aggressive malignancy with the exception of primary CNS lymphoma, head and neck cancer, and malignant GTD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pharmacokinetics, metabolism, and excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when given identical doses of HDMTX, patients vary significantly in their response and pattern of toxicity. This diversity can, to some extent, be linked to sequence variations in genes involved in drug absorption, metabolism, excretion, cellular transport, and effector targets or target pathways. A review of advances in the individual prediction of MTX toxicity and the impact of genetic polymorphisms on MTX efficacy and toxicity is beyond the scope of this review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of pharmacogenomics\", section on 'Drug transport'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following IV administration, MTX is widely distributed through the body. In the serum, approximately 50 percent is",
"    <span class=\"nowrap\">",
"     protein/albumin-bound",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/10\">",
"     10",
"    </a>",
"    ]. Peak serum levels following MTX doses &gt;1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are in the range of 500 to 1500 microM (50 to 150 X 10 [-5] M) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/30\">",
"     30",
"    </a>",
"    ]. The overall half-life following IV administration is between 8 and 12 hours.",
"   </p>",
"   <p>",
"    The decay curve varies widely: 30 to 300 microM (3 to 30 X 10 [-5] M) at 24 hours; 3 to 30 microM (3 to 30 X 10 [-6] M) at 48 hours; &lt;0.3 microM (&lt;3 x 10 [-7] M) at 72 hours. Levels in excess of 5 to 10 microM (5 to 10 x 10 [-6] M) at 24 hours, 1 microM (1 x 10 [-6] M) at 48 hours, and 0.1 micro M (1 x 10 [-7] M) at 72 hours portend greater toxicity, and must be managed by increasing intravenous hydration and augmenting the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Management of patients with renal failure and prolonged high plasma MTX levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because MTX is not a lipophilic compound, it penetrates only slowly across intact cellular barriers such as the vascular endothelium. Third-space fluid collections (eg, ascites, pleural effusions) can accumulate high levels of the drug that slowly leak back into the circulation long after the initial dose. Particularly if renal function is impaired, this can result in prolonged drug elimination and severe delayed toxicity. If possible, these fluid collections should be drained prior to administration of HDMTX.",
"   </p>",
"   <p>",
"    MTX also crosses the blood-brain barrier (BBB). The level of cerebrospinal fluid (CSF) penetration is variable but CSF levels are approximately 3 to 10 percent of plasma concentrations. Thus, high serum levels (typically requiring IV administration of MTX doses &ge;1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    are required to achieve therapeutic concentrations in the CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Excretion and metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost 90 percent of MTX is excreted unchanged in the urine, the bulk within 12 hours of administration. Although the mechanism of MTX excretion in the human kidney has not been completely elucidated, the finding that MTX clearance exceeds creatinine clearance in several studies suggests that there is active tubular secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with renal insufficiency require MTX dose adjustment. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Pretreatment assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Many drugs inhibit renal excretion of MTX and may increase treatment-related toxicity. These include NSAIDs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , penicillin-type drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and proton pump inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/11,33,34\">",
"     11,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concurrent use of the antibiotic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    increases treatment-related toxicity and, at least in theory, may also interfere with antitumor efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Sulfa drugs inhibit MTX renal excretion, while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    (also an antifolate) can compete with MTX for binding sites on the DHFR molecule.",
"   </p>",
"   <p>",
"    During HDMTX infusion, rapid drug excretion leads to high MTX concentrations in the urine. These concentrations, approaching 10 mM, exceed the solubility of the drug below pH 7.0 and are thought responsible for intrarenal precipitation of the drug and renal failure. Renal failure interferes with MTX excretion, predisposing patients to potentially severe mucosal toxicity and myelosuppression. In order to prevent intrarenal precipitation, hydration and urinary alkalinization are recommended for HDMTX regimens. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Renal toxicity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H30\">",
"     'Hydration and urinary alkalinization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although most MTX is excreted unchanged in the urine, a small amount of the administered dose is excreted unchanged into the bile and undergoes enterohepatic circulation; this is neither clinically relevant nor harmful.",
"   </p>",
"   <p>",
"    Approximately 10 percent of the parent drug is metabolized to 7-hydroxymethotrexate by hepatic aldehyde oxidase. This metabolite is a less potent inhibitor of DHFR but can contribute to renal toxicity due to its lower water solubility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/10\">",
"     10",
"    </a>",
"    ]. Due to its longer half-life, the serum concentration of 7-hydroxymethotrexate may exceed that of MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A less important metabolite, 4-amino-4-deoxy-N10-methylpteroic acid (dAMPA), is produced by bacteria in the intestine as a very small percentage of the administered dose and is not clinically relevant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OVERVIEW OF ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDMTX can be associated with multiple potential adverse effects, some of which are related to both drug dose and duration of drug exposure; some are idiosyncratic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX has the potential for hepatotoxicity at all doses. The association between MTX and hepatic dysfunction has been studied most extensively in patients receiving chronic oral low-dose MTX for psoriasis and rheumatoid arthritis. Hepatotoxicity can be manifested as a mild transaminitis, but patients are at risk for fibrosis and cirrhosis when the total dose exceeds 1.5 to 2 grams. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HDMTX can cause an acute elevation in the serum transaminases from two to twenty-fold normal levels, even in patients who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue. Acute transaminitis occurs in as many as 60 to 80 percent of patients and typically resolves spontaneously within one to two weeks. If the level of alanine transferase (ALT) has not returned to less than 180",
"    <span class=\"nowrap\">",
"     IU/L",
"    </span>",
"    by the beginning of the next treatment cycle, the next dose should be reduced",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed.",
"   </p>",
"   <p>",
"    Rarely, HDMTX causes a temporary elevation in serum bilirubin, which usually normalizes within a few days. Subsequent cycles do not require dose reduction unless the peak serum bilirubin level exceeds 3",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients receiving IV MTX for treatment of cancer, hepatic fibrosis (with a subsequent risk for hepatocellular cancer) is reported only rarely. All cases have been in children receiving MTX for acute lymphoblastic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H25#H25\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other hepatotoxic medications and alcohol should be avoided during HDMTX therapy, if at all possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nausea, vomiting, and stomatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX doses above 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are considered moderately emetogenic; smaller doses have low or minimal emetogenic potential (",
"    <a class=\"graphic graphic_table graphicRef58756 \" href=\"mobipreview.htm?7/23/7549\">",
"     table 3",
"    </a>",
"    ). In keeping with guidelines from the American Society of Clinical Oncology (ASCO), patients receiving MTX &ge;250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    should be pretreated with a serotonin receptor antagonist and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucositis is typically avoided in patients who undergo successful",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue. Mucositis may be severe after HDMTX if leucovorin rescue is delayed or in the setting of prolonged elevated serum levels (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Rationale for leucovorin rescue'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Renal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;At low doses, MTX is not nephrotoxic. However, HDMTX can affect the kidneys in two different ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MTX can precipitate in the tubules and directly induce tubular injury. The risk is increased in the presence of acidic urine (since MTX and its two major metabolites are poorly soluble at an acid pH), with volume depletion (which decreases urine flow rate and increases the concentration of MTX in tubular fluid) and when high plasma MTX concentrations are sustained.",
"     </li>",
"     <li>",
"      MTX also causes a transient decline in glomerular filtration rate (GFR) after each dose, with complete recovery within six to eight hours. The mechanism responsible for this functional renal impairment involves afferent arteriolar constriction or mesangial cell constriction. The effect can be exacerbated when additional nephrotoxic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) are administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MTX-induced acute renal failure is typically nonoliguric and is reversible in almost all cases. Plasma creatinine levels usually peak within the first week and return toward baseline levels within one to three weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=see_link&amp;anchor=H4164341#H4164341\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major risk with MTX-induced renal dysfunction is that MTX clearance is severely compromised, resulting in delayed excretion of the drug, higher than expected plasma concentrations, and increased systemic toxicity.",
"   </p>",
"   <p>",
"    The likelihood of MTX-induced renal dysfunction in patients receiving HDMTX can be minimized (but not eliminated) by hydration both to maintain a high urine flow and to lower the concentration of MTX in the tubular fluid and by alkalinization of the urine to a pH above 7.0. Raising the urine pH from 5.0 to 7.0 increases the solubility of MTX ten-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Hydration and urinary alkalinization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite these measures, the risk of renal failure after HDMTX is still approximately 2 percent. In a review of the literature and clinical trial reports of children treated with HDMTX for osteosarcoma after 1980, a time during which hydration and alkalinization were administered routinely, the incidence of renal dysfunction was 1.8 percent and the mortality among patients who developed renal dysfunction was 4.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/41\">",
"     41",
"    </a>",
"    ]. The incidence may be higher in adults.",
"   </p>",
"   <p>",
"    Management of patients with renal failure and prolonged excretion of MTX is discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Management of patients with renal failure and prolonged high plasma MTX levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hematologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the situation with low-dose oral MTX, in which hematologic toxicity can be the major dose-limiting side effect, there is usually little evidence of treatment-related myelosuppression following HDMTX with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue. Myelosuppression may become evident if rescue is delayed or in the setting of prolonged elevated serum levels. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Rationale for leucovorin rescue'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of lung toxicity most frequently seen in patients treated with MTX is a hypersensitivity pneumonitis. Although this most often occurs after long-term oral therapy, pulmonary toxicity can occur following HDMTX. In contrast to bone marrow and GI epithelial toxicity, the repletion of folate stores does",
"    <strong>",
"     not",
"    </strong>",
"    reduce the risk for MTX pulmonary toxicity, suggesting that it results from an idiosyncratic mechanism unrelated to folate antagonism.",
"   </p>",
"   <p>",
"    The majority of patients who develop pulmonary toxicity do so within the first year of therapy, although cases are reported as early as 12 days and as late as 18 years after drug initiation. The presentation may be acute, subacute, or chronic. Subacute presentations are most common, manifesting with dyspnea, nonproductive cough, fever, crackles on auscultation of the lungs, hypoxemia, and peripheral blood eosinophilia in up to one-half of affected patients. Widespread interstitial lung opacities are the earliest radiographic findings and may progress rapidly to patchy acinar consolidation.",
"   </p>",
"   <p>",
"    For patients who develop pulmonary findings during treatment, the drug should be discontinued and an infectious etiology for the pulmonary findings excluded. If symptoms, radiographic findings, or physiologic abnormalities persist despite drug discontinuation or if the patient is severely ill, glucocorticoids are indicated, although they have varying degrees of success. This topic is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=see_link\">",
"     \"Methotrexate-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute or subacute encephalopathy is the most important neurotoxicity of HDMTX. This complication is characterized by somnolence, confusion, and seizures within 24 hours of treatment. Symptoms usually resolve spontaneously without sequelae, and retreatment is often possible. Neurologic toxicity of MTX is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=see_link&amp;anchor=H2#H2\">",
"     \"Neurologic complications of non-platinum cancer chemotherapy\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dermatologic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 5 to 10 percent of patients develop a nonspecific morbilliform drug rash, which is usually erythematous, pruritic, and often confined to the neck and trunk. In severe cases, it can progress to bullous formation or desquamation. MTX can also cause photoreactivation and photoenhancement as well as skin hyperpigmentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alopecia is occasionally encountered but is usually not complete. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44232?source=see_link\">",
"     \"Chemotherapy-induced alopecia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;True hypersensitivity reactions to MTX are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/42\">",
"     42",
"    </a>",
"    ]. Successful rechallenge has been reported using a desensitization protocol. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ONCOLOGIC INDICATIONS FOR HDMTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (HDMTX) is a component of modern treatment protocols for certain leukemias, high-risk peripheral as well as central nervous system lymphomas, osteosarcoma, and is an alternative to intrathecal (IT) MTX for treatment of leptomeningeal metastases.",
"   </p>",
"   <p>",
"    The specific dose and schedule of HDMTX vary according to the disease and the specific regimen and are discussed in depth under the specific disorders. The following sections provide a brief overview as to how HDMTX is incorporated into the treatment of these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Leukemia and lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemic and lymphomatous meningitis are fairly common at presentation; the incidence is between 3 and 5 percent. Furthermore, central nervous system (CNS) relapse develops in 5 to 10 percent of patients.",
"   </p>",
"   <p>",
"    For non-Hodgkin lymphomas, the risk of CNS disease is greatest in patients with highly aggressive lymphomas (eg, Burkitt's lymphoma) and in patients with aggressive lymphomas who have advanced disease. Specific risk factors for lymphomatous meningitis include aggressive histologic features, a high International Prognostic Index (IPI), multiple extranodal sites, disease involving the sinuses, testes, and possibly the bone marrow (this is quite controversial), and in patients with HIV disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Acute lymphoblastic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least in part due to the gradual shift away from radiation therapy for CNS prophylaxis, many if not all protocols for treating acute lymphoblastic leukemia (ALL) incorporate HDMTX to provide systemic and CNS cytotoxic effects.",
"   </p>",
"   <p>",
"    There is no \"standard\" method of administering HDMTX for ALL. The dose, infusion duration, and timing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue vary markedly among various protocols (",
"    <a class=\"graphic graphic_table graphicRef72577 \" href=\"mobipreview.htm?1/15/1277\">",
"     table 4",
"    </a>",
"    ). A major area of controversy is whether higher peak plasma MTX levels (as can be achieved with higher doses given over a shorter period of time) or greater AUC (area under the concentration x time curve, achieved with longer infusion times and lower doses) correlate best with clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific protocols that incorporate HDMTX into treatment are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Primary CNS lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDMTX is the mainstay of most treatment regimens for primary CNS lymphoma. It has been used as the sole therapeutic agent as well as in multi-agent chemotherapy regimens, with or without radiotherapy. Response rates and outcomes are superior when HDMTX is combined with radiation therapy, but toxicity rates are higher, especially in elderly patients who receive both MTX and radiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment and prognosis of primary central nervous system lymphoma\", section on 'Initial Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Systemic non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDMTX is an integral component of therapeutic regimens for the highly aggressive Burkitt lymphomas to treat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevent CNS involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HDMTX (or intrathecal MTX) is also employed for CNS prophylaxis in patients with certain diffuse large B cell lymphomas that are associated with a high risk of CNS relapse, as well as in patients with known CNS involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=see_link\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Osteosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the recognition that almost all osteosarcomas have micrometastatic disease at diagnosis even if they appear localized, systemic chemotherapy has become an integral part of curative therapy for this disease. The majority of pediatric protocols include HDMTX at doses range from 8 to 12",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef68668 \" href=\"mobipreview.htm?11/40/11917\">",
"     table 5",
"    </a>",
"    ). Many studies indicate a correlation between peak MTX plasma levels, tumor response, and long-term outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H3#H3\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of adjuvant HDMTX is more controversial in adults with osteosarcoma because randomized studies have failed to show an advantage for higher as compared to intermediate doses of MTX or for HDMTX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    versus",
"    <span class=\"nowrap\">",
"     doxorubicin/cisplatin",
"    </span>",
"    alone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H9#H9\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Choice of regimen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HDMTX is also an important agent for metastatic osteosarcoma; response rates, when used as a single agent in the metastatic setting, are in the range of 30 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=see_link&amp;anchor=H14#H14\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\", section on 'Treatment of patients with metastatic disease at diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Leptomeningeal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX is the chemotherapeutic agent most commonly used for IT chemotherapy in patients with leptomeningeal metastases. Furthermore, systemic administration of HDMTX is the most widely used alternative to IT chemotherapy in this setting. The level of cerebrospinal fluid (CSF) penetration is variable but CSF levels are approximately 3 to 10 percent of plasma concentrations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=see_link\">",
"     \"Treatment of leptomeningeal metastases (carcinomatous meningitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PRACTICAL TIPS FOR MANAGING HDMTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the specific details of MTX dose, infusion duration, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue are generally disease- and protocol-specific. However, there are some general aspects of HDMTX administration and posttreatment management that are common to all regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pretreatment assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDMTX requires central venous access or excellent large-caliber peripheral venous access and at least two to three days of inpatient care. Although outpatient administration of HDMTX is feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/46\">",
"     46",
"    </a>",
"    ], it requires a highly motivated and reliable patient, daily outpatient visits, and rigorous attention to hydration status, urinary output, and urine pH. The development of nausea or diarrhea leading to volume depletion renders outpatient management unsuitable.",
"   </p>",
"   <p>",
"    As noted above, patients with ascites or pleural effusions can accumulate MTX in these \"third spaces\", which can lead to delayed elimination as the MTX slowly leaches out of the fluid collection, particularly if renal function is impaired. If present, these effusions should be treated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drained prior to the first dose of MTX. If this is not feasible, the possibility that plasma MTX levels may remain elevated for longer than 72 hours should be anticipated. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pharmacokinetics, metabolism, and excretion'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because MTX is cleared predominantly by the kidney, assessment of renal function is necessary prior to each dose of HDMTX. Dose reduction may be warranted for GFR (as estimated by the creatinine clearance, CrCl) &lt;80",
"    <span class=\"nowrap\">",
"     mL/min:",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CrCl",
"      61 to 80",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Reduce dose to 75 percent of usual dose",
"     </li>",
"     <li>",
"      CrCl 51 to 60",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Reduce dose to 70 percent of usual dose",
"     </li>",
"     <li>",
"      CrCl 10 to 50",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Reduce dose to 30 to 50 percent of usual dose",
"     </li>",
"     <li>",
"      CrCl &lt;10",
"      <span class=\"nowrap\">",
"       mL/minute",
"      </span>",
"      &mdash; Avoid use of MTX",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no consensus on how best to periodically assess CrCl during treatment regimens that include drugs that are dependent on renal elimination. Some protocols require 24-hour urine collection and measurement of CrCl as an obligatory part of each pre-dose evaluation. However, it is not clear that 24-hour urine collection is necessary or sufficient for all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/47\">",
"     47",
"    </a>",
"    ]. Some studies suggest greater accuracy for estimating CrCl (and therefore, GFR) using the Wright formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/48\">",
"     48",
"    </a>",
"    ], the Cockcroft-Gault formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/49\">",
"     49",
"    </a>",
"    ], or by use of the simplified MDRD (modification of diet in renal disease) equation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, any estimation of GFR based upon either a 24-hour urine collection or calculated from the serum creatinine is imprecise, and a patient may be incorrectly labeled as having a low GFR. This must be considered when weighing the potential risk of increased drug toxicity in a patient with reduced GFR against the potential benefit to be derived from therapy. These issues are addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=see_link&amp;anchor=H2#H2\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Estimation of GFR for possible dose adjustment'",
"    </a>",
"    .) The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for CKD, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines_commentaries.cfm\">",
"     National Kidney Foundation's",
"    </a>",
"    website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5670353\">",
"    <span class=\"h3\">",
"     Use of proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coadministration of proton pump inhibitors (PPIs) such as such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    appears to be a major risk factor for delayed elimination of MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/34,50,51\">",
"     34,50,51",
"    </a>",
"    ]. Although the mechanism underlying this interaction is unclear, PPIs should be avoided, if possible, during HDMTX treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Prevention and management of HDMTX toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guiding principles for prevention of HDMTX toxicity, namely maintaining urine output, urinary alkalinization, monitoring serum creatinine, electrolytes, and plasma MTX concentrations, and pharmacokinetically-guided",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue, are also the cornerstones of management for patients who develop early signs of renal dysfunction and delayed MTX elimination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Hydration and urinary alkalinization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintaining adequate hydration and urine output are essential for rapid clearance of MTX. Most protocols recommend at least 2.5 to 3.5",
"    <span class=\"nowrap\">",
"     liters/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of IV fluid hydration per day, starting four to 12 hours prior to the initiation of the MTX infusion.",
"   </p>",
"   <p>",
"    The pH of the urine should be measured at baseline. As noted above, MTX precipitates in acid urine; maintaining the urine pH 7.0 or higher increases MTX solubility, prevents drug precipitation in renal tubules, and drastically decreases the chance of renal damage. In clinical practice, it is customary to begin the MTX infusion only after the urine pH is &ge;7.0 and to maintain it in this range until plasma MTX levels have declined to less than 0.1 microM.",
"   </p>",
"   <p>",
"    Urinary alkalinization is most easily accomplished by adding ampules of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    to each liter of IV fluid hydration. This accomplishes both fluid hydration and urinary alkalinization.",
"   </p>",
"   <p>",
"    A typical choice is IV D5W with 100 to 150 mEq of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    per liter, administered by continuous infusion at 125 to 150",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"    A cation concentration of 80.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    is roughly equivalent to one-half normal saline. The amount of bicarbonate in each liter and the IV fluid composition can then be modified according to the urine pH and serum sodium. If only 50 mEq of sodium bicarbonate is added to each liter of IV fluid, clinicians should be aware that the resultant fluid will be hypotonic if D5W is used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link&amp;anchor=H8#H8\">",
"     \"Maintenance and replacement fluid therapy in adults\", section on 'Replacement fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    dosing can be accomplished intermittently either by the IV or oral route:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      50 mL of D5W containing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"      can be infused IV over 30 minutes every four or six hours.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      can also be given starting with two x 650 mg tablets, and increased up to five tablets every two to four hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with continuous administration of IV bicarbonate-containing fluid, the urine pH should be &ge;7.0 before the MTX infusion is begun, and urine pH must be monitored closely until serum MTX levels are below 0.1 microM to ensure that the urine is still adequately alkalinized. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Laboratory monitoring during treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some protocols restrict dietary intake of acidic foods (eg, orange juice, tomato products) during HDMTX treatment until levels are below 0.1 microM. There are no data to support benefit from this practice, and as long as urine pH can be maintained above 7.0, dietary restriction is unnecessary. Others recommend avoidance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs and vitamins (particularly vitamin C) until plasma MTX levels are less than 0.1 microM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Leucovorin administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    rescue should be started within 24 to 36 hours of the start of the MTX infusion. Most American patients receive a racemic mixture of d,l-leucovorin (leucovorin or leucovorin calcium). However, the l-isomer is the biologically active moiety (ie, has the capacity to rescue cells from MTX toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/52\">",
"     52",
"    </a>",
"    ]), and an intravenous preparation of l-leucovorin is now commercially available in the US (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    , Fusilev). It is dosed at one-half that of d,l leucovorin.",
"   </p>",
"   <p>",
"    A variety of dosing schedules have been published, but most administer 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV or 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium orally (or 5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     levoleucovorin",
"    </a>",
"    IV) every six hours until plasma MTX levels are less than 0.05 to 0.1 microM. The size and number of leucovorin doses do not appear to be critical in patients who have normal MTX clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7\">",
"     7",
"    </a>",
"    ]. Even doses of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    are often in excess of those required to achieve rescue in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/53\">",
"     53",
"    </a>",
"    ]. In contrast, higher concentrations of leucovorin are needed if rapid elimination of MTX is compromised by renal insufficiency. Management of leucovorin in patients with delayed elimination and prolonged elevated plasma MTX levels is discussed below. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Increased dose and frequency of leucovorin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067627855\">",
"    <span class=\"h4\">",
"     Oral versus IV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orally administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    can successfully reverse MTX toxicity. The inactive d-isomer has a longer plasma half-life than the active l-isomer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/54\">",
"     54",
"    </a>",
"    ], and at least in theory, repeated parenteral administration of the d,l racemic mixture may result in selective accumulation of the inactive d-isomer, which could, at least in theory, compete with the active isomer for cellular uptake, compromising efficacy. Since the active l-isomer is preferentially absorbed from the intestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/55\">",
"     55",
"    </a>",
"    ], oral rather than IV administration of leucovorin calcium may be preferred in this setting as long as the dose is less than 50 mg.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    is not available as an oral preparation.",
"   </p>",
"   <p>",
"    For doses higher than 50 mg, oral bioavailability of the active l-isomer is significantly decreased, and IV administration of either the d,l racemic mixture or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     levoleucovorin",
"    </a>",
"    is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Laboratory monitoring during treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine and electrolytes as well as plasma MTX levels should be followed daily. A rise in the serum creatinine above normal values indicates renal dysfunction and the potential for delayed MTX elimination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/53\">",
"     53",
"    </a>",
"    ]. It is mandatory that all patients receiving HDMTX have plasma MTX levels determined after dosing. Monitoring of serum creatinine alone is inadequate since there are large interindividual variations in MTX clearance and a poor correlation between serum creatinine and MTX clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is customary to assay plasma MTX levels at 24, 48, and 72 hours after the start of the MTX infusion. For 24-hour infusional regimens, the initial MTX measurement may be at 36 hours (ie, 12 hours after the completion of the infusion).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    doses are then adjusted based upon the MTX drug levels, and",
"    <span class=\"nowrap\">",
"     hydration/alkalinization",
"    </span>",
"    is continued or increased provided that adequate urine output can be maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/59\">",
"     59",
"    </a>",
"    ]. Drug levels should continue to be monitored with ongoing alkaline hydration and leucovorin rescue until they are &lt;0.05 to 0.1 microM (&lt;0.05 to 0.1",
"    <span class=\"nowrap\">",
"     microgram/mL).",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Management of patients with renal failure and prolonged high plasma MTX levels'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early studies conducted in the 1970s revealed that the following drug levels after MTX infusion indicated a high risk for bone marrow and gastrointestinal mucosal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/53,57,60-62\">",
"     53,57,60-62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Levels above 5 to 10 microM at 24 hours",
"     </li>",
"     <li>",
"      Levels above 0.9 to 1 microM at 48 hours",
"     </li>",
"     <li>",
"      Levels above 0.1 microM at 72 hours",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies also showed that the risk of MTX-associated toxicity is minimal in the absence of elevated MTX concentrations, and that in most circumstances, the development of MTX-associated toxicities can be ameliorated or prevented when patients with MTX drug levels in this range at these time points receive pharmacokinetically-guided doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Management of patients with renal failure and prolonged high plasma MTX levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed renal elimination can result in elevated plasma MTX levels for as long as two to three weeks, which increases systemic toxicity. Risk factors contributing to renal failure and delayed clearance of MTX include urine pH &lt;7, less than 3",
"    <span class=\"nowrap\">",
"     L/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    of IV fluid hydration per 24 hours, high body mass index, use of comedications with nephrotoxic potential or known interference with MTX elimination (eg, salicylates, nonsteroidal antiinflammatory drugs, beta-lactam antibiotics, sulfonamides, aminoglycosides, and proton pump inhibitors), preexisting hepatic or renal dysfunction, and the presence of third-space fluid collections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this setting, the risk of treatment-related toxicity may be diminished by the following maneuvers:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Augmenting urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the rate of MTX elimination is dependent on urine output, hydration and urinary alkalinization should be continued or increased, provided that adequate urine output can be maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Increased dose and frequency of leucovorin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the reversal of MTX action by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    is competitive, proportionately higher leucovorin concentrations are required to achieve rescue in the presence of high MTX levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7,53,64\">",
"     7,53,64",
"    </a>",
"    ]. In one study, five of 12 patients with 48-hour MTX levels &gt;0.9 microM who were treated with leucovorin doses 6 to 30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    developed toxicity, compared to none of those who received 50 to 150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/53\">",
"     53",
"    </a>",
"    ]. Others have observed occasional patients with delayed MTX clearance and sustained plasma levels &gt;10 microM in whom toxicity seemed to improve when large doses of leucovorin were given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific dose modification schema for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    varies broadly among protocols and institutions. The following table shows a typical pharmacokinetically-guided schedule for dose adjustment of leucovorin (the d,l racemic mixture) based upon plasma MTX levels used in our institutions (",
"    <a class=\"graphic graphic_table graphicRef51155 \" href=\"mobipreview.htm?8/49/8988\">",
"     table 6",
"    </a>",
"    ). Guidelines for dose and schedule adjustments for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    in patients with delayed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    clearance recommended by the manufacturer are outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef64297 \" href=\"mobipreview.htm?8/39/8827\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The dosage interval for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    has been derived empirically; the half-life of its primary active metabolite is approximately four to six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/55\">",
"     55",
"    </a>",
"    ]. The benefit of dosing every three to four as compared to every six hours has not been proven, although mean plasma levels are two to three times higher with every three hour administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/66\">",
"     66",
"    </a>",
"    ]. The duration of leucovorin rescue is often more critical than the dose or dosing interval, since elevated plasma levels may persist for several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted previously,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    selectively rescues normal but not malignant cells from the effects of MTX. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Rationale for leucovorin rescue'",
"    </a>",
"    above.) It is not clear that there is any dose of leucovorin that is sufficiently high to interfere with antitumor efficacy. Although leucovorin \"overrescue\" has rarely been described in children receiving HDMTX for childhood ALL or osteosarcoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], its clinical relevance is debated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Alternative rescue techniques for patients with renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    alone are sufficient in the setting of renal failure and severe MTX intoxication is debated. In vitro data suggest that rescue of the toxic effects of MTX by leucovorin is not observed when cells are exposed to MTX concentrations &ge;100 microM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/70\">",
"     70",
"    </a>",
"    ]. Clinical data are scarce. In a retrospective review of 13 patients with MTX levels &gt;100 microM at 24 hours and &gt;10 microM at 48 hours after HDMTX, all patients recovered with the use of high-dose leucovorin alone in conjunction with hydration and alkalinization, but short-term morbidity (myelosuppression, mucositis, diarrhea) was prominent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, these data support the view that leucovorin alone is not optimal.",
"   </p>",
"   <p>",
"    Alternative rescue techniques have been utilized in an attempt to enhance MTX clearance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    minimize severe systemic toxicity. These include extracorporeal removal of MTX by means of peritoneal dialysis, hemodialysis, hemoperfusion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    charcoal hemofiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39,41,72-78\">",
"     39,41,72-78",
"    </a>",
"    ], administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    in conjunction with thymidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/79\">",
"     79",
"    </a>",
"    ], and administration of the metabolizing enzyme carboxypeptidase G2 (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    , Voraxaze&reg;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Glucarpidase (carboxypeptidase G2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When renal dysfunction severely compromises clearance of MTX, exogenous administration of the recombinant bacterial enzyme carboxypeptidase G2 (CPDG2,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    , Voraxaze&reg;) can rapidly lower serum MTX levels that remain unacceptably high despite adequate hydration and urinary alkalinization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39,63,80-83\">",
"     39,63,80-83",
"    </a>",
"    ]. Glucarpidase metabolizes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) and chemically-similar antifolates such as MTX to inactive metabolites. In the case of MTX, the molecule is cleaved at the c-terminal glutamate residue into glutamate and the inactive metabolite DAMPA (2,4-diamino-N-methylpteroic acid) (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Pharmacokinetics, metabolism, and excretion'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    After a single dose of 50 units per kg by bolus IV injection over five minutes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    rapidly decreases plasma MTX levels by 98 percent in the first 30 minutes, which in the majority of patients, is sustained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/63,81,82\">",
"     63,81,82",
"    </a>",
"    ]. In a series of 43 adult patients treated with glucarpidase for renal dysfunction and delayed MTX elimination, only three required a second dose, which was administered 24 to 48 hours after the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of early administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    was shown in a study of 100 patients who had either a MTX concentration &ge;10 micromolar &ge;42 hours after the start of the HDMTX infusion or HDMTX-induced renal dysfunction (creatinine &ge;1.5 times the upper limit of normal or creatinine clearance &le;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and plasma MTX concentration &ge;2 standard deviations above the mean &ge;12 hours after MTX administration) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/84\">",
"     84",
"    </a>",
"    ]. All patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and glucarpidase at one of three dose schedules (single dose, two doses 24 hours apart, or three doses every four hours of 50",
"    <span class=\"nowrap\">",
"     U/kg/dose).",
"    </span>",
"    The initial cohort of 35 patients also received IV thymidine for 48 hours or longer after the last dose of glucarpidase, and subsequent patients received thymidine prior to glucarpidase only if there was &gt;96 hour exposure to high levels of MTX, or if the patients had substantial MTX toxicity at the time of the request for glucarpidase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    was administered at a median of 96 hours in the 44 patients who received thymidine and at 66 hours in the 56 patients who did not receive thymidine. Plasma MTX concentrations decreased by 99 percent within 15 minutes of glucarpidase. Six of the 12 patient deaths were directly attributable to irreversible MTX toxicity. All deaths occurred among the 14 patients with grade 4 toxicity prior to glucarpidase administration, and five of them occurred in patients who received insufficient",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue and delayed administration of glucarpidase after 96 hours.",
"   </p>",
"   <p>",
"    Adverse effects are minimal. In a report of data on 290 patients with markedly delayed MTX clearance secondary to renal dysfunction who were treated in two single-arm open-label multicenter trials, the most common adverse reactions that were not hematologic, hepatic, or renal events included paresthesias, flushing, and nausea and vomiting, which each occurred in 2 percent of patients; infusional-related allergic reactions are reported but are uncommon (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     Glucarpidase",
"    </a>",
"    was approved in the US in January 2012 for treatment of toxic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    plasma concentrations (&gt;1",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [&gt;1 microM]) in patients with delayed methotrexate clearance due to impaired renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/85\">",
"     85",
"    </a>",
"    ]. Although the indications for glucarpidase are not well established, it is reasonable to consider use of this drug in a patient with early renal dysfunction if the serum MTX level is still greater than 10 microM beyond 42 to 48 hours.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    (either the d,l racemic mixture or l-leucovorin [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"     LEVOleucovorin",
"    </a>",
"    ]) must be continued for two days beyond glucarpidase administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39,54\">",
"     39,54",
"    </a>",
"    ]. However, because leucovorin is a substrate for glucarpidase, leucovorin doses should not be administered within two hours before or after the dose of glucarpidase.",
"   </p>",
"   <p>",
"    MTX concentrations within 48 hours following administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    can only be reliably measured by a chromatographic method, as the inactive metabolite that results from cleavage of the MTX molecule, DAMPA, interferes with measurement of MTX levels by immunoassay. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Laboratory monitoring during treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3521377\">",
"    <span class=\"h4\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible to safely resume HDMTX after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    treatment. This was shown in a series of 20 children who received glucarpidase for HDMTX-induced acute kidney injury, 13 of whom were rechallenged after recovery of renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/86\">",
"     86",
"    </a>",
"    ]. Twelve received a reduced dose (33 to 75 percent of the original dose that was associated with acute kidney injury), while one patient with osteosarcoma received the full recommended dose (12",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"    </span>",
"    The maximal serum creatinine after the initial rechallenge was 0.8",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and none of the patients required further glucarpidase with subsequent HDMTX courses. These data support the view that use of glucarpidase is associated with complete renal recovery and that resumption of HDMTX is safe after glucarpidase, with close monitoring of renal function and plasma MTX levels. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5926916\">",
"    <span class=\"h3\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of MTX by peritoneal dialysis is ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/87\">",
"     87",
"    </a>",
"    ], and other dialysis methods are of limited effectiveness. This was illustrated in a review of the efficacy of dialysis-based methods of MTX removal in 49 patients with HDMTX-induced renal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/41\">",
"     41",
"    </a>",
"    ]. The most frequently used methods were hemodialysis (n = 10), high-flux hemodialysis (n = 9), and charcoal hemofiltration (n = 7); 16 patients were treated with multiple modalities. High-flux hemodialysis resulted in the greatest decrease in plasma MTX concentration (median 76 percent) within the shortest period of time (median four hours). However, only three patients had a &gt;90 percent decrease in MTX drug concentration with the use of a single method in one dialysis session.",
"   </p>",
"   <p>",
"    A major limitation to the use of dialysis-based methods to remove MTX is the marked rebound in plasma MTX concentration that occurs once dialysis is stopped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/74-78\">",
"     74-78",
"    </a>",
"    ]. Further limitations of these methods are the accompanying risks for complications, which can include bleeding, thrombocytopenia, hypokalemia, and severe hypophosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/72,76\">",
"     72,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, these techniques are best utilized temporarily, when combined with higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    rescue, while awaiting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"     glucarpidase",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1044994849\">",
"    <span class=\"h3\">",
"     Thymidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thymidine supplementation can restore DNA synthesis, even at low serum levels. Unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , thymidine does not compete with MTX for uptake into cells. Several older clinical trials and case reports documented the success of thymidine (continuous IV infusion of 8",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     /day)",
"    </span>",
"    as a rescue agent, often in combination with higher doses of leucovorin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/79,88-91\">",
"     79,88-91",
"    </a>",
"    ]. However, thymidine was not effective in the previously discussed series of 100 consecutive patients with HDMTX-induced nephrotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/55/33658/abstract/84\">",
"     84",
"    </a>",
"    ]. Thus, there is no indication for thymidine in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (HDMTX) is an integral component of therapy for a variety of malignant conditions. When given at high doses, MTX can precipitate in the renal tubules and directly induce tubular injury. The risk is increased in the presence of acidic urine and with volume depletion. The major risk with MTX-induced renal dysfunction is that MTX clearance is severely compromised, resulting in delayed excretion of the drug, higher than expected plasma concentrations, and increased systemic toxicity.",
"   </p>",
"   <p>",
"    The guiding principles for prevention of HDMTX toxicity are as follows (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Practical tips for managing HDMTX'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pretreatment assessment of renal function is needed prior to each dose; if feasible, third-space fluid collections (pleural effusions, ascites) should be drained prior to treatment, as they provide a drug reservoir that prolongs MTX excretion. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Pretreatment assessment'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Concomitant use of proton pump inhibitors may delay elimination, and their use should be avoided, if possible, during HDMTX treatment. (See",
"      <a class=\"local\" href=\"#H5670353\">",
"       'Use of proton pump inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintaining adequate hydration and urine output are essential for rapid clearance of HDMTX. Aggressive hydration (2.5 to 3.5 liters of IV",
"      <span class=\"nowrap\">",
"       fluid/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) should start four to 12 hours before the MTX infusion is begun and continue until plasma MTX levels are &le;0.1 microM. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Hydration and urinary alkalinization'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Urinary alkalinization, usually with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      added to each liter of IV fluid hydration, should be used to maintain the urine pH &ge;7.0 until plasma MTX levels are below 0.1 microM.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      rescue is promptly initiated within 24 to 36 hours of the start of the MTX infusion, with continued leucovorin until MTX plasma levels are &lt;0.1 microM. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Leucovorin administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum creatinine, electrolytes, and plasma MTX concentrations are monitored daily, with modification of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      dose if plasma MTX levels are &ge;5 to 10 microM at 24 hours, &ge;1.0 microM at 48 hours,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &ge;0.1 microM at 72 hours. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Laboratory monitoring during treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even when these guidelines are strictly followed, approximately 2 percent of patients will develop acute renal failure following HDMTX. Early recognition of renal dysfunction should prompt the following maneuvers (see",
"    <a class=\"local\" href=\"#H33\">",
"     'Management of patients with renal failure and prolonged high plasma MTX levels'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hydration and urinary alkalinization should be increased, provided that adequate urine output can be maintained.",
"     </li>",
"     <li>",
"      Doses of d,l",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/63/14326?source=see_link\">",
"       LEVOleucovorin",
"      </a>",
"      should be increased based upon the measured plasma MTX levels (",
"      <a class=\"graphic graphic_table graphicRef51155 \" href=\"mobipreview.htm?8/49/8988\">",
"       table 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If plasma MTX levels are greater than 10 microM beyond 42 to 48 hours, a single dose of the recombinant enzyme",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/27/7605?source=see_link\">",
"       glucarpidase",
"      </a>",
"      (carboxypeptidase G2) can rapidly decrease plasma MTX levels by 98 percent within 15 to 30 minutes. Early administration is crucial to preventing severe toxicity and death. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Glucarpidase (carboxypeptidase G2)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/1\">",
"      FARBER S, DIAMOND LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948; 238:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/2\">",
"      Yarris JP, Hunter AJ. Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. Gynecol Oncol 2003; 89:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/3\">",
"      Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/4\">",
"      Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003; 66:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/5\">",
"      Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. Pharmacol Ther 1985; 28:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/6\">",
"      Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997; 24:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/7\">",
"      Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987; 5:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/8\">",
"      Jolivet J, Chabner BA. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase. J Clin Invest 1983; 72:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/9\">",
"      Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/10\">",
"      Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 1977; 4:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/11\">",
"      Green MR, Chowdhary S, Lombardi KM, et al. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 2006; 6:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/12\">",
"      Clarke L, Waxman DJ. Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists. Arch Biochem Biophys 1987; 256:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/13\">",
"      Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260:9720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/14\">",
"      Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/15\">",
"      Zaharko DS, Fung WP, Yang KH. Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Res 1977; 37:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/16\">",
"      Goulian M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil into DNA. Proc Natl Acad Sci U S A 1980; 77:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/17\">",
"      Evans WE, Crom WR, Abromowitch M, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986; 314:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/18\">",
"      Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984; 44:3190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/19\">",
"      Whitehead VM, Shuster JJ, Vuchich MJ, et al. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2005; 19:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/20\">",
"      Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996; 97:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/21\">",
"      Vazquez A, Tedeschi PM, Bertino JR. Overexpression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res 2013; 73:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/22\">",
"      Goldin A, Venditti JM, Kline I, Mantel N. Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 1966; 212:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/23\">",
"      Matherly LH, Barlowe CK, Goldman ID. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Res 1986; 46:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/24\">",
"      Fry DW, Anderson LA, Borst M, Goldman ID. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983; 43:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/25\">",
"      Andreassi JL 2nd, Moran RG. Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry 2002; 41:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/26\">",
"      Koizumi S, Curt GA, Fine RL, et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 1985; 75:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/27\">",
"      Gorlick R, Goker E, Trippett T, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996; 335:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/28\">",
"      Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/29\">",
"      Matherly LH, Taub JW, Ravindranath Y, et al. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995; 85:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/30\">",
"      Comandone A, Passera R, Boglione A, et al. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results. Acta Oncol 2005; 44:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/31\">",
"      Hande KR, Balow JE, Drake JC, et al. Methotrexate and hemodialysis. Ann Intern Med 1977; 87:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/32\">",
"      Monjanel S, Rigault JP, Cano JP, et al. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach. Cancer Chemother Pharmacol 1979; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     Kamen B, Cole P, Bertino J. Folate Antagonists. In: Cancer Medicine, Holland F (Ed), BD Decker, Hamilton, Ontario 2003. p.727.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/34\">",
"      Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009; 67:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/35\">",
"      Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/36\">",
"      Bartha P, Bron R, Levy Y. [Fatal pancytopenia and methotrexate-trimethoprim-sulfamethoxazole interaction]. Harefuah 2004; 143:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/37\">",
"      Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/38\">",
"      American Society of Clinical Oncology, Kris MG, Hesketh PJ, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/39\">",
"      Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11:694.",
"     </a>",
"    </li>",
"    <li>",
"     Chu E, Allegra CJ. Antifolates. In: Cancer Chemotherapy and Biotherapy, 2nd, Chabner B, Longo D (Eds), Lippincott-Raven, Philadelphia 1996. p.130.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/41\">",
"      Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/42\">",
"      Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996; 77:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/43\">",
"      Wolfrom C, Hartmann R, Fengler R, et al. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/44\">",
"      Borsi JD, Schuler D, Moe PJ. Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison. Cancer Chemother Pharmacol 1988; 22:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/45\">",
"      Goorin AM, Abelson HT, Frei E 3rd. Osteosarcoma: fifteen years later. N Engl J Med 1985; 313:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/46\">",
"      Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 2006; 8:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/47\">",
"      Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/48\">",
"      Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/49\">",
"      Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 2007; 59:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/50\">",
"      Santucci R, Lev&ecirc;que D, Lescoute A, et al. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res 2010; 30:3807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/51\">",
"      Joerger M, Huitema AD, van den Bongard HJ, et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/52\">",
"      Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 1978; 38:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/53\">",
"      Stoller RG, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977; 297:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/54\">",
"      Hempel G, Lingg R, Boos J. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol 2005; 55:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/55\">",
"      Straw JA, Szapary D, Wynn WT. Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 1984; 44:3114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/56\">",
"      Kerr IG, Jolivet J, Collins JM, et al. Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 1983; 33:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/57\">",
"      Isacoff WH, Eilber F, Tabbarah H, et al. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue. Cancer Treat Rep 1978; 62:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/58\">",
"      Joannon P, Oviedo I, Campbell M, Tordecilla J. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 2004; 43:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/59\">",
"      Sk&auml;rby T, J&ouml;nsson P, Hjorth L, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 2003; 51:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/60\">",
"      Evans WE, Pratt CB, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979; 3:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/61\">",
"      Nirenberg A, Mosende C, Mehta BM, et al. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 1977; 61:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/62\">",
"      Pitman SW, Parker LM, Tattersall MH, et al. Clinical trial of high-dose methotrexate (NSC 740) with citrovorum factor (NSC 3590) - toxicologic and therapeutic observations. Cancer Chemother Rep 1975; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/63\">",
"      Schwartz S, Borner K, M&uuml;ller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007; 12:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/64\">",
"      Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/65\">",
"      Djerassi I, Kim JS, Nayak N, et al. New \"rescue\" with massive doses of citrovorum factor for potentially lethal methotrexate toxicity. Cancer Treat Rep 1977; 61:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/66\">",
"      Sasaki K, Tanaka J, Murakami T, et al. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. Cancer Drug Deliv 1985; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/67\">",
"      Cohen IJ. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. Pediatr Hematol Oncol 2003; 20:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/68\">",
"      Sk&auml;rby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006; 20:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/69\">",
"      Cohen IJ. Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphatic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 2004; 26:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/70\">",
"      Pinedo HM, Zaharko DS, Bull JM, Chabner BA. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 1976; 36:4418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/71\">",
"      Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999; 17:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/72\">",
"      Saland JM, Leavey PJ, Bash RO, et al. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002; 17:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/73\">",
"      Wall SM, Johansen MJ, Molony DA, et al. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 1996; 28:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/74\">",
"      Bouffet E, Frappaz D, Laville M, et al. Charcoal haemoperfusion and methotrexate toxicity. Lancet 1986; 1:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/75\">",
"      Greil J, Wyss PA, Ludwig K, et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr 1997; 156:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/76\">",
"      Relling MV, Stapleton FB, Ochs J, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988; 62:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/77\">",
"      Kawabata K, Makino H, Nagake Y, et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron 1995; 71:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/78\">",
"      Jambou P, Levraut J, Favier C, et al. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol 1995; 116:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/79\">",
"      van den Bongard HJ, Math��t RA, Boogerd W, et al. Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother Pharmacol 2001; 47:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/80\">",
"      Krause AS, Weihrauch MR, Bode U, et al. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma 2002; 43:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/81\">",
"      Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997; 15:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/82\">",
"      Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005; 92:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/83\">",
"      DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 1996; 14:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/84\">",
"      Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010; 28:3979.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf?et_cid=28599956&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f125327lbl.pdf (Accessed on January 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/86\">",
"      Christensen AM, Pauley JL, Molinelli AR, et al. Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 2012; 118:4321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/87\">",
"      Ahmad S, Shen FH, Bleyer WA. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978; 138:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/88\">",
"      Grem JL, King SA, Sorensen JM, Christian MC. Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs 1991; 9:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/89\">",
"      Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983; 1:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/90\">",
"      Ensminger WD, Frei E 3rd. The prevention of methotrexate toxicity by thymidine infusions in humans. Cancer Res 1977; 37:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/55/33658/abstract/91\">",
"      Howell SB, Herbst K, Boss GR, Frei E 3rd. Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res 1980; 40:1824.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1155 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33658=[""].join("\n");
var outline_f32_55_33658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF HIGH-DOSE MTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69716673\">",
"      - Interference with folate metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Importance of polyglutamation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69716653\">",
"      - Other mechanisms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Rationale for leucovorin rescue",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Resistance to MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pharmacokinetics, metabolism, and excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Excretion and metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OVERVIEW OF ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nausea, vomiting, and stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Renal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hematologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dermatologic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ONCOLOGIC INDICATIONS FOR HDMTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Leukemia and lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Primary CNS lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Systemic non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Leptomeningeal metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PRACTICAL TIPS FOR MANAGING HDMTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pretreatment assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Renal function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5670353\">",
"      - Use of proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Prevention and management of HDMTX toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Hydration and urinary alkalinization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Leucovorin administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1067627855\">",
"      Oral versus IV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Laboratory monitoring during treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Management of patients with renal failure and prolonged high plasma MTX levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Augmenting urine output",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Increased dose and frequency of leucovorin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Alternative rescue techniques for patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Glucarpidase (carboxypeptidase G2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3521377\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5926916\">",
"      - Dialysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1044994849\">",
"      - Thymidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1155\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1155|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/39/9847\" title=\"figure 1\">",
"      Folate pathway MTX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1155|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/27/12731\" title=\"table 1\">",
"      Cytotoxic uses MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/7/120\" title=\"table 2\">",
"      Non onc indic MTX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/23/7549\" title=\"table 3\">",
"      Emetogenicity chemo drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/15/1277\" title=\"table 4\">",
"      Modern ALL protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/40/11917\" title=\"table 5\">",
"      Mod osteosarcoma protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/49/8988\" title=\"table 6\">",
"      LV dose adjustment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/39/8827\" title=\"table 7\">",
"      LEVO LV dose adjustment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=related_link\" title=\"calculator 2\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44232?source=related_link\">",
"      Chemotherapy-induced alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37914?source=related_link\">",
"      Treatment and prognosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26458?source=related_link\">",
"      Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_55_33659="Complications of arterial catheters";
var content_f32_55_33659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of arterial catheters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        All sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain and swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limb ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudoaneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diagnostic blood loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arteriovenous fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Radial artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Femoral artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Axillary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brachial plexopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Brachial artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral embolization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median nerve damage",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33659=[""].join("\n");
var outline_f32_55_33659=null;
var title_f32_55_33660="HAI reliability";
var content_f32_55_33660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraobserver reliability in HAI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 263px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Duplicate readings by the same observer demonstrate good concordance of the histologic activity index (HAI) in sixteen liver biopsies from five patients with chronic hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Knodell RG, Ishak KG, Black WC, et al. Hepatology 1981; 1:431.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33660=[""].join("\n");
var outline_f32_55_33660=null;
var title_f32_55_33661="Contents: Somatoform disorders";
var content_f32_55_33661=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Somatoform disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Somatoform disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/21/7512\">",
"           Factitious disorder and Munchausen syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/24/392\">",
"           Hypochondriasis: Epidemiology, clinical presentation, assessment, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/26/21926\">",
"           Hypochondriasis: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/38/27242\">",
"           Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/20/5450\">",
"           Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/34/18984\">",
"           Somatization: Treatment and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B341603370-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_55_33661=[""].join("\n");
var outline_f32_55_33661=null;
var title_f32_55_33662="MV repair in heart failure";
var content_f32_55_33662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Mitral valve annuloplasty improves left ventricular function in heart failure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 267px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among nine patients with severe mitral regurgitations due to an end-stage congestive cardiomyopathy, mitral valve repairs resulted in a significant improvement in left ventricular ejection fraction measured 16 weeks post-operatively, from 18 to 24 percent (p = 0.02*) (panel A), and in cardiac output, from 3.1 to 4.6 L/min (p = 0.004&bull;) (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bach DS, Bolling SF. Am Heart J 1995; 129:1165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33662=[""].join("\n");
var outline_f32_55_33662=null;
var title_f32_55_33663="Doppler signal echocardiogram";
var content_f32_55_33663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler signal from intracardiac blood flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAbcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKQZyc+vFAC0ZopDyCKAFzRmkHt0pAOxxQAuaCcA005z070hBZh2waAHFiAT6VDcXcNvbSTzzRRQxjLySMEVR7k9KlY9ePpXkX7RGrQxeFI9EjcPf6hNG/kjqsSNuZ29sgAe/0oA9IbxLoq5/4nGmf+BSf403/hKNDz/yGtLxjn/Sk/xr5TtbbMYzGvIOcqMila3QK20IcdMqMmgD6rPivw+g/ea7pK/W8jH9a2VYMoZSCpGQRyCK+GvEdm09tNDHChL4ByK+lP2evFceu+A7PS7mQjWNHjW0uYn4bYOI3A7qVAH1BoA9S70UCigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACigD9aBQAUUUUABoooAxQAUZooxQAUHpRQKADPT3pm75NwFOxz+OaQLjv3oAQHqcce1L0zn680BQOmM0FeP/rUAISCwFfLd/fNrOq3+pXBEtxPO/zHkqqsVAA9AB0r6iA55I+tfI2nSOFuSu7/AF8hyv8Avn9aALl6qiFdpwT/AHT29P8APSqTkYz5eQGAz3NFxcBnOSGYHBI4x/nvURfftHGemOx9z+lAFtmUx7dowFPIHX/PpXNa1q0ug3tnqGlO9rfQyoI54WKsMsMqcdQe4PFbrO20bnO456dc+/vXE+NC/wDoqk5BlQcDr8woA+9s+x9KM9famkfMcnvkcdKcO9AC0UhB3AhsAdR60tABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnv7QGu6l4a+Eevatod01pqNv5HlTKoJXdcRqeCCOQxH41xV98RNX8F6v4t04agfFFjptraTW95dGNTbTTyiPy55IlC7fm39AcDHuPbNV02x1ewlsdVsra+spceZb3MSyxvggjKsCDggH6gVWsfDuiafpk2m2Gj6ba6dNkS2sNqiRSZ67kAwc+4oA8um+Kms28P2N7LSJdTTxHDoL3Mczi0YSQtIJFPJBXABXn61Xsvi1rd9JpFhBa6FDe3d1qlpLezzuLPNnsIlQjko249T2613+vfDzw3rOl6TpkmnQWumabfpqMdnawRpDI6qy7XTaVKEOcjAJ9aTWfhz4Z1i/0Ca8022NpoqTx22nCCL7IRMFDboipHGwEYxg+tAHkn/C39TjuX8VSWk/2U+EIL7+yjKRELhr5ofM6dMYOcZ2it+H4q+J1sbOOfQtObUbrWrbTIHaZ4YJo54pHD4+d0wY8HIORyM162dE0ozGU6ZYmU2wsi/2dNxgByIs4+5kn5enPSqll4S8N2CRx2Ph/SLZI51ukWGyjQLMoIWQALw4BIDdRk0AcR8a9T8Taf4A0gadc29jqt7f2dndyW8rgIZGAYRPt3Bd3G7AO3tniuftfHmqaCt/pVuq3Got4ih0KG51S9klhjP2dWMjE/Nzg4UYyTmvaL+wstRiji1C0t7uOORZkSeNXCupyrAEcMDyD1FYPivwPpHiLSbqwkiSyjurhbq4e2toC08gGMuJI3VzjHJUngc8UAcN4c+Ls15qnh611eLTLSDULzVLSa6E5WNfsm3aVLcfPuPWovA/xU8QeLtR0O3stG0xEutJXV7tnuJA0cf2qSF1jUKd7bY8gHaMnk13Ph/4eeGtF8PWmjDTLe/tbaZrlGv4knfzWOTJyuA3PYCtrTdA0bSpY5NM0nT7KSOH7MjW9skZWLcX8sFQMLuJbb0ySetAHmnwp+KOs+NNYtRd6NbW+kX0EssE0UhLQujf6t8n5yRnJUDBGMd69erJsvDeh2GqS6nZaNpltqMufMu4bWNJXz13OBk/ia1iAetACY5zzQeuKWigAooooAKKKKAA0UY5z3ooAbnnHQ0o6e9LikI5zxxQBXuZAkMjA/dViD9Aa+NNDvlm01SzfK5Y8+5JNfZcyhkZWGQwIJHXkV8q/FPw3B8P9SsLDR555rSe3MoN1gurb2BGVAGMY7etZ1akaUeaWx14HBVcdWVCj8T7+RiTXCBNwTcGOW/z/nNRtdoclflb6f5/KsRtUuWXBK8e1NGpXGP4T+Fc39oUT3P9UMx7L7zbFwGQqOBj16D/AArlvFswNxZqOnnR8f8AAxV8alMOyH6g/lXofwb8EaX481G9utckuQdKkt5oo4XVUkJZjhwynI+QdCO9XTxlOpJRjuc2N4cxuCoyr1kuVW693b9T6mLASFSDz+tPUkk8g4piKA24k5xTwoBB79K6jwR1A6DNFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANkYIjMeigk1wC/FjQiEJtdUXf0zAv/AMVXe3P/AB7S/wC4f5V8tNujgVUwzYHLenoPegD2w/FPQx1ttT9/3K8f+PUo+KWhkE+RqIHvEv8A8VXjMTeZAoZV37uM8A1JKgA3bMHvnn8vagD2FvipoKkgw6hkdvKX/wCKqI/Fnw+CAYdTXnr5A4/8erxKQbpZHcbeBgYzgioXG7MjPknoOnP+NAHuTfFfw8SpMOpcHr5K8f8Aj1B+LPh/OfJ1Pp2gGD/49XhIYbXAPuARg5/wqUt0CsACM9en1oA9vX4seHs5KaiTz0gGMf8AfVKPi74dOf3OpYHX9yvH/j1eFMjkEuuCOG9j/nFR5RnyGwT0BHI+nvQB7t/wt7w4c5g1MEesA6+n3qG+MPhwKCItSbPQCAf/ABVeD4ypXYC2STgHFRSId6uTkDgD0oA97Hxi8NnjytTz/wBcF/8AiqcPi/4dA5h1TPceQM5/76r59aREcg4DHnGP5e9AZlfkgcHG0dB/hQB9N+EPH+keKtSlsdNjvVmiiMxM8QUEAqDzk85YV11fP/7P7M3jO+OTt+wPx/20jr6AoAKKKKACiiigAooooATPIFDdPaloI4OKAK8gwvfpXzt+06v/ABONBfnJtpBj0w//ANevomY459ccV8+ftQD/AE/w83rFMP8Ax5a5Md/Afy/M+h4Vf/CpT/7e/wDSWeHUUUV4B+vBXvf7LC5/4Shu4FqP/Rv+FeCV77+yv08UDv8A6L/7WrqwP8ePz/I+f4p/5FdX/t3/ANKR72MgtjrxTvQ0ijjAwOe1O+nJr6A/IBRXN+NvGek+C7KO8103iWz7sywWkkyoBjJcoDtHI5OK6MgMMMMj0rmPid4euvFPgDW9D054Iru+tzFG87FUByOpAJxx6GgCx4d8X6Pr2nJe2k8kETk7FvYmtnYcfMFkAJX5hzjHNX7fXdIubm4trfVLCW4tgWnijuEZogOpYA5XHvXES/Dv7d4z8Mapq9vpd9p+k6ObJ4Z08w/aNyFZEVlxgbTzkEZ6VxEHwf8AFT+IpdRvrzRXc2+qQNPFLIhm+0oyxfuhEEjCk/MASepyxoA9vg1vSrj7R5Gp2Mot0Ek2y4RvKUjIZsHgY5yajXxFojaeL8axppsTJ5QuRdJ5e/8Au7s4z7V4zdfBK6GnwQWttoSqfC0GkXcaSSQC4u0nhkaUsiZIIjbDkE5xlSMinaV8KvE9mNCurifQdTuNN1C6uDY3gPkNHNCkalpFhBlkTZkM0Y4OMjAoA9Y8JeLtJ8U+H7PWNPm8u2uoWuEjuCqSCNWKlmXJwMg89K0bjWtLtntVuNSsomugDbiSdFMwPTZk/Nn2rxDS/hJ4u0bRtJh0280GS6Tw9daDei4ebYqyzNKJIyEyTyBhgMc9a19F+GOuaLe2M6weGtY3aRp2m3A1PzG+yNbJtZoMIdysctg7DkA5FAHrEes6XJc3dvHqVk1xaKXuIlnUtCB1LjOVH1qzbXMF0jNbTxTKpwTG4YA4Bxx7EH8RXgGkfBDWtOtdRtDPpdw7afqNlbag11Kskn2mN1XzYhHj7zAsdzdMgZr2XwH4btfCnhXT9LtbOytpY4Y/tRtIwizThFV5DgAsTt+8Rk4GaAOgooooAKKKKACiiigAooooAKKKKACiiigAooooAiuuLaY/7B/lXy8cyW6K64YHJPf6fSvqC9JFnOR18tv5V8zwxokETTEbtoPH3s+tACwxqV5yMDbuPenzJlSWyGHQ9c//AF6cdgj4YdflI7j/AAqWUrHKMqSMfKD2JoAy7wYj8s4DseNvpWXIz5KnDADGD0+n0962bqLemCoLdAEPX86y5Mb1BPGMZPTp6UAVSpE6L8u4D5mzzVxISWXlR6DPXHf6+1RLEwIZlAPXGP5+1XEjyowctwOuM+n4+9AELqWiABBHOSOf8ioJEKthArvjAGfyrQEQjOXOGHLAdqh2snK5wDknGMeh+lAGeIQ0YWQyJtb5h90n6/55obiRsEnuD2qaQBy7Ebmx8248Z7U1kySFzxwOec/40AV7i3RoShX5m6kdh2qB1wVznA4zjv61HqMN9JfWz2d6sEQP7xWXO8entUUUN6dSnlmu0ksmBVISv3PQk96APVP2fQv/AAmV6VOf9Aft1/eR819AV4B8AP8Akdb7gj/QH/8ARkde/wBABRRRQAUUUUAFFFFABTSDnr+Ap1FAETjcMZr58/agXE3hpsEEpcf+hJ/jX0MRkkjp/OvAP2qE2nwwfa5H/oquTHfwJfL8z6Dhb/kaUv8At7/0lnglFFFeAfr4V79+yr08T/W1/wDa1eA19B/srwutr4knKOI3e3RXx8pKiQkA+o3D8xXXgf48fn+R89xU7ZXV/wC3f/Ske8fhRS0V75+QhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEGoHFhcn0ib+Rr5thiBgj6D5ARxn8z/KvpHUV36fdKehiYfoa+dbZkigjjIXfjGMdcigCGRQJVJGD3GO/wDiafIS8Y2fLsY5Y85FWGAbHm4O3GGzwPb/AOvT3AERLcHoARyfYUAUnj3hSWAz1OOKyryAq6vLu5Ibp3rdmaLfjl9nPTn/AD7VnXAVwGZMbT+VAGbGvmJgqRIM4x0FTJC6gO2Dkf5/CpEQPleQGOPp7f8A16sJgITsfIycDv8A4UAVQG+ZZVCseSCOvpTpGfzBtBOBzn1x3qR1Dx7iWJzuz6D/AD2qJ2JcEMCV5J/z1/pQBWuMpCVGBk8jHp1NUETzMsoxjJA9Pr7ValLshJUY6Zz71CpYBSAPrj/P5UAMnQ+Ucrljxj3qF8L1IGeDgc5HFSSs/mbXbBJ6L0qKRCCF2Djrg4Lfj/WgD0b9n7DeNb5ixJ+wOBnsPMjr6BrwD4AEHxnenIz9gfOP+ukf5V7/AEAFGOc5/CiigAooooAKKKKACijvRQAEZFZuu6HpmvWf2TWLGC8t87gsq52n1B6g+4rSopNJqzKhOUGpRdmjiB8KvBWMf2BB/wB/JP8A4qph8MvBoz/xT9nz/vf412NFR7Kn/KvuOp5hi3vVl/4E/wDM5GP4b+DkYFfD1hxz8yZ/nXS6dYWem2qWunWsFpbJkrFBGEQZ5OAOKs0VShGOyMamIrVVapNv1bYUUUVRiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAR3P/HtL/uH+VfONuqKp4GeCP8favo+fmCQdflPX6V84x7mixjnbhuOTQApHzNjAJHr2/wAPap3XepBI4Xr1psSK5IVmXIHBPJ/Hsalgtw7fd56Yz7dvegCo8XygIzK+Pm46+nPr71AVJG0uASR17n0q87j7QYmIICgso9exFMa3DzSEJjA4J5H/AOqgDPeE7gXAJ6Fe1BiEkmdo3LwQM4P19q0fKKOSFUEKc5Gfz96HiCSF1OWbqCO+KAMyRXjYqB05UEcn2zVOYKCrRhhnIXHc962pkwSpYE7SABwPqPaqJMTW6zAhjjaD0GOxoAy93mFQwAVRj2qqi8kNySc5Lfl+NW7hGEwDkDcxGDwM/wCNUWbyyDkdwPTGf5UAIybWYjOFJ75OaFCjBTBJXr26/niotRaRbWRreDzZVGQmep7D6e9UtJmuZ7Vft0QtpW4KA5K49/WgD1L9n1dvjO/xgg2LnOcn/WR/pX0DXgXwCA/4TG7IwCbB+B/10j7V77QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACSZKNjOcdq+d4kYQ5LEZJPHHHevoh/uN06d6+fthfIDMCGI6d80AQxfLPyN6gAAn0/wq2oILL6ZOfSq8MD/bCzO+xVwqt2PtV0AyEMqElVxkD88UAZ0cbrq1zIWVg8afK/XI71YnCrPvZ2AzjGeM/41m3MTp4st1jzs+ysrAjgc1pzIx5K/KMduMdvwoAGUbWDgHfgkjp/n1qIxgjmNQo+6CcZ/wDrVKDlGUrkbs5A5U+9PMJJAZwoIO7Hc/40AZmqRF7C4BypMbbTnkNg45/lXP8AhyKQeHrG1d/OdIsuRjKHrgj1rrpLdGyC+QOd2c4z2x6V43cXuq+GdYufMjP2eW6Iyx42k8CgD0F08wRqwzkHA4x0/lWc9uHPPyleCe2frVXSNbGp63faesg8i3RWRu7Hv/8AqrWSNhlc5jDlj64oApzRMqqFYoCO/JH096zzFgFQMPjOc54/wralgDAlVynY59ff+tUzEwZlySwP0wf89qAO4/Z/yfGl8xJydPbqO3mR4r6Arwb4DIV8Y324BSbFzjP/AE0jr3mgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEb7p+leFRqVVnTbnJ+XOc17sRkEV5R/wh+sqzkWY28kDzlzj060AYBTbsC8My9qa7MjkA42r/AA9/pXQL4R14Ox+yRYx/z3X8qX/hENe35+yw7cEf65fzoA55hg7yoZk6sR2/w9qajh424ZMHof8APSuhPg7X8uy20XK42tOvJpU8Ga2wHmW1ujDn/XAjNAGIkQeJByoPBOe/vTdvLGQgkjbn/PeuhXwdroIJhtgRnH739KfH4L1YBQ8MBx1Al6/p0oA5OQBsFMEHjAHXFYXiXR4tZ097aUhVDqy8dMHPPtXoj+B9a8pgotUI6fvT/hVefwJrDR7f9E3Y7zHA/TrQB5Npfhq10a8nvLcO7SkDaf8APWtUH5nGPmX73Ocmu6n+H2uSbdkungxncMyk8e3HSq//AArbWud8+nt8wYnziCfTt0oA4q4TdvKOBk7QoOF/L0qpJkTYI+YD6/5Negj4aazgBrjSz1xiVhj9Ov6VBP8AC/XZFAW+0peO8rZ/PbQA74GA/wDCZXhz/wAuL/h+8jr3SvMvhl4I1Dw14guby9vLGaKW2MYWB2LZLKcnIHHymvTaACiuF+JPxGs/At7o9pc6ddX0+ppcvEIZIowogRXfc0jKOjcDPOMdSAZR8TvDEWh6VqmpXkunQ6lbLdRJcwPuSM8AvtBCjPcnHvQB2tFc3L448Nx69Hox1aBtSdo0EUYZwGcAoGZQVUsCCASMgj1rC134s+GLLRNavdKv4NVudMt2uWtYnK+aisFJRyMMATglcgGgD0GiuOPxA0i1n1f+2bqz06109rVGmkuNx3Txh1Drj5OvHJyOeKdH8SvCEui/2rFrts9l9oNoGUMXMwGSgTG8tjnGOnPSgDr6Kz9O1vTNS0e31WyvrebTZ03x3IcbGH1NVn8VeHkYq+vaSrDqDeRg/wA6ANmisYeKvDx6a7pR/wC3yP8AxoPirw8DzrulD/t8j/xoA2aKyF8T6A5+XXNLP0u4z/WnDxHohPGs6b/4FJ/jQBq0VmjXtHIyNW08j/r5T/GlGu6QemqWH/gQn+NAGjRWeNc0n/oKWP8A4EJ/jR/belf9BOx/8CE/xoA0KKojV9NPTULM55/16/407+1NPxn7daY/67L/AI0AXKKqDU7A9L21P/bVf8ad/aFl/wA/dv8A9/V/xoAs0VWF/Znpd25/7aD/ABpwvbU9LmE/SQUAT0VCLu2PS4hP/AxThcQnpNGf+BCgCSimCaM9JE/76FL5if31/OgCpq95PYWZntdNu9TkDAfZ7Volcg98yui4H+9WF/wlGr/9CJ4k/wC/+nf/ACVXU7h6j86WgDlf+Eo1f/oRPEn/AH/07/5Kr5u/aK+JnjPQfiRpT6MdY8OBdORhZ3EkMgmYyyZcpG8kZHAHJzweBkZ+u6oz6PptxqkOpXFhaS6hCnlxXMkStJGuc4ViMgZ9KAPIfgt4/wDiP4nEC+JvBnl2DAf8TTd9l49fKfJf6rgUzxp408S6f4s+IVk9zaHRtL0ZLuCBJTDOpMbnMbqu7cSvOTwAMd69vrK1Hw5omp3hu9S0bTby6MJtzNcWqSOYjkFNxBO05OR05NAHknib4r6/on2z+ztL065stKstMurlrq4kE0ouWCbVIUjIJ+8fyNF/8Xte060uLK80nTv7cj11tG8yF5HtgBEJQ2DhixB2hcjJ59q9bn8OaHcLOtxo2myrOkccoe1RhIkZzGrZHIUgFQenai58O6JdW95BdaPps0F5J51zHJaoyzyYA3uCMM2AOTzxQBQ+Hmu33iPwpa6hq9gmn6gzSRz26PvVWRyuQfQgA4PIzjtXSVV0zTrLSbKOz0uztrKzjzsgtoljjXJycKoAHNWqACiiigAooooAD0NeGm8uFMhNxdE7yVJlbA/WvcW+6fpXhTYZZQjkkscHHv8AzoAdJdzKkmyaYnd3kb8T1qMyykh2mnIBwf3jcfr+tThQyArnnAyOvvVS9YQtFsDPuO3IOBg/0oAdcTSPgiWTc2EA8xunfv8ArUSySFtwkmYHj7zZGPxrH8Sak1lcaRHjcLm4ETH1GP5VssVDkJnJ657H1NAFh5M/MGbkDncRuPryf0pXct8gckc5O4n6VWiZnk/djd2yeg+vvUokJjOVCRjoT1oAjYomM4Xb/eYnGfX8apbY5A29dwAK9fxx/wDXryz4n+KJ01hLTTrnMBRS2w/xAnIFem6E4udEsZmwGeIMQT045oAe6QdgFP3h17dvpVe4W3YAKkZXjIIwOelWZkLLuGQDyCBz9PY1VlVSCNxOOFCjPNAFGbaFISCI7DwO5NZu2NgSyqOTxtrVlO0n5wQerAcY/wAKzLjIU4DfMQCT/CPp60Ad78CxEPGl35YUH+z34AxgebHXu9eFfAzZ/wAJlelOf9BYZ6A/vI/1r3WgDz74nfDyXxprXhzU4NRsrWTRxdAQ3umi9hm85FX5kLqPl25Gc849OeS1T4ESXPhzS9Ft/FU/2Kz02TTzHeWpuF3PIz+ciiRQjjdtGd2FCgYxmvbqKAPJx8IG/wCEwsdaGumCO3MHmx2ds0EtyscYTy5HWXayNjnKFscbqxofgGkGi3mlRa7AbV7SW0tppNN3XESOQfmfzcMBj+FUzxmvcaKAPL9S+FH23U9VvP7Z2fbtQ0y+2fZc7PsaKuzO/nftznjbnoap658GY9S1O91KPWvJvpdWk1SAtab44xJEsbxOocFwQudwZSK9cooA5fw34PtNL8FW3h28Fvc28XmFvIhNvGS7s52oGJUfMf4ie+a5a8+A3w6u5WluNCZnbkn7ZOP/AGevUaKAPJx+z18Nd2f7Ak+n22f/AOLprfs8fDU/8wKUfS+n/wDi69aooHc+I/i94A8PeGfHN3puk2DRWaRxMivM7nlATyTnrmuL/sDTP+fUf99t/jXsf7RQA+JU2M/8esOSe/BrzCvAxFapGrJKT37n65lGW4OrgaM50YtuKu+Vf5GX/YGmf8+o/wC+2/xrrPhX4J8P694+0jTdUsfNsp3fzEErruxGzAZBz1ArHruPgm234paCf+mjj843FTRr1HUinJ7rqa5lleChg6soUYpqMre6uz8j3L/hQHwzxj/hGh/4G3H/AMcpp/Z/+GZz/wAU3jPpe3H/AMcr1SivoT8dPKx+z/8ADMD/AJFvP/b9cf8AxymN+z38NCRjw+4+l9cf/F16vRQB5Kf2ePhqT/yA5h9L6f8A+Lpv/DO3w2/6Ak//AIHT/wDxVeuUUDueRH9nX4b/APQGuB/2/Tf/ABVJ/wAM6fDf/oEXP/gbN/8AFV69RQFzyBv2c/hwemk3Q+l7L/8AFU3/AIZy+HH/AEC7v/wNl/xr2GiiwXPHf+GcPhzx/wAS28/8DZP8aP8AhnH4c9tNvB/2+yf417FRSsPmZ4+P2c/h2P8AmHXv/gbJ/jR/wzr8Ph0stQH0vpOP1r2CqWuanb6LouoapfFhaWNvJczFRkhEUs2B3OAaLBzM8tX9nf4fqc/Y9QPsb+X/ABp5/Z5+H/QWWoAegv5f8a9copibueQn9njwF2ttTH0v5P8AGm/8M7+A+f3Oq8/9P717BRQI8gH7PHgUHhNWH/b+9ekeEvD1j4V8PWei6V532K1DCPzpDI/zMWOWPXljWvRQAUUUUAFFFFABRRRQAyc4hc/7J/lXgNkXWNkDM244JPB6175dHFvIM8lSB9cV4FYjCDdwx+9kc/l6+1AGjGGaQEcAA5z1z2zTJlXaoIGE/PP+NIoWNs4LM3IA7d/xptxIQFzgbuB1Of8APrQB598Wp5LKy0y7iBQW92H+XnFdNplyZ7dJo2LCZVkyfcfyrn/i5FHJ4PuiASYmRtx7nNbmhCNtD02ROF8mMH/a4oA0RK+duFVR0wa5z4kao9p4fUxykE3CI2Dglc81pm6X7Zdo5GIYgxH58/8A1q87+LzTSWum3CMDbsPmQHnceRxQBz/hfR21jxdJ5kTmGK7Bk4OFU5P4V7zHbQxRxRQIPKjBwAOgz+v0rg/gjATpOo3cgbdPcBdx7gL/AJ57V6M5CxlRlR0AHX/PvQBQdUWU9Sw+bGcjn371mbUY7sEbnYKAcfh9K07h1RinO4EZ2isOa7SJg7MFE7ExkjgigBJpNowF5YnPoMf56Vl3RdZM424GRk8D8avXhBRXBOByc8Y+p/rWPFdLeLLLbTpcRKdpZWyM+n+etAHo/wABWZvF95k5AsXA/wC/kf8AnNe814R8B23eLbsZyBYOB7/vI693oAKKKMUAFFFFAADkZFFFFABQc4ODg0UUAFFFFAHyt+0eCPiOSTkNZxEfT5v/AK9eWV6x+0sCPiHDnobCLH/fT15PXzmK/jS9T9pyL/kXUf8ACgrsvg8+z4meHznH+kY/NSK42ut+E7bPiR4eP/T2g/Pioo/xI+qOnMlfB1V/dl+TPs+iiivpj8NCiuS+K/i1/AvgHVPEcVot69l5WIGk2B98qR/ewcY356dq4TSvjFe6lYW0kWn6cJf+EmtNCleG5aaJ45jzImVRwR23Lg+/YA9oorhbT4o+G7jWDYl7uGEvcRRX0sBW2neAEzKj9yoDdQAdpwTUNj8W/DFxY313cNfWEFtYDVFN5bNGbi1LbVmjHO5SxAHQ5Ycc0AegUVwXw/8AHVz4s8V+J9Ok0yfT7XTIrKSBLqIx3B85HY71yQPuDGOx5rjtP+Lut3+uhY9Igt9LbxRH4eX7RDKsuCJNz7shd48vlcfLuGc5oA9uorz+H4s+HJp5kRdRMIjupLa4+ynyr37MCZhCc/MVCtxgZwcZol+LfhNFuNt1PK8VvaXPlxxEtItyU8oKO7fvEyO24UAegUUUUAFcr8WP+SWeMv8AsC3v/oh66qvB/wBpr4pyeENPuvC50J7pNc0yaJL03OxY96tG3y7TuK5BxkdRQB7xRXD/AAe8eP8AEXwj/braS+lxmd4Ujafzd+3GWDbV4ySOnUGu4oAKKKKACgUUUAFFFFABRRRQAUUUUAR3AzBJ/unnHTivB7ZHdUJAI5wQPz//AF17zNxDIf8AZNeHWhUQKd7Bck8Dr9PagB0qBV3LgEjnPXGaZIAz/KcFTxg/5/Kp4iHBIznk7jUVwZVilEQQyqDtDfdLY4yRQBxvxNtJL/wjfLCMuqeYQT2HX/8AVWT8ONWW68KpCXUywR7AhPJxnnHftWb4J8N65Y6vdSajYvaWU2nPDOnnxvGZtwI2gOxPy5+Zueua4XRb240LV7QxSbXZ9rjHRSRkc0Aes6e0zRX13dq6j7MqlSOT1/X3ry+G0ufE3iia0DNgfMsZbH3cDH5Zr0/WNXE2j7rIFoLiUQOQMbAeCP0ri/AdrPc+L77VLRd0dpJh1wMkNxQB7JY2VnoulBYo1t7OJSzYGcd2P6U23urW7tIr61lWe0nXzI3yRuUjg4P8q5b4jaTqOp6jYSR2T6jp6W80bWyXAi2TsBslbcwDY5Ht1xWr4SsZ9O8HaVp9/CEuIbZIpUJDbSFGeQcdqALdxcIVZFHA4JHPbp7/AFrKu4EAiZ4wI16Y7HPH41pK0e5hlTsyDjtx0+lVbxhHGoVVEak49Bn+nvQBl3RZ4mDYwwIKkYGD/T2rDis4dOiaKxiEMbfMVTgVr3srMNrkAA4znnPv6VRnbY5HONvXHT2xQB6F+z/k+LLstnd9gcHJzj95HXvleC/ANs+L70DoLF+v/XSPiveqACiiigAPSkz+WKWigAo7mjNFAAKAck9eKKKAEBpenWiigD5d/aYH/FwLUnqdOjJ/77kryWvXP2mv+SgWfBGdOj/9GSV5HXzmK/jS9T9oyH/kXUf8IV1Hwwbb8RPDhP8Az/RD/wAeFcvXSfDY4+IPhv8A7CEH/oYrOl8a9Tsxyvhqi/uv8j7Yooor6c/Czn/HvhSx8b+E77w9qstzDZXnl+Y9syrINkiuMFgR1Udjxmubg+E2jLdte3Wo6xe6nJqlpqs17cTRmSaS1BEKMFQKEAJGFUH3q78YbnVrXwY50K11O4uZLmGN205nEsMZcbpMIpdlA6qgyQeoryi11D4m2Pg60vbePXr68g1W/wBNFvPayJJLBJERbXDqwLbEkwdxzwSCTjgA9PtfhR4eg1b7VJJf3FmklzNDpk0wNrA9wCsrIoUNyGbgsQNxwBVa2+Dvh1NNvrK9udV1CK405dJjN3OrNa2qsGWOLaowAwU5bcflHOBiuFgu/iLHovittTt9fuZdIgi0q1Ftuie/YXLF7yPClm/deX90EkFgMHmsxfEXjnwx8PtS8Q39zq0qaJrqMkOpQyQG9spFRCmJBvIDuCCSSMEewAPaPCHgy08J6lrOqnV9U1G81KOAXVxqUsbHbCrBSNqKBw5zn0HvnL0zwH4b1C1gudN1S4u7YeIn8SpLBcRyI10SwKZC48sFjx97j71ZniPRNfn/AGdtQ03UrnUL/wARzaSzzmIbppJmG8xAAcjny8AcrWV4T0DxLZeIbbTLO+1uy0fT9CtrmCNo0SCe8LOWjkYx+4DKpDYxmgDrtD+F2haPrNvfQzX88FoblrKwnlVrazNwT5vlqFB+bLD5mbAY4xmsjR/gf4U0p9Ce3k1N30e8a9haSZSZWPl7UlO35kXyY9o4xtHJrjfDd18QBpWuOf8AhJ2ul8NXT3Y1CAjbqoz5YtBt+bvgJlfu96oXlt8RbOw1O5ttU8Yz3FraaTfW8TxbhLcSuq3MZAjyyopJMY4HVgaAPpOiiigArxT9q/wbL4o+HcV5p8DTalpdyskaKPmaOQhHUfiUb/gNe10UAc/8P/DsXhLwVo2hQYIsrZY3YfxSdXb8WLH8a6A1yXxU1XV9B8EahrOgKkl1p4W5kiZN3mwqwMq+x2bjn2ryjXPiZ4tHhjRNYhmg0/S9d1C8aG/kgUC0tUwLZHL/ACBpMM25u3AxQB9CUV80T+NPEkWr3XiK3W1vNbTwVDIRahpYC39oOjzKo+8AmX49PStx/iP4jj0DVJLPU7fUNKg1m0sU8ULZfu0tpI900xRflby2wmfu/MM9KAPe6K+bvEPiPU7+bxQNC8QR6lcw+EJLqDWrK1MMz7LyQFV2kDhVI3L3+YelXrz4heKtM07wnbaTqNtrv/CSWKWun34txtS+E6rIZOTlVjY5yeWjJ7nAB9B0U1AVRQzbmAwWxjJ9adQAUUUUAFFFFAEdz/x7y/7p/lXhFqVKRqGGW6HPX/P617vc/wDHvL0+6evTpXz0lyqq+9hlV78nGe39KANiNSGj83IAHGO/+NQzMVZVI3MTgnPX2/8Ar1WilygdC/zdB0x7expyyEjLrtOCAc9v8KAFCKFyCA7qQyZ6kfyrxbxnojyeN5ZFQJalRMGUYBVcZx6V7A7gMG3Fipx9R61j6/aw3FrPKy5dIXQfQjmgDyuXXF046laQuWtTOs8WDyDx09vau8+FWmrbeHpL4F2mv5N5XHRQeK8gtLcXgjibcZZZ1iX6cD86+g7CCKys4LeElEgURqAcZ+n9aANXz12kcb1OBzn8KpTTMXzjCYIGD1qEkrHKoCLtP3s8Y+vpVK4CxqxB+d+W/unigBZrlY4GIy3GQRxn3/8ArVVuLtAgYM2T95ccVXlf5VYOCwABGe/+NVZpvm6gkHt2FADZnUFjj5m7k/19feqUpO1gM56gj9afM+G4yyg9c/p9KrByyt0Oeg9fc0Aem/AByfGd2pU/8g9znt/rY6+gK8A/Z+I/4TG+UHpYPx6/vI69/oAKQcdutLRQAhzkelL6UUE4oAKKD7UZoAT8qU9KKO1ABSHOR1paQkCgD5i/ad/5HzT/APsGR/8Ao2WvIa9e/ad58eaf/wBgyP8A9Gy15DXzuL/jSP2fIP8AkXUfQK6L4df8j/4a/wCwlb/+jFrna6D4ef8AI/eGv+wlbf8Ao1ayp/Gjvxn+71PR/kfblFFFfTn4Scd8SvG48EW2jTHS7rUf7R1GGw22+cpvONwAB3N6JxuPGRUcHxI0i4u9Wtbay1qabSw/2ry9PkKxsqByhfG3cQ3Ck5rV8a+FbPxdpttaXtzeWrWt3FfW9xaOqyRTRnKsNysp+hBrIl+G2jz6F4o0m5udRmg8RS+feSNKokV9qrlCFGPuA8g857cUAZ1n8ZPC91ps12q6iHhv4dOe2W28yXzpQTGAELBt2D0JORjFUtW+K3gvUNJthqmnXl1JLfy2q6Zd2K+bHcW4V33LIQqld6Ec5+YY5zi5YfB/RLS4M7alq9xOdRstUZ5XhGZbUFY1wsagIQeQAOnBFGtfCDRNWg1GCbUdVjhv9RuNSnjUwOrSTKisNrxMAAIxtP3hlvm5oAo+P/i/b6JpN6dD068u9TtYrOadZ7ZlhtBcOgVJzkFXKMSF55xmupb4haEvmZkuPk1xfDx/dH/j7bbgf7vzD5q57UPgr4euree2ttQ1qwsrmC0guLa2uEKTi22+Szb0Y7gFUcEZA6VaufhJo0/iJ9WGp63EratFrZsY7lfs32pCDv2FCfm2jPP0xQBNH8WPDzabe6q0WqJodujuuqNZt9mn2OIyI2HJJYgDIGecdKrW/wAZPC81uH2aotz9sWxNmtm0s4laMyKNke7IZVOMZp6fCTRF0a80R9Q1qTw9PG8celNcr9nt90gkDR4UPlWUFdzMBzxUum/CzS7O502eTVNWupbC9S+hMxgX50R0CkJEoIw5z3JxzQB3VncC6s4LhY5YhLGsgSZCjrkZwynkEdwelTUUUAHQc0gpaKAEz7GgjJpaKACiiigArKv/AA/pmoa5pesXlt5uoaZ5n2SUyMBF5i7XIUHaSQMZIJHbFatFABRRRQAUUUUAFFFFAEN7/wAec/X/AFbdPpXzfAmFYhyTt6np/wDr/lX0ff8A/Hjc/wDXNv5V82RSM5iWNTjB68Yx1NAF+yVY0dgc9wWbOam3kKcEAMenpWcsrB1DE7Qe/wDEKT7UBGSX+Uccjn86AJHLGU7jkY4UioLgEkRk5LAgkDpnr+HvVea9zNHgLlgQCeDj2rD8Va5LYyabFaRxGS7uBBukchFG0nPH05FAGToPhq3ttcuGcboIZsxlumTgjH4969Bdv3LEMWJ6fnXky6/qWuaxoNvE8VrFJJP55gkZVm8o4JBAztx0HrnNemiU7FbhQOo65PqfagCyZFlj44XO3GOPwqjcgKuNgK52qRyB608uTggAbeduNvH+NMuG2xkyngk8EdP/AK9AGVIAgbblSDgjrUc7AKyIcg+n8qSeTYMg7iMHPT8PpTJdvmvxgbsn1+lAGZqlmmoxLC9xLAoYNuhOCSO309qhbTv+JlFfLNPiNNoj3fKw6c1psFLu3PTOD1//AF1F5gJBC8Hjrx+H9aAPTvgBhvGF6xA3GxfkenmR179XgPwBP/FY3gBGBYSdP+ukde/UABpCMjBpT0ozQAgz3NGOc96CSOgzzRknOKADHvSAE5JJ60ufSheAAaADHPWl7UjMAyjnJoLYGaADbyc9PSo2HXHcg5zWd4nTVH0O7/sCaOHU1UPA0iB1dgQdhB7MAVz1GcjpXlHhv462vnGy8XaZNp13G3lySwqWRWGQ25D8y4Ixgbj9KynWhTaU9LnoYXLMRjKcqmHXNy7pb+tuvyOO/acBHjzT8nP/ABLI/wD0bLXkNenfH7WtN1/xXpt7o97DeWx02NS8RztbzJDgjqpwRwQDzXmNeDimnVk0frORQlDL6UZKzSCug+Hv/I/eGv8AsJ23/o1a5+tzwNNFbeNvD888ixwxajbu7ucBVEikknsMVlT+JHdi1ehNLs/yPt9V29O5zS15p4v+MnhnQleKwmOr3oHCWpzGDjI3SdMf7u4j0rU+Fut6/wCJtNudb1yGKzsrlgLC1RORGCcyMx5JOQOwwuQOa+jVeEp8kXdn4xUyvE0qH1mrHlj0vo36Lfz9Dt6KKK1PPCiiigAooooAKKKKACiijrQAUUUUAFFN6HvRwcHmgBQMd6WgUUAFFFFABRRRQAUUUUAFFFFAFbUjt066PpE5/Q18v2kqvFGysRlcYB/zxX0/qxxpV4en7l//AEE18mx3KGGIZ6DLHH+eaANnz8zhW3DdwPc+9Mcq8ZTKleSQBiqYlYn5GO/GVGCQc0krv5cihHODknace3/1qAGXEkbXMJxwMqoJ4+lUdc06z1kWhu42ZIJfNCMAQ5wRhgQQRg1ZZXZkcI5CDPKHr+XWnDexBMThW/h2E5x1A46UAQx6dbQT27x28AeFdsRWMDYO+309wK0RIwV5Rw/bvjPoKqqjj70U23t+7bp+XT3pRDOZFBt7gjPH7tuf0oAlNxNIyfMQAuOec5pt7O5O3aGB4OT0HvTpLa5OxltrliBnIibp+XWmPb3oDN9jvMrwMQPxn8OtAFGUZOEwABwD39zUDy5ixkAdOKurYag5B/s7UM+9rJj6fdqtHpWpyblOm6iNrH/l2k5P5UAV2YR5Jwx6df8APFNVsgFjz1ye9XpdI1RmVjpGo/dzkWj/AOH6USaJqzF9mk6mfYWkmP5dKAPQP2fGLeNL3cTk6e5wf+ukdfQVeCfATTtQtPGN7JeWF7bRGxdd00LIC3mR8ZI64BNe90AFJjmkbO8HcQB2oB5655oAXAxijGMnJoY4/OmuccL14oAdgZB9KAMDApMnJ9M0HqCR0NAC4Bo2j+lC57kHmj1570AIwBWvn79ojwKIj/wlOmRYBIS/UN3OAsgH6HHscdTX0BnB469agvLeK6glguI0lglQxvG6hldTwQQeCCKxr0VWg4s9HK8xqZdiY14fNd11X9dT4Norsfij4Ol8G+JZLVd76dPmW0mZcbk7qT3ZTwfwPGa46vnZwcJOMt0fs+GxFPE0o1qTvGSugooqaztpr27gtbWMyXEzrHGg6sxOAPzNSbNpK7Ow+Evg1/GXiqK3lU/2bbYmu3wcFc8JkdC3TqOMkdK+wraCK2gjgt40ihjUIiIMKoHQADoK5n4a+EofBvha305cNdN+9upFYkPKQM46cDAA4HA9a6qvoMJh/Yw13Z+P8Q5s8yxPuP3I6L9X8/ysFFFFdR4IUUUUAFFFFABRRRQAUnfvS96KAE4P4Uh4PuadSHn+tACemaPQDil96OvTqKAFFFFFABRRRQAUUUUAFFFFABRRRQAEZGD0qJbaBfuwRD6IKlooAYIoxjCJx7U7avoPypaKAE2j0FGB6ClooAMelFFFABRRRQAUUUUAFGOvXn3oooATv3paKa5wp9KAHGkApOf/AK9L05oAWijv7UUAFIBQTyBg8/pSKO5z1yKAHYpCM4z2pjbjwB8pGD604dM4OcUAKRRgcUmD0zwBQc9geTQByvxI8IW3jHw3Pp8oC3KZktZc48uUDgnrwehGOh9cGvjjUrG502/uLK+haG6t3MckbdVYHBH/ANevvBed2fXGK8T/AGhfAn26ybxPpkSi6tkxeIicyxjpJx3Udc/w9/lxXnY7D88faR3R9jwpnP1ar9UrP3JbeT/yf5/M+cq9/wD2cfBBGfFeoxkH5o7BSR05DyEfmo6fxccg15h8LvBs3jPxNFabZF0+HEl3Mq8InZc9i2MD8Tg4NfY1rbxWltDb20aRQQqESNFCqqgYAAHAFc+Aw/M/aS2Wx7HF2cexp/UqT96XxeS7fP8AL1JqKKK9k/NgooooAKKKKACiiigAooooADzQBRRQAAY6UmOKWigA7Gmoip90e1OpAaAFNFIevBpaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKRgGUg9CMUtFAGD4S8J6R4Ut7mHRrfyluZmmkLHJJJ4UHsoHAH9SSd6iilGKirI0q1Z1ZOdR3b6sKKKKZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this display, time is on the x-axis and flow velocity on the y-axis. By convention, flow away from the transducer is displayed below the line and that toward the transducer above the line; this spectral information can be displayed in real time (Doppler figure). The Doppler signal portrays the entire period of flow, ie, acceleration (a), peak flow (pf), and deceleration (d).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_55_33663=[""].join("\n");
var outline_f32_55_33663=null;
